

PATENT COOPERATION TREATY

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Assistant Commissioner for Patents
 United States Patent and Trademark
 Office
 Box PCT
 Washington, D.C. 20231
 ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 04 October 2000 (04.10.00)	
International application No. PCT/US00/04526	Applicant's or agent's file reference BB1332 PCT
International filing date (day/month/year) 22 February 2000 (22.02.00)	Priority date (day/month/year) 22 February 1999 (22.02.99)
Applicant CAHOON, Edgar, B. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:30 August 2000 (30.08.00)☐ in a notice effecting later election filed with the International Bureau on:2. The election ☒ was☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland Facsimile No.: (41-22) 740.14.35	Authorized officer C. Cupello Telephone No.: (41-22) 338.83.38
---	--

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

PATENT COOPERATION TREATY

RECEIVED

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

APR 11 2001

PCT

RECEIVED

To:

KENING LI
E.I. DU PONT DE NEMOURS AND COMPANY
Legal/Patent Records Center
1007 Market Street
Wilmington, Delaware 19898
ETATS-UNIS D'AMERIQUE

NOTIFICATION OF TRANSMITTAL OF THE INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Rule 71.1)

Date of mailing
(day/month/year)

05.04.2001

Applicant's or agent's file reference
BB1332 PCT

IMPORTANT NOTIFICATION

International application No.
PCT/US00/04526

International filing date (day/month/year)
22/02/2000

Priority date (day/month/year)
22/02/1999

Applicant

E. I. DU PONT DE NEMOURS AND COMPANY et al.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices) (Article 39(1)) (see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

REY NOTED

Name and mailing address of the IPEA/

European Patent Office
D-80298 Munich
Tel +49 89 2399 - 0 Tx: 523656 epmu d
Fax: +49 89 2399 - 4465

Authorized officer

Guerin, A

Tel +49 89 2399-8061



22 AU 2001



PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference BB1332 PCT	<div style="display: flex; justify-content: space-between;"> <div> FOR FURTHER ACTION </div> <div> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416) </div> </div>	
International application No. PCT/US00/04526	International filing date (day/month/year) 22/02/2000	Priority date (day/month/year) 22/02/1999
International Patent Classification (IPC) or national classification and IPC C12N15/54		
Applicant E. I. DU PONT DE NEMOURS AND COMPANY et al.		
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of 8 sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of sheets.</p>		
<p>3. This report contains indications relating to the following items:</p> <ul style="list-style-type: none"> I <input checked="" type="checkbox"/> Basis of the report II <input checked="" type="checkbox"/> Priority III <input checked="" type="checkbox"/> Non-establishment of opinion with regard to novelty, inventive step and industrial applicability IV <input checked="" type="checkbox"/> Lack of unity of invention V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement VI <input checked="" type="checkbox"/> Certain documents cited VII <input type="checkbox"/> Certain defects in the international application VIII <input checked="" type="checkbox"/> Certain observations on the international application 		
Date of submission of the demand 30/08/2000	Date of completion of this report 05.04.2001	
Name and mailing address of the international preliminary examining authority: <div style="display: flex; align-items: center;"> <div> European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465 </div> </div>	Authorized officer Roscoe, R Telephone No +49 89 2399 2554	





**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04526

I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

Description, pages:

1-36 as originally filed

Claims, No.:

1-42 as originally filed

Sequence listing part of the description, pages:

1-50, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
☐ the language of publication of the international application (under Rule 48.3(b)).
☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
☐ filed together with the international application in computer readable form.
☐ furnished subsequently to this Authority in written form.
☒ furnished subsequently to this Authority in computer readable form.
☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

- ☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04526

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)

6. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

☐ copy of the earlier application whose priority has been claimed.

☐ translation of the earlier application whose priority has been claimed.

2. ☐ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:
see separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. (1-20)part, 21-42.

because:

☐ the said international application, or the said claims Nos. relate to the following subject matter which does not require an international preliminary examination (*specify*):

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☒ no international search report has been established for the said claims Nos. (1-20)part, 21-42.



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04526

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.
☐ the computer readable form has not been furnished or does not comply with the standard.

IV. Lack of unity of invention

1. In response to the invitation to restrict or pay additional fees the applicant has:

- ☐ restricted the claims.
☐ paid additional fees.
☐ paid additional fees under protest.
☐ neither restricted nor paid additional fees.

2. ☒ This Authority found that the requirement of unity of invention is not complied and chose, according to Rule 68.1, not to invite the applicant to restrict or pay additional fees.

3. This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is

- ☐ complied with.
☒ not complied with for the following reasons:
see separate sheet

4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:

- ☐ all parts.
☒ the parts relating to claims Nos. (1-20)part.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2, 4-6, 9-15, 17, 19, 20
	No:	Claims	1, 3, 7, 8, 16, 18
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-20
Industrial applicability (IA)	Yes:	Claims	1-20
	No:	Claims	



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

International application No. PCT/US00/04526

2. Citations and explanations
see separate sheet

VI. Certain documents cited

1. Certain published documents (Rule 70.10)

and / or

2. Non-written disclosures (Rule 70.9)

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet



II. Priority

Sequence ID Nos. 27/28, 39/40, 45/46 not found in prio document. So insofar as claims relate to these sequences, only filing date establishes priority.

The methods of 11-13 and 19-20 also do not appear to be disclosed in the priority document and thus are also only entitled to priority from filing date.

III. No Opinion

Claims for which no Search Report established due to lack of unity: claims 1-20(all partially) and 21-42.

IV. Lack of Unity

The IPEA agrees entirely with the opinion set out by the ISA with regard to unity. No additional Search Fees were paid by applicant and hence only invention group 1 can be subject to examination. The objection arises since the prior art discloses LPAATs from various plant species (see e.g. D1 or D2). Hence, there is no novel concept spanning the claimed sequences.

V. Reasoned statement on Novelty, Inventive Step and Industrial Applicability

The documents mentioned in the present written opinion / International Preliminary Examination Report are numbered as in the search report, i.e. D1 corresponds to the first document of the search report etc.

- Novelty (Art.33(2) PCT)

In view of the priority situation, following novelty objections are raised:
D5 discloses a maize EST having 98.9% identity to Seq.ID No.27 over 637 bp.
Cited against claims 1, 3, 7, 8, 16, 18.

D6 discloses an EST with over 80% identity to antisense of Seq.ID No.27 in 524



bp overlap. Cited against claims 1, 3, 7, 8, 16, 18. D7 anticipates same claims for similar reasons.

D8 discloses a maize EST having 100% identity to antisense of Seq.ID No.39 in 398 bp overlap. Cited against claims 1, 3, 7, 8, 16, 18.

D9 discloses a maize EST having 100% identity in 585 bp overlap to Seq ID No.45. Cited against claims 1, 3, 7, 8, 16, 18.

Inventive Step (Art.33(3) PCT)

The problem solved by the present application is the provision of further LPAAT-like sequences. The solution of this problem is obvious, since several LPAAT sequences are already known, one merely has to scan through EST libraries either by mass sequencing and subsequent computer sequence comparisons or by hybridization screening using the known sequences. These are trivial methods used by a vast number of companies in the biotech industry. Applicant has not demonstrated function for any of his enzymes and thus could not have claimed to have solved any more specific problem (e.g. relating to substrate-specificity) by identifying any particular enzyme. Thus, no inventive activity at all can be detected in the present application.

Industrial Applicability (Art.33(4) PCT)

The present claims appear to have industrial applicability.

VI. Certain documents

In accordance with Rule 70.10, PCT, applicants attention is drawn to the following document(s):

D10: WO-A-00/18889 (Publication date, 06.04.00; Priority date, 25.09.99; Filing date, 24.09.99)

It is noted that D10 discloses sequences of high identity to Seq. ID Nos. 1, 2, 27,



**INTERNATIONAL PRELIMINARY
EXAMINATION REPORT - SEPARATE SHEET**

International application No. PCT/US00/04526

28, 39, 40 and 45 of the present application.

VIII. Certain observations

- Clarity (Art.6 PCT)

Claim 9 - a host cell cannot be a virus, since a virus is not a form of cell.

Claims 11, 14, 15, 18 - "nucleotide sequence of at least one of 30 contiguous nucleotides" is literally understood to include one nucleotide. Basically sequences of these claims totally undefined. However, it would seem that applicant means a sequence with at least one stretch of 30 nucleotides as defined in the listed sequence numbers. Examination has been provisionally performed on the basis of this interpretation.

Claim 17 - claim 10 defines a polypeptide



INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference BB1332 PCT	FOR FURTHER ACTION see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
International application No. PCT/US 00/ 04526	International filing date (day/month/year) 22/02/2000	(Earliest) Priority Date (day/month/year) 22/02/1999
Applicant E. I. DU PONT DE NEMOURS AND COMPANY et al.		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 8 sheets.

☐ It is also accompanied by a copy of each prior art document cited in this report.

1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☐ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☒ furnished subsequently to this Authority in computer readable form.

☒ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☒ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☐ **Certain claims were found unsearchable** (See Box I).

3. ☒ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ None of the figures.



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04526

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-20, all partially.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-20, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 2,8,28,40, or 46, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

1.1. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.2.

1.2. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.8.

1.3. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.28.

1.4. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.40.

1.5. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.46.

2. Claims: 42 completely, and 1-19,21-40 partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 4,10,18,22,34,44,50,52, or 56, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

3. Claims: 1-20,22-41, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 6,12,24,38, or 58, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

4. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to seq.ID.14, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

5. Claims: 1-20,22-41, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 16,20,30,42,48, or 54, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 26 or 36, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

7. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to seq.ID.32, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.



INTERNATIONAL SEARCH REPORT

International Application No.

US 00/04526

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/82 C12Q1/68 C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BROWN, A.P. ET AL.: "Isolation and characterization of a maize cDNA that complements a 1-acyl sn-glycerol-3-phosphate acyltransferase mutant of Escherichia coli and encodes a protein which has similarities to other acyltransferases." PLANT MOLECULAR BIOLOGY, vol. 26, 1994, pages 211-23, XP002143283 the whole document ---	
A	WO 95 27791 A (CALGENE INC ;DAVIES HUW MAELOR (US); HAWKINS DEBORAH (US); NELSEN) 19 October 1995 (1995-10-19) the whole document --- -/--	

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

26 July 2000

Date of mailing of the international search report

08.11.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Te (+31-70) 340-2040, Tx 31 651 epo nl,
Fax (+31-70) 340-3015

Authorized officer

Smalt, R



INTERNATIONAL SEARCH REPORT

International Application No

US 00/04526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 24674 A (GENE SHEARS PTY LTD ;SLABAS ANTONI RYSZARD (GB); BROWN ADRIAN PAUL) 15 August 1996 (1996-08-15) the whole document ---	
A	ZOU J ET AL: "Modification of seed oil content and acyl composition in the Brassicacea by expression of a yeast sn-2 acyltransferase gene" PLANT CELL,US,AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 9, no. 9, June 1997 (1997-06), pages 909-923-923, XP002122743 ISSN: 1040-4651 the whole document ---	
P,X	DATABASE EMBL - EMBL_PLN3 [Online] Entry/Acc.no. Aw065739, 18 October 1999 (1999-10-18) WALBOT, V.: "614060H09.y1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143284 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBL_PLN2 [Online] Entry/Acc.no. AI939764, 4 August 1999 (1999-08-04) WALBOT, V.: "618028B06.x1 618 - Inbred Tassel cDNA Library Zea mays cDNA, mRNA sequence." XP002143464 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBL_PLN3 [Online] Entry/Acc.no. AW065739, 18 October 1999 (1999-10-18) WALBOT, V.: "614060H09.y1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143465 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBL_PLN3 [Online] Entry/Acc.no. Aw055524, 26 September 1999 (1999-09-26) WALBOT, V.: "614082G11.x1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence" XP002143466 the whole document ---	1-4,7,8, 16,18

-/--



INTERNATIONAL SEARCH REPORT

International Application No

/US 00/04526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE EMBL - EMBEST PLN1 [Online] Entry/Acc.no. Ai783420, 2 July 1999 (1999-07-02) WALBOT, V.: "614011F05.x1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143467 the whole document ---	1-4,7,8, 16,18
E	WO 00 18889 A (CALGENE LLC) 6 April 2000 (2000-04-06) the whole document -----	1-20



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

US 00/04526

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9527791	A	19-10-1995	US 5563058 A	08-10-1996
			US 6093568 A	25-07-2000
			US 5824858 A	20-10-1998
			US 5910630 A	08-06-1999
			CA 2186607 A	19-10-1995
			EP 0754232 A	22-01-1997
			JP 9511650 T	25-11-1997
			US 5968791 A	19-10-1999

WO 9624674	A	15-08-1996	AU 4669096 A	27-08-1996
			CA 2212570 A	15-08-1996
			CA 2235267 A	24-04-1997
			EP 0808368 A	26-11-1997

WO 0018889	A	06-04-2000	NONE	



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/54, 15/82, C12Q 1/68, C12N 9/10	A2	(11) International Publication Number: WO 00/49156
		(43) International Publication Date: 24 August 2000 (24.08.00)

(21) International Application Number: PCT/US00/04526
(22) International Filing Date: 22 February 2000 (22.02.00)
(30) Priority Data:
60/121,119 22 February 1999 (22.02.99) US

(71) Applicant (for all designated States except US): E.I. DU PONT
DE NEMOURS AND COMPANY [US/US]; 1007 Market
Street, Wilmington, DE 19898 (US).

(72) Inventors; and
(75) Inventors/Applicants (for US only): CAHOON, Edgar, B.
[US/US]; 2331 West 18th Street, Wilmington, DE 19806
(US). CAHOON, Rebecca, E. [US/US]; 2331 West 18th
Street, Wilmington, DE 19806 (US). HITZ, William, D.
[US/US]; 404 Hillside Road, Wilmington, DE 19807 (US).
KINNEY, Anthony, J. [GB/US]; 609 Lore Avenue, Wilm-
ington, DE 19809 (US). RIPP, Kevin, G. [US/US]; 2310
West 18th Street, Wilmington, DE 19806 (US).

(74) Agent: CHRISTENBURY, Lynne, M.; E.I. Du Pont de
Nemours and Company, Legal Patent Records Center, 1007
Market Street, Wilmington, DE 19898 (US).

(81) Designated States: AE, AL, AU, BA, BB, BG, BR, CA, CN,
CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS,
JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX,
NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ,
VN, YU, ZA, ARIPO patent (GH, GM, KE, LS, MW, SD,
SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG,
KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT,
SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW,
ML, MR, NE, SN, TD, TG).

Published

*Without international search report and to be republished
upon receipt of that report.*

(54) Title: LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES

(57) Abstract

An isolated nucleic acid fragment encoding an LPAAT isozyme is disclosed. Construction of a chimeric gene encoding all or a portion of the LPAAT isozyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the LPAAT isozyme in a transformed host cell is also disclosed.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon	KR	Republic of Korea	PL	Poland		
CN	China	KZ	Kazakhstan	PT	Portugal		
CU	Cuba	LC	Saint Lucia	RO	Romania		
CZ	Czech Republic	LI	Liechtenstein	RU	Russian Federation		
DE	Germany	LK	Sri Lanka	SD	Sudan		
DK	Denmark	LR	Liberia	SE	Sweden		
EE	Estonia			SG	Singapore		

TITLE

LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES

This application claims the benefit of U.S. Provisional Application No. 60/121,119, filed February 22, 1999.

5

FIELD OF THE INVENTION

This invention is in the field of plant molecular biology and, in particular, this invention pertains to isolated polynucleotides encoding lysophosphatidic acid acyltransferases in plants and seeds.

BACKGROUND OF THE INVENTION

10

Triacylglycerols are nonpolar, water-insoluble fatty acid triesters of glycerols. Triacylglycerols differ according to the identity and placement of their three fatty acid residues. Lysophosphatidic acid acyltransferase (EC 2.3.1.51), also called 1-acyl-sn-glycerol-3-phosphate acyltransferase, 1-AGP acyltransferase, 1-AGPAT, lysophosphatidic acid transferase, and LPAAT, catalyzes the attachment of the second acyl group to the

15

glycerol backbone during de-novo biosynthesis of triacylglycerols. The fatty acid distribution in triacylglycerols is thought to be dependent on the specificities of the acyltransferases involved in their biosynthesis. Although no plant LPAAT has been purified to completion, spinach leaves have at least two systems which reside in different subcellular compartments (chloroplast inner membrane and the endoplasmic

20 reticulum) and which incorporate different fatty acids into the glycerol backbone (Frentzen et al. (1984) in *Structure, function and metabolism of plant lipids*; Siegenthaler and Eichenberger, eds. pp 105-110). Isolation of LPAAT genes from *Limnanthes douglasii* is dependent on the approach used to isolate the clone. Two different clones have been

25 isolated which varied in their expression patterns, in their ability to complement an *E. coli* temperature-sensitive mutant defective in LPAAT activity and in their ability to hybridize to the already known maize LPAAT (Brown et al. (1995) *Plant Mol. Biol.* 29:267-278). Thus, the presence of many other LPAATs with different specificities, subcellular locations and activities is expected.

25

30

Production of industrially-significant oils in seed oil plants has been a quest of the agricultural industry of some time now. Introduction of the yeast LPAAT sequence into *Arabidopsis* and *B. napus* results in increased seed oil content in many transgenic plants and in changes in seed oil composition (Zou et al. (1997) *Plant Cell* 9:909-923).

SUMMARY OF THE INVENTION

35

The invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) a first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or

(b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

In a second embodiment, it is preferred that the isolated polynucleotide of the claimed invention comprises a first nucleotide sequence which comprises a nucleic acid sequence
5 selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In a third embodiment, this invention concerns a chimeric gene comprising an isolated
10 polynucleotide of the present invention operably linked to suitable regulatory sequences.

In a fourth embodiment, this invention concerns an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention. The host cell may be eukaryotic, such as a yeast or a plant cell, or prokaryotic, such as a bacterial cell. The present invention also relates to a virus, preferably a baculovirus,
15 comprising an isolated polynucleotide of the present invention or a chimeric gene of the present invention.

In a fifth embodiment, the present invention concerns a process for producing an isolated host cell comprising a chimeric gene of the present invention or an isolated polynucleotide of the present invention, the process comprising either transforming or
20 transfecting an isolated compatible host cell with a chimeric gene or isolated polynucleotide of the present invention.

In a sixth embodiment, the invention also relates to lysophosphatidic acid acyltransferase (LPAAT isozymes) polypeptides of at least 100 amino acids comprising at least 80% homology based on the Clustal method of alignment compared to a polypeptide
25 selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In a seventh embodiment, the invention concerns a method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a host cell, preferably a plant cell, the method comprising the steps of: (a) constructing an
30 isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; (b) introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; (c) measuring the level the LPAAT isozyme polypeptide in the host cell containing the isolated polynucleotide; and (d) comparing the level of the LPAAT isozyme polypeptide in the host cell containing the isolated polynucleotide with the level of the LPAAT isozyme
35 polypeptide in the host cell that does not contain the isolated polynucleotide.

In an eighth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding a substantial portion of an LPAAT isozyme polypeptide, preferably a plant LPAAT isozyme polypeptide, comprising the steps of: synthesizing an

oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences; and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of an LPAAT isozyme amino acid sequence.

In a ninth embodiment, the invention concerns a method of obtaining a nucleic acid fragment encoding all or a substantial portion of the amino acid sequence encoding an LPAAT isozyme polypeptide comprising the steps of: probing a cDNA or genomic library with an isolated polynucleotide of the present invention; identifying a DNA clone that hybridizes with an isolated polynucleotide of the present invention; isolating the identified DNA clone; and sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

In a tenth embodiment, this invention concerns a composition, such as a hybridization mixture, comprising an isolated polynucleotide of the present invention.

In an eleventh embodiment, this invention concerns an isolated polynucleotide of the present invention comprising at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51.

In a twelfth embodiment, this invention concerns a method for positive selection of a transformed cell comprising: (a) transforming a host cell with the chimeric gene of the present invention or an expression cassette of the present invention; and (b) growing the transformed host cell, preferably plant cell, such as a monocot or a dicot, under conditions which allow expression of the LPAAT isozyme polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

In a thirteenth embodiment, this invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58 or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence. All of the embodiments described above are applicable with the exception of the particular sequences involved and the sequence identity being at least 95% as noted in the appropriate claims.

BRIEF DESCRIPTION OF THE SEQUENCE LISTINGS

The invention can be more fully understood from the following detailed description and the accompanying Sequence Listing which form a part of this application.

Table 1 lists the polypeptides that are described herein, the designation of the cDNA clones that comprise the nucleic acid fragments encoding polypeptides representing all or a substantial portion of these polypeptides, and the corresponding identifier (SEQ ID NO:) as used in the attached Sequence Listing. The sequence descriptions and Sequence Listing attached hereto comply with the rules governing nucleotide and/or amino acid sequence disclosures in patent applications as set forth in 37 C.F.R. §1.821-1.825.

TABLE 1
Lysophosphatidic Acid Acyltransferases

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Corn Polypeptide Similar to <i>Mus musculus</i> LPAAT	Contig of: p0018.chssd06r p0104.cabbd29r cca.pk0027.c9 p0018.chstw94r p0094.csssl20r	1	2
Soybean Polypeptide Similar to <i>Mus musculus</i> LPAAT	sl2.pk121.a19	3	4
Wheat Polypeptide Similar to <i>Mus musculus</i> LPAAT	Contig of: wlm1.pk0018.g6 wre1n.pk0040.h11 wre1n.pk0064.g7	5	6
Corn Polypeptide Similar to <i>B. pseudomallei</i> LPAAT	Contig of: ceb5.pk0049.b3 cen3n.pk0027.f6	7	8
Soybean Polypeptide Similar to <i>B. pseudomallei</i> LPAAT	sgslc.pk001.i16	9	10
Wheat Polypeptide Similar to <i>B. pseudomallei</i> LPAAT	wre1n.pk0027.d4	11	12
Arabidopsis Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein	ads1c.pk005.i10	13	14
Rice Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein	Contig of: rls6.pk0076.d5 rlr24.pk0068.e3	15	16
Soybean Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein	scblc.pk003.d18	17	18
Rice Polypeptide Similar to Corn LPAAT	Contig of: rr1.pk0004.a10 rr1.pk0039.e10	19	20
Soybean Polypeptide Similar to Corn LPAAT	Contig of: se4.cp0008.b2 sl2.pk0033.c1	21	22
Wheat Polypeptide Similar to Corn LPAAT	Contig of: wlk1.pk0004.e7 wle1n.pk0002.g3	23	24

Protein	Clone Designation	SEQ ID NO:	
		(Nucleotide)	(Amino Acid)
Catalpa Polypeptide Similar to <i>Mus musculus</i> LPAAT	ncs.pk0013.d2:fis	25	26
Corn Polypeptide Similar to <i>Mus musculus</i> LPAAT	Contig of: ceb1.pk0011.d11 ceb5.pk0053.e3 p0010.cbpbq45r p0018.chssd06r:fis	27	28
Rice Polypeptide Similar to <i>Mus musculus</i> LPAAT	rlr2.pk0028.d6:fis	29	30
Sorghum Polypeptide Similar to <i>Mus musculus</i> LPAAT	gds1c.pk002.a19:fis	31	32
Soybean Polypeptide Similar to <i>Mus musculus</i> LPAAT	sl2.pk121.a19:fis	33	34
Catalpa Polypeptide Similar to <i>B. pseudomallei</i> LPAAT	ncs.pk0009.f12:fis	35	36
Wheat Polypeptide Similar to <i>B. pseudomallei</i> LPAAT	wre1n.pk0027.d4:fis	37	38
Corn Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein	Contig of: ceb1.mn0001.d12:fis cpe1c.pk006.e1	39	40
Rice Polypeptide Similar to <i>A. thaliana</i> Protein	rls6.pk0076.d5:fis	41	42
Soybean Polypeptide Similar to <i>Arabidopsis thaliana</i> Protein	scb1c.pk003.d18:fis	43	44
Corn Polypeptide Similar to <i>A. thaliana</i> acyltransferase	cco1n.pk062.p19	45	46
Rice Polypeptide Similar to <i>A. thaliana</i> acyltransferase	rlr6.pk0094.f6:fis	47	48
Soybean Polypeptide Similar to <i>A. thaliana</i> acyltransferase	sdp4c.pk006.n11:fis	49	50
Soybean Polypeptide Similar to <i>A. thaliana</i> acyltransferase	Contig of: sgs1c.pk005.k7 sgs5c.pk0003.e7	51	52
Rice Polypeptide Similar to Corn LPAAT	rr1.pk0004.a10:fis	53	54
Soybean Polypeptide Similar to Corn LPAAT	sl2.pk0033.c1:fis	55	56
Wheat Polypeptide Similar to Corn LPAAT	wlk1.pk0004.e7:fis	57	58

The Sequence Listing contains the one letter code for nucleotide sequence characters and the three letter codes for amino acids as defined in conformity with the IUPAC-IUBMB

standards described in *Nucleic Acids Res.* 13:3021-3030 (1985) and in the *Biochemical J.* 219 (No. 2):345-373 (1984) which are herein incorporated by reference. The symbols and format used for nucleotide and amino acid sequence data comply with the rules set forth in 37 C.F.R. §1.822.

DETAILED DESCRIPTION OF THE INVENTION

In the context of this disclosure, a number of terms shall be utilized. The terms "polynucleotide" and "nucleic acid fragment"/"isolated nucleic acid fragment" are used interchangeably herein. These terms encompass nucleotide sequences and the like. A polynucleotide may be a polymer of RNA or DNA that is single- or double-stranded, that optionally contains synthetic, non-natural or altered nucleotide bases. A polynucleotide in the form of a polymer of DNA may be comprised of one or more segments of cDNA, genomic DNA, synthetic DNA, or mixtures thereof. An isolated polynucleotide of the present invention may include at least one of 60 contiguous nucleotides, preferably at least one of 40 contiguous nucleotides, most preferably one of at least 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, or the complement of such sequences and /or (b) SEQ ID NOs:19, 21, 23, 53, 55, and 57 or the complement of such sequences. The term "isolated" polynucleotide is one that has been substantially separated or purified away from other nucleic acid sequences in the cell of the organism in which the nucleic acid naturally occurs, i.e., other chromosomal and extrachromosomal DNA and RNA, by conventional nucleic acid purification methods. The term also embraces recombinant polynucleotides and chemically synthesized polynucleotides.

As used herein, "contig" refers to a nucleotide sequence that is assembled from two or more constituent nucleotide sequences that share common or overlapping regions of sequence homology. For example, the nucleotide sequences of two or more nucleic acid fragments can be compared and aligned in order to identify common or overlapping sequences. Where common or overlapping sequences exist between two or more nucleic acid fragments, the sequences (and thus their corresponding nucleic acid fragments) can be assembled into a single contiguous nucleotide sequence.

As used herein, "substantially similar" refers to nucleic acid fragments wherein changes in one or more nucleotide bases results in substitution of one or more amino acids, but do not affect the functional properties of the polypeptide encoded by the nucleotide sequence. "Substantially similar" also refers to nucleic acid fragments wherein changes in one or more nucleotide bases does not affect the ability of the nucleic acid fragment to mediate alteration of gene expression by gene silencing through for example antisense or co-suppression technology. "Substantially similar" also refers to modifications of the nucleic acid fragments of the instant invention such as deletion or insertion of one or more

nucleotides that do not substantially affect the functional properties of the resulting transcript vis-à-vis the ability to mediate gene silencing or alteration of the functional properties of the resulting protein molecule. It is therefore understood that the invention encompasses more than the specific exemplary nucleotide or amino acid sequences and includes functional equivalents thereof. The terms "substantially similar" and "corresponding substantially" are used interchangeably herein.

Substantially similar nucleic acid fragments may be selected by screening nucleic acid fragments representing subfragments or modifications of the nucleic acid fragments of the instant invention, wherein one or more nucleotides are substituted, deleted and/or inserted, for their ability to affect the level of the polypeptide encoded by the unmodified nucleic acid fragment in a plant or plant cell. For example, a substantially similar nucleic acid fragment representing at least one of 30 contiguous nucleotides derived from the instant nucleic acid fragment can be constructed and introduced into a plant or plant cell. The level of the polypeptide encoded by the unmodified nucleic acid fragment present in a plant or plant cell exposed to the substantially similar nucleic fragment can then be compared to the level of the polypeptide in a plant or plant cell that is not exposed to the substantially similar nucleic acid fragment.

For example, it is well known in the art that antisense suppression and co-suppression of gene expression may be accomplished using nucleic acid fragments representing less than the entire coding region of a gene, and by nucleic acid fragments that do not share 100% sequence identity with the gene to be suppressed. Moreover, alterations in a nucleic acid fragment which result in the production of a chemically equivalent amino acid at a given site, but do not effect the functional properties of the encoded polypeptide, are well known in the art. Thus, a codon for the amino acid alanine, a hydrophobic amino acid, may be substituted by a codon encoding another less hydrophobic residue, such as glycine, or a more hydrophobic residue, such as valine, leucine, or isoleucine. Similarly, changes which result in substitution of one negatively charged residue for another, such as aspartic acid for glutamic acid, or one positively charged residue for another, such as lysine for arginine, can also be expected to produce a functionally equivalent product. Nucleotide changes which result in alteration of the N-terminal and C-terminal portions of the polypeptide molecule would also not be expected to alter the activity of the polypeptide. Each of the proposed modifications is well within the routine skill in the art, as is determination of retention of biological activity of the encoded products. Consequently, an isolated polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of (a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences, and/or (b) SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such

nucleotide sequences may be used in methods of selecting an isolated polynucleotide that affects the expression of an LPAAT isozyme polypeptide in a host cell. A method of selecting an isolated polynucleotide that affects the level of expression of a polypeptide in a host cell (eukaryotic, such as plant or yeast, prokaryotic such as bacterial, or viral) may
5 comprise the steps of: constructing an isolated polynucleotide of the present invention or an isolated chimeric gene of the present invention; introducing the isolated polynucleotide or the isolated chimeric gene into a host cell; measuring the level a polypeptide in the host cell containing the isolated polynucleotide; and comparing the level of a polypeptide in the host cell containing the isolated polynucleotide with the level of a polypeptide in a host cell that
10 does not contain the isolated polynucleotide.

Moreover, substantially similar nucleic acid fragments may also be characterized by their ability to hybridize. Estimates of such homology are provided by either DNA-DNA or DNA-RNA hybridization under conditions of stringency as is well understood by those skilled in the art (Hames and Higgins, Eds. (1985) *Nucleic Acid Hybridisation*, IRL Press,
15 Oxford, U.K.). Stringency conditions can be adjusted to screen for moderately similar fragments, such as homologous sequences from distantly related organisms, to highly similar fragments, such as genes that duplicate functional enzymes from closely related organisms. Post-hybridization washes determine stringency conditions. One set of preferred conditions uses a series of washes starting with 6X SSC, 0.5% SDS at room
20 temperature for 15 min, then repeated with 2X SSC, 0.5% SDS at 45°C for 30 min, and then repeated twice with 0.2X SSC, 0.5% SDS at 50°C for 30 min. A more preferred set of stringent conditions uses higher temperatures in which the washes are identical to those above except for the temperature of the final two 30 min washes in 0.2X SSC, 0.5% SDS was increased to 60°C. Another preferred set of highly stringent conditions uses two final
25 washes in 0.1X SSC, 0.1% SDS at 65°C.

Substantially similar nucleic acid fragments of the instant invention may also be characterized by the percent identity of the amino acid sequences that they encode to the amino acid sequences disclosed herein, as determined by algorithms commonly employed by those skilled in this art. Suitable nucleic acid fragments (isolated polynucleotides of the
30 present invention) encode polypeptides that are at least about 70% identical, preferably at least about 80% identical to the amino acid sequences reported herein. Preferred nucleic acid fragments encode amino acid sequences that are about 85% identical to the amino acid sequences reported herein. More preferred nucleic acid fragments encode amino acid sequences that are at least about 90% identical to the amino acid sequences reported herein.
35 Most preferred are nucleic acid fragments that encode amino acid sequences that are at least about 95% identical to the amino acid sequences reported herein. Suitable nucleic acid fragments not only have the above homologies but typically encode a polypeptide having at least 50 amino acids, preferably at least 100 amino acids, more preferably at least 150 amino

acids, still more preferably at least 200 amino acids, and most preferably at least 250 amino acids. Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5.

A "substantial portion" of an amino acid or nucleotide sequence comprises an amino acid or a nucleotide sequence that is sufficient to afford putative identification of the protein or gene that the amino acid or nucleotide sequence comprises. Amino acid and nucleotide sequences can be evaluated either manually by one skilled in the art, or by using computer-based sequence comparison and identification tools that employ algorithms such as BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/). In general, a sequence of ten or more contiguous amino acids or thirty or more contiguous nucleotides is necessary in order to putatively identify a polypeptide or nucleic acid sequence as homologous to a known protein or gene. Moreover, with respect to nucleotide sequences, gene-specific oligonucleotide probes comprising 30 or more contiguous nucleotides may be used in sequence-dependent methods of gene identification (e.g., Southern hybridization) and isolation (e.g., *in situ* hybridization of bacterial colonies or bacteriophage plaques). In addition, short oligonucleotides of 12 or more nucleotides may be used as amplification primers in PCR in order to obtain a particular nucleic acid fragment comprising the primers. Accordingly, a "substantial portion" of a nucleotide sequence comprises a nucleotide sequence that will afford specific identification and/or isolation of a nucleic acid fragment comprising the sequence. The instant specification teaches amino acid and nucleotide sequences encoding polypeptides that comprise one or more particular plant proteins. The skilled artisan, having the benefit of the sequences as reported herein, may now use all or a substantial portion of the disclosed sequences for purposes known to those skilled in this art. Accordingly, the instant invention comprises the complete sequences as reported in the accompanying Sequence Listing, as well as substantial portions of those sequences as defined above.

"Codon degeneracy" refers to divergence in the genetic code permitting variation of the nucleotide sequence without effecting the amino acid sequence of an encoded polypeptide. Accordingly, the instant invention relates to any nucleic acid fragment comprising a nucleotide sequence that encodes all or a substantial portion of the amino acid sequences set forth herein. The skilled artisan is well aware of the "codon-bias" exhibited by a specific host cell in usage of nucleotide codons to specify a given amino acid. Therefore, when synthesizing a nucleic acid fragment for improved expression in a host cell,

it is desirable to design the nucleic acid fragment such that its frequency of codon usage approaches the frequency of preferred codon usage of the host cell.

“Synthetic nucleic acid fragments” can be assembled from oligonucleotide building blocks that are chemically synthesized using procedures known to those skilled in the art. These building blocks are ligated and annealed to form larger nucleic acid fragments which may then be enzymatically assembled to construct the entire desired nucleic acid fragment. “Chemically synthesized”, as related to nucleic acid fragment, means that the component nucleotides were assembled *in vitro*. Manual chemical synthesis of nucleic acid fragments may be accomplished using well established procedures, or automated chemical synthesis can be performed using one of a number of commercially available machines. Accordingly, the nucleic acid fragments can be tailored for optimal gene expression based on optimization of nucleotide sequence to reflect the codon bias of the host cell. The skilled artisan appreciates the likelihood of successful gene expression if codon usage is biased towards those codons favored by the host. Determination of preferred codons can be based on a survey of genes derived from the host cell where sequence information is available.

“Gene” refers to a nucleic acid fragment that expresses a specific protein, including regulatory sequences preceding (5' non-coding sequences) and following (3' non-coding sequences) the coding sequence. “Native gene” refers to a gene as found in nature with its own regulatory sequences. “Chimeric gene” refers any gene that is not a native gene, comprising regulatory and coding sequences that are not found together in nature. Accordingly, a chimeric gene may comprise regulatory sequences and coding sequences that are derived from different sources, or regulatory sequences and coding sequences derived from the same source, but arranged in a manner different than that found in nature. “Endogenous gene” refers to a native gene in its natural location in the genome of an organism. A “foreign” gene refers to a gene not normally found in the host organism, but that is introduced into the host organism by gene transfer. Foreign genes can comprise native genes inserted into a non-native organism, or chimeric genes. A “transgene” is a gene that has been introduced into the genome by a transformation procedure.

“Coding sequence” refers to a nucleotide sequence that codes for a specific amino acid sequence. “Regulatory sequences” refer to nucleotide sequences located upstream (5' non-coding sequences), within, or downstream (3' non-coding sequences) of a coding sequence, and which influence the transcription, RNA processing or stability, or translation of the associated coding sequence. Regulatory sequences may include promoters, translation leader sequences, introns, and polyadenylation recognition sequences.

“Promoter” refers to a nucleotide sequence capable of controlling the expression of a coding sequence or functional RNA. In general, a coding sequence is located 3' to a promoter sequence. The promoter sequence consists of proximal and more distal upstream elements, the latter elements often referred to as enhancers. Accordingly, an “enhancer” is a

nucleotide sequence which can stimulate promoter activity and may be an innate element of the promoter or a heterologous element inserted to enhance the level or tissue-specificity of a promoter. Promoters may be derived in their entirety from a native gene, or be composed of different elements derived from different promoters found in nature, or even comprise synthetic nucleotide segments. It is understood by those skilled in the art that different promoters may direct the expression of a gene in different tissues or cell types, or at different stages of development, or in response to different environmental conditions. Promoters which cause a nucleic acid fragment to be expressed in most cell types at most times are commonly referred to as "constitutive promoters". New promoters of various types useful in plant cells are constantly being discovered; numerous examples may be found in the compilation by Okamuro and Goldberg (1989) *Biochemistry of Plants* 15:1-82. It is further recognized that since in most cases the exact boundaries of regulatory sequences have not been completely defined, nucleic acid fragments of different lengths may have identical promoter activity.

The "translation leader sequence" refers to a nucleotide sequence located between the promoter sequence of a gene and the coding sequence. The translation leader sequence is present in the fully processed mRNA upstream of the translation start sequence. The translation leader sequence may affect processing of the primary transcript to mRNA, mRNA stability or translation efficiency. Examples of translation leader sequences have been described (Turner and Foster (1995) *Mol. Biotechnol.* 3:225-236).

The "3' non-coding sequences" refer to nucleotide sequences located downstream of a coding sequence and include polyadenylation recognition sequences and other sequences encoding regulatory signals capable of affecting mRNA processing or gene expression. The polyadenylation signal is usually characterized by affecting the addition of polyadenylic acid tracts to the 3' end of the mRNA precursor. The use of different 3' non-coding sequences is exemplified by Ingelbrecht et al. (1989) *Plant Cell* 1:671-680.

"RNA transcript" refers to the product resulting from RNA polymerase-catalyzed transcription of a DNA sequence. When the RNA transcript is a perfect complementary copy of the DNA sequence, it is referred to as the primary transcript or it may be a RNA sequence derived from posttranscriptional processing of the primary transcript and is referred to as the mature RNA. "Messenger RNA (mRNA)" refers to the RNA that is without introns and that can be translated into polypeptide by the cell. "cDNA" refers to a DNA that is complementary to and derived from a mRNA template using the enzyme reverse transcriptase. The cDNA can be single-stranded or converted into the double stranded form using, for example, the klenow fragment of DNA polymerase I. "Sense" RNA refers to an RNA transcript that includes the mRNA and so can be translated into a polypeptide by the cell. "Antisense RNA" refers to an RNA transcript that is complementary to all or part of a target primary transcript or mRNA and that blocks the

expression of a target gene (see U.S. Patent No. 5,107,065, incorporated herein by reference). The complementarity of an antisense RNA may be with any part of the specific nucleotide sequence, i.e., at the 5' non-coding sequence, 3' non-coding sequence, introns, or the coding sequence. "Functional RNA" refers to sense RNA, antisense RNA, ribozyme RNA, or other RNA that may not be translated but yet has an effect on cellular processes.

The term "operably linked" refers to the association of two or more nucleic acid fragments on a single nucleic acid fragment so that the function of one is affected by the other. For example, a promoter is operably linked with a coding sequence when it is capable of affecting the expression of that coding sequence (i.e., that the coding sequence is under the transcriptional control of the promoter). Coding sequences can be operably linked to regulatory sequences in a sense or antisense orientation.

The term "recombinant" means, for example, that a recombinant nucleic acid sequence is made by an artificial combination of two otherwise separated segments of sequence, e.g., by chemical synthesis or by the manipulation of isolated segments of nucleic acids by genetic engineering techniques.

The term "expression", as used herein, refers to the transcription and stable accumulation of sense (mRNA) or antisense RNA derived from the nucleic acid fragment of the invention. Expression may also refer to translation of mRNA into a polypeptide. "Antisense inhibition" refers to the production of antisense RNA transcripts capable of suppressing the expression of the target protein. "Overexpression" refers to the production of a gene product in transgenic organisms that exceeds levels of production in normal or non-transformed organisms. "Co-suppression" refers to the production of sense RNA transcripts capable of suppressing the expression of identical or substantially similar foreign or endogenous genes (U.S. Patent No. 5,231,020, incorporated herein by reference).

"Altered levels" or "altered expression" refers to the production of gene product(s) in transgenic organisms in amounts or proportions that differ from that of normal or non-transformed organisms.

"Mature" protein refers to a post-translationally processed polypeptide; i.e., one from which any pre- or propeptides present in the primary translation product have been removed. "Precursor" protein refers to the primary product of translation of mRNA; i.e., with pre- and propeptides still present. Pre- and propeptides may be but are not limited to intracellular localization signals.

A "chloroplast transit peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the chloroplast or other plastid types present in the cell in which the protein is made. "Chloroplast transit sequence" refers to a nucleotide sequence that encodes a chloroplast transit peptide. A "signal peptide" is an amino acid sequence which is translated in conjunction with a protein and directs the protein to the secretory system (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53).

If the protein is to be directed to a vacuole, a vacuolar targeting signal (*supra*) can further be added, or if to the endoplasmic reticulum, an endoplasmic reticulum retention signal (*supra*) may be added. If the protein is to be directed to the nucleus, any signal peptide present should be removed and instead a nuclear localization signal included (Raikhel (1992) *Plant Phys.* 100:1627-1632).

"Transformation" refers to the transfer of a nucleic acid fragment into the genome of a host organism, resulting in genetically stable inheritance. Host organisms containing the transformed nucleic acid fragments are referred to as "transgenic" organisms. Examples of methods of plant transformation include *Agrobacterium*-mediated transformation (De Blaere et al. (1987) *Meth. Enzymol.* 143:277) and particle-accelerated or "gene gun" transformation technology (Klein et al. (1987) *Nature (London)* 327:70-73; U.S. Patent No. 4,945,050, incorporated herein by reference). Thus, isolated polynucleotides of the present invention can be incorporated into recombinant constructs, typically DNA constructs, capable of introduction into and replication in a host cell. Such a construct can be a vector that includes a replication system and sequences that are capable of transcription and translation of a polypeptide-encoding sequence in a given host cell. A number of vectors suitable for stable transfection of plant cells or for the establishment of transgenic plants have been described in, e.g., Pouwels et al., *Cloning Vectors: A Laboratory Manual*, 1985, supp. 1987; Weissbach and Weissbach, *Methods for Plant Molecular Biology*, Academic Press, 1989; and Flevin et al., *Plant Molecular Biology Manual*, Kluwer Academic Publishers, 1990. Typically, plant expression vectors include, for example, one or more cloned plant genes under the transcriptional control of 5' and 3' regulatory sequences and a dominant selectable marker. Such plant expression vectors also can contain a promoter regulatory region (e.g., a regulatory region controlling inducible or constitutive, environmentally- or developmentally-regulated, or cell- or tissue-specific expression), a transcription initiation start site, a ribosome binding site, an RNA processing signal, a transcription termination site, and/or a polyadenylation signal.

Standard recombinant DNA and molecular cloning techniques used herein are well known in the art and are described more fully in Sambrook et al. *Molecular Cloning: A Laboratory Manual*; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989 (hereinafter "Maniatis").

"PCR" or "polymerase chain reaction" is a technique for the synthesis of large quantities of specific DNA segments. It consists of a series of repetitive cycles (Perkin Elmer Cetus Instruments, Norwalk, CT). Typically, the double-stranded DNA is heat denatured, the two primers complementary to the 3' boundaries of the target segment are annealed at low temperature and then extended at an intermediate temperature. One set of these three consecutive steps is referred to as a cycle.

The present invention concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID-NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

The present invention also concerns an isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of: (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58 or (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

Preferably, the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

Nucleic acid fragments encoding at least a portion of several LPAAT isozymes have been isolated and identified by comparison of random plant cDNA sequences to public databases containing nucleotide and protein sequences using the BLAST algorithms well known to those skilled in the art. The nucleic acid fragments of the instant invention may be used to isolate cDNAs and genes encoding homologous proteins from the same or other plant species. Isolation of homologous genes using sequence-dependent protocols is well known in the art. Examples of sequence-dependent protocols include, but are not limited to, methods of nucleic acid hybridization, and methods of DNA and RNA amplification as exemplified by various uses of nucleic acid amplification technologies (e.g., polymerase chain reaction, ligase chain reaction).

For example, genes encoding other LPAAT isozymes, either as cDNAs or genomic DNAs, could be isolated directly by using all or a portion of the instant nucleic acid fragments as DNA hybridization probes to screen libraries from any desired plant employing methodology well known to those skilled in the art. Specific oligonucleotide probes based upon the instant nucleic acid sequences can be designed and synthesized by methods known in the art (Maniatis). Moreover, the entire sequences can be used directly to synthesize DNA probes by methods known to the skilled artisan such as random primer DNA labeling,

nick translation, or end-labeling techniques, or RNA probes using available *in vitro* transcription systems. In addition, specific primers can be designed and used to amplify a part or all of the instant sequences. The resulting amplification products can be labeled directly during amplification reactions or labeled after amplification reactions, and used as probes to isolate full length cDNA or genomic fragments under conditions of appropriate stringency.

In addition, two short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols to amplify longer nucleic acid fragments encoding homologous genes from DNA or RNA. The polymerase chain reaction may also be performed on a library of cloned nucleic acid fragments wherein the sequence of one primer is derived from the instant nucleic acid fragments, and the sequence of the other primer takes advantage of the presence of the polyadenylic acid tracts to the 3' end of the mRNA precursor encoding plant genes. Alternatively, the second primer sequence may be based upon sequences derived from the cloning vector. For example, the skilled artisan can follow the RACE protocol (Frohman et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:8998-9002) to generate cDNAs by using PCR to amplify copies of the region between a single point in the transcript and the 3' or 5' end. Primers oriented in the 3' and 5' directions can be designed from the instant sequences. Using commercially available 3' RACE or 5' RACE systems (BRL), specific 3' or 5' cDNA fragments can be isolated (Ohara et al. (1989) *Proc. Natl. Acad. Sci. USA* 86:5673-5677; Loh et al. (1989) *Science* 243:217-220). Products generated by the 3' and 5' RACE procedures can be combined to generate full-length cDNAs (Frohman and Martin (1989) *Techniques* 1:165). Consequently, a polynucleotide comprising a nucleotide sequence of at least one of 60 (preferably one of at least 40, most preferably one of at least 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of:

(a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide, and/or

(b) SEQ ID NOs:19, 21, 23, 53, 55 and 57 and the complement of such nucleotide sequences may be used in such methods to obtain a nucleic acid fragment encoding a substantial portion of an amino acid sequence of a polypeptide.

The present invention relates to a method of obtaining a nucleic acid fragment encoding a substantial portion of an LPAAT isozyme polypeptide preferably a substantial portion of a plant LPAAT isozyme polypeptide, comprising the steps of: synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 60 (preferably at least one of 40, most preferably at least one of 30) contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of:

(a) SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences; and/or

(b) SEQ ID NOs:19, 21, 23, 53, 55 and 57 and the complement of such nucleotide sequences.

- 5 and amplifying a nucleic acid fragment (preferably a cDNA inserted in a cloning vector) using the oligonucleotide primer. The amplified nucleic acid fragment preferably will encode a portion of an LPAAT isozyme polypeptide.

Availability of the instant nucleotide and deduced amino acid sequences facilitates immunological screening of cDNA expression libraries. Synthetic peptides representing
10 portions of the instant amino acid sequences may be synthesized. These peptides can be used to immunize animals to produce polyclonal or monoclonal antibodies with specificity for peptides or proteins comprising the amino acid sequences. These antibodies can be then be used to screen cDNA expression libraries to isolate full-length cDNA clones of interest (Lerner (1984) *Adv. Immunol.* 36:1-34; Maniatis).

- 15 In another embodiment, this invention concerns host cells comprising either the chimeric genes of the invention as described herein or an isolated polynucleotide of the invention as described herein. Examples of host cells which can be used to practice the invention include, but are not limited to, yeast, bacteria, plants, and viruses.

As was noted above, the nucleic acid polynucleotides of the instant invention may be
20 used to create transgenic plants in which the disclosed polypeptides are present at higher or lower levels than normal or in cell types or developmental stages in which they are not normally found. This would have the effect of altering the level of specific triacylglycerols in those cells. For example overexpression of an LPAAT similar to the maize LPAAT, such as those contained in Example 6, will result in higher oil content in the seed, stem and leaf
25 while overexpression of LPAAT similar to *Burkholderia pseudomallei* will result in larger accumulation of oil in seed.

Overexpression of the proteins of the instant invention may be accomplished by first constructing a chimeric gene in which the coding region is operably linked to a promoter capable of directing expression of a gene in the desired tissues at the desired stage of
30 development. The chimeric gene may comprise promoter sequences and translation leader sequences derived from the same genes. 3' Non-coding sequences encoding transcription termination signals may also be provided. The instant chimeric gene may also comprise one or more introns in order to facilitate gene expression.

Plasmid vectors comprising the isolated polynucleotide (or chimeric gene) may be
35 constructed. The choice of plasmid vector is dependent upon the method that will be used to transform host plants. The skilled artisan is well aware of the genetic elements that must be present on the plasmid vector in order to successfully transform, select and propagate host cells containing the chimeric gene. The skilled artisan will also recognize that different

independent transformation events will result in different levels and patterns of expression (Jones et al. (1985) *EMBO J.* 4:2411-2418; De Almeida et al. (1989) *Mol. Gen. Genetics* 218:78-86), and thus that multiple events must be screened in order to obtain lines displaying the desired expression level and pattern. Such screening may be accomplished by Southern analysis of DNA, Northern analysis of mRNA expression, Western analysis of protein expression, or phenotypic analysis.

For some applications it may be useful to direct the instant polypeptides to different cellular compartments, or to facilitate its secretion from the cell. It is thus envisioned that the chimeric gene described above may be further supplemented by directing the coding sequence to encode the instant polypeptides with appropriate intracellular targeting sequences such as transit sequences (Keegstra (1989) *Cell* 56:247-253), signal sequences or sequences encoding endoplasmic reticulum localization (Chrispeels (1991) *Ann. Rev. Plant Phys. Plant Mol. Biol.* 42:21-53), or nuclear localization signals (Raikhel (1992) *Plant Phys.* 100:1627-1632) with or without removing targeting sequences that are already present. While the references cited give examples of each of these, the list is not exhaustive and more targeting signals of use may be discovered in the future.

It may also be desirable to reduce or eliminate expression of genes encoding the instant polypeptides in plants for some applications. In order to accomplish this, a chimeric gene designed for co-suppression of the instant polypeptide can be constructed by linking a gene or gene fragment encoding that polypeptide to plant promoter sequences.

Alternatively, a chimeric gene designed to express antisense RNA for all or part of the instant nucleic acid fragment can be constructed by linking the gene or gene fragment in reverse orientation to plant promoter sequences. Either the co-suppression or antisense chimeric genes could be introduced into plants via transformation wherein expression of the corresponding endogenous genes are reduced or eliminated.

Molecular genetic solutions to the generation of plants with altered gene expression have a decided advantage over more traditional plant breeding approaches. Changes in plant phenotypes can be produced by specifically inhibiting expression of one or more genes by antisense inhibition or cosuppression (U.S. Patent Nos. 5,190,931, 5,107,065 and 5,283,323). An antisense or cosuppression construct would act as a dominant negative regulator of gene activity. While conventional mutations can yield negative regulation of gene activity these effects are most likely recessive. The dominant negative regulation available with a transgenic approach may be advantageous from a breeding perspective. In addition, the ability to restrict the expression of specific phenotype to the reproductive tissues of the plant by the use of tissue specific promoters may confer agronomic advantages relative to conventional mutations which may have an effect in all tissues in which a mutant gene is ordinarily expressed.

The person skilled in the art will know that special considerations are associated with the use of antisense or cosuppression technologies in order to reduce expression of particular genes. For example, the proper level of expression of sense or antisense genes may require the use of different chimeric genes utilizing different regulatory elements known to the skilled artisan. Once transgenic plants are obtained by one of the methods described above, it will be necessary to screen individual transgenics for those that most effectively display the desired phenotype. Accordingly, the skilled artisan will develop methods for screening large numbers of transformants. The nature of these screens will generally be chosen on practical grounds. For example, one can screen by looking for changes in gene expression by using antibodies specific for the protein encoded by the gene being suppressed, or one could establish assays that specifically measure enzyme activity. A preferred method will be one which allows large numbers of samples to be processed rapidly, since it will be expected that a large number of transformants will be negative for the desired phenotype.

In another embodiment, the present invention concerns an polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

In still another embodiment, the present invention also concerns a polypeptide of at least 100 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

The instant polypeptides (or portions thereof) may be produced in heterologous host cells, particularly in the cells of microbial hosts, and can be used to prepare antibodies to the these proteins by methods well known to those skilled in the art. The antibodies are useful for detecting the polypeptides of the instant invention *in situ* in cells or *in vitro* in cell extracts. Preferred heterologous host cells for production of the instant polypeptides are microbial hosts. Microbial expression systems and expression vectors containing regulatory sequences that direct high level expression of foreign proteins are well known to those skilled in the art. Any of these could be used to construct a chimeric gene for production of the instant polypeptides. This chimeric gene could then be introduced into appropriate microorganisms via transformation to provide high level expression of the encoded LPAAT isozyme. An example of a vector for high level expression of the instant polypeptides in a bacterial host is provided (Example 9).

All or a substantial portion of the polynucleotides of the instant invention may also be used as probes for genetically and physically mapping the genes that they are a part of, and as markers for traits linked to those genes. Such information may be useful in plant breeding in order to develop lines with desired phenotypes. For example, the instant nucleic acid fragments may be used as restriction fragment length polymorphism (RFLP) markers.

Southern blots (Maniatis) of restriction-digested plant genomic DNA may be probed with the nucleic acid fragments of the instant invention. The resulting banding patterns may then be subjected to genetic analyses using computer programs such as MapMaker (Lander et al. (1987) *Genomics* 1:174-181) in order to construct a genetic map. In addition, the nucleic acid fragments of the instant invention may be used to probe Southern blots containing restriction endonuclease-treated genomic DNAs of a set of individuals representing parent and progeny of a defined genetic cross. Segregation of the DNA polymorphisms is noted and used to calculate the position of the instant nucleic acid sequence in the genetic map previously obtained using this population (Botstein et al. (1980) *Am. J. Hum. Genet.* 32:314-331).

The production and use of plant gene-derived probes for use in genetic mapping is described in Bernatzky and Tanksley (1986) *Plant Mol. Biol. Reporter* 4:37-41. Numerous publications describe genetic mapping of specific cDNA clones using the methodology outlined above or variations thereof. For example, F2 intercross populations, backcross populations, randomly mated populations, near isogenic lines, and other sets of individuals may be used for mapping. Such methodologies are well known to those skilled in the art.

Nucleic acid probes derived from the instant nucleic acid sequences may also be used for physical mapping (i.e., placement of sequences on physical maps; see Hoheisel et al. In: *Nonmammalian Genomic Analysis: A Practical Guide*, Academic press 1996, pp. 319-346, and references cited therein).

In another embodiment, nucleic acid probes derived from the instant nucleic acid sequences may be used in direct fluorescence *in situ* hybridization (FISH) mapping (Trask (1991) *Trends Genet.* 7:149-154). Although current methods of FISH mapping favor use of large clones (several to several hundred KB; see Laan et al. (1995) *Genome Res.* 5:13-20), improvements in sensitivity may allow performance of FISH mapping using shorter probes.

A variety of nucleic acid amplification-based methods of genetic and physical mapping may be carried out using the instant nucleic acid sequences. Examples include allele-specific amplification (Kazazian (1989) *J. Lab. Clin. Med.* 11:95-96), polymorphism of PCR-amplified fragments (CAPS; Sheffield et al. (1993) *Genomics* 16:325-332), allele-specific ligation (Landegren et al. (1988) *Science* 241:1077-1080), nucleotide extension reactions (Sokolov (1990) *Nucleic Acid Res.* 18:3671), Radiation Hybrid Mapping (Walter et al. (1997) *Nat. Genet.* 7:22-28) and Happy Mapping (Dear and Cook (1989) *Nucleic Acid Res.* 17:6795-6807). For these methods, the sequence of a nucleic acid fragment is used to design and produce primer pairs for use in the amplification reaction or in primer extension reactions. The design of such primers is well known to those skilled in the art. In methods employing PCR-based genetic mapping, it may be necessary to identify DNA sequence differences between the parents of the mapping cross in the region corresponding to the

instant nucleic acid sequence. This, however, is generally not necessary for mapping methods.

Loss of function mutant phenotypes may be identified for the instant cDNA clones either by targeted gene disruption protocols or by identifying specific mutants for these genes contained in a maize population carrying mutations in all possible genes (Ballinger and Benzer (1989) *Proc. Natl. Acad. Sci USA* 86:9402-9406; Koes et al. (1995) *Proc. Natl. Acad. Sci USA* 92:8149-8153; Bensen et al. (1995) *Plant Cell* 7:75-84). The latter approach may be accomplished in two ways. First, short segments of the instant nucleic acid fragments may be used in polymerase chain reaction protocols in conjunction with a mutation tag sequence primer on DNAs prepared from a population of plants in which Mutator transposons or some other mutation-causing DNA element has been introduced (see Bensen, *supra*). The amplification of a specific DNA fragment with these primers indicates the insertion of the mutation tag element in or near the plant gene encoding the instant polypeptides. Alternatively, the instant nucleic acid fragment may be used as a hybridization probe against PCR amplification products generated from the mutation population using the mutation tag sequence primer in conjunction with an arbitrary genomic site primer, such as that for a restriction enzyme site-anchored synthetic adaptor. With either method, a plant containing a mutation in the endogenous gene encoding the instant polypeptides can be identified and obtained. This mutant plant can then be used to determine or confirm the natural function of the instant polypeptides disclosed herein.

EXAMPLES

The present invention is further defined in the following Examples, in which all parts and percentages are by weight and degrees are Celsius, unless otherwise stated. It should be understood that these Examples, while indicating preferred embodiments of the invention, are given by way of illustration only. From the above discussion and these Examples, one skilled in the art can ascertain the essential characteristics of this invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. Thus, various modifications of the invention in addition to those shown and described herein will be apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

The disclosure of each reference set forth above is incorporated herein by reference in its entirety.

EXAMPLE 1

Composition of cDNA Libraries; Isolation and Sequencing of cDNA Clones

cDNA libraries representing mRNAs from various *Arabidopsis*, catalpa, corn, rice, sorghum, soybean, and wheat tissues were prepared. The characteristics of the libraries are described below.

TABLE 2

cDNA Libraries from Arabidopsis, Catalpa, Corn,
Rice, Sorghum, Soybean, and Wheat

Library	Tissue	Clone
ads1c	<i>Arabidopsis Wassilewskija</i> 6 day old seedlings	ads1c.pk005.i10
cca	Corn Callus Type II Tissue, Undifferentiated, Highly Transformable	cca.pk0027.c9
ccoln	Corn Cob of 67 Day Old Plants Grown in Green House ¹	ccoln.pk062.p19:fis
ceb1	Corn Embryo 10 to 11 Days After Pollination	ceb1.mn0001.d12:fis
ceb1	Corn Embryo 10 to 11 Days After Pollination	ceb1.pk0011.d11
ceb5	Corn Embryo 30 Days After Pollination	ceb5.pk0049.b3
ceb5	Corn Embryo 30 Days After Pollination	ceb5.pk0053.e3
cen3n	Corn Endosperm 20 Days After Pollination ¹	cen3n.pk0027.f6
cpe1c	Corn pooled BMS treated with chemicals related to phosphatase ²	cpe1c.pk006.e1
gds1c	Sorghum Seed 20 Days After Pollination	gds1c.pk002.a19:fis
ncs	<i>Catalpa speciosa</i> Developing Seed	ncs.pk0009.f12:fis
ncs	<i>Catalpa speciosa</i> Developing Seed	ncs.pk0013.d2:fis
p0010	Corn Log Phase Suspension Cells Treated With A23187 ³ to Induce Mass Apoptosis	p0010.cbpbq45r
p0018	Corn Seedling After 10 Day Drought, Heat Shocked for 24 Hours, Harvested After Recovery at Normal Growth Conditions for 8 Hours	p0018.chssd06r
p0018	Corn Seedling After 10 Day Drought, Heat Shocked for 24 Hours, Harvested After Recovery at Normal Growth Conditions for 8 Hours	p0018.chstw94r
p0094	Corn Leaf Collars for the Ear Leaf (EL) and the Next Leaf Above and Below the EL ¹	p0094.csssl20r
p0104	Corn Roots V5 Stage ⁴ , Corn Root Worm Infested ¹	p0104.cabbd29r
rlr2	Rice Leaf 15 Days After Germination, 2 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant	rlr2.pk0028.d6:fis
rlr24	Rice Leaf 15 Days After Germination, 24 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant	rlr24.pk0068.e3
rlr6	Rice Leaf 15 Days After Germination, 6 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-62 (AVR2-YAMO); Resistant	rlr6.pk0094.f6:fis
rls6	Rice Leaf 15 Days After Germination, 6 Hours After Infection of Strain <i>Magaporthe grisea</i> 4360-R-67 (AVR2-YAMO); Susceptible	rls6.pk0076.d5
rr1	Rice Root of Two Week Old Developing Seedling	rr1.pk0004.a10

Library	Tissue	Clone
rr1	Rice Root of Two Week Old Developing Seedling	rr1.pk0039.e10
scb1c	Soybean Embryogenic Suspension Culture Subjected to — 4 Bombardments and Collected 12 Hours Later	scb1c.pk003.d18
sdp4c	Soybean Developing Pods (10-12 mm)	sdp4c.pk006.n11:fis
se4	Soybean Embryo, 19 Days After Flowering	se4.cp0008.b2
sgs1c	Soybean Seeds 4 Hours After Germination	sgs1c.pk001.i16
sgs1c	Soybean Seeds 4 Hours After Germination	sgs1c.pk005.k7
sgs5c	Soybean Seeds 4 Days After Germination	sgs5c.pk0003.e7
sl2	Soybean Two-Week-Old Developing Seedlings Treated With 2.5 ppm chlorimuron	sl2.pk0033.c1
sl2	Soybean Two-Week-Old Developing Seedlings Treated With 2.5 ppm chlorimuron	sl2.pk121.a19
wle1n	Wheat Leaf From 7 Day Old Etiolated Seedling ¹	wle1n.pk0002.g3
wlk1	Wheat Seedlings 1 Hour After Treatment With Herbicide ⁵	wlk1.pk0004.e7
wlm1	Wheat Seedlings 1 Hour After Inoculation With <i>Erysiphe graminis f. sp tritici</i>	wlm1.pk0018.g6
wre1n	Wheat Root From 7 Day Old Etiolated Seedling ¹	wre1n.pk0027.d4
wre1n	Wheat Root From 7 Day Old Etiolated Seedling ¹	wre1n.pk0040.h11
wre1n	Wheat Root From 7 Day Old Etiolated Seedling ¹	wre1n.pk0064.g7

¹These libraries were normalized essentially as described in U.S. Patent No. 5,482,845, the disclosure of which is hereby incorporated by reference.

²Chemicals used included okadaic acid, cyclosporin A, calyculin A, cypermethrin.

5 ³A23187 is commercially available from several vendors including Calbiochem.

⁴Corn developmental stages are explained in the publication "How a corn plant develops" from the Iowa State University Coop. Ext. Service Special Report No. 48 reprinted June 1993.

10 ⁵Application of 6-iodo-2-propoxy-3-propyl-4(3H)-quinazolinone; synthesis and methods of using this compound are described in USSN 08/545,827, the disclosure of which is hereby incorporated by reference.

cDNA libraries may be prepared by any one of many methods available. For example, the cDNAs may be introduced into plasmid vectors by first preparing the cDNA
15 libraries in Uni-ZAP™ XR vectors according to the manufacturer's protocol (Stratagene Cloning Systems, La Jolla, CA). The Uni-ZAP™ XR libraries are converted into plasmid libraries according to the protocol provided by Stratagene. Upon conversion, cDNA inserts will be contained in the plasmid vector pBluescript. In addition, the cDNAs may be
20 introduced directly into pre-cut Bluescript II SK(+) vectors (Stratagene) using T4 DNA ligase (New England Biolabs), followed by transfection into DH10B cells according to the manufacturer's protocol (GIBCO BRL Products). Once the cDNA inserts are in plasmid

vectors, plasmid DNAs are prepared from randomly picked bacterial colonies containing recombinant pBluescript plasmids, or the insert cDNA sequences are amplified via polymerase chain reaction using primers specific for vector sequences flanking the inserted cDNA sequences. Amplified insert DNAs or plasmid DNAs are sequenced in dye-primer
5 sequencing reactions to generate partial cDNA sequences (expressed sequence tags or "ESTs"; see Adams et al., (1991) *Science* 252:1651-1656). The resulting ESTs are analyzed using a Perkin Elmer Model 377 fluorescent sequencer.

EXAMPLE 2

Identification of cDNA Clones

10 cDNA clones encoding LPAAT isozymes were identified by conducting BLAST (Basic Local Alignment Search Tool; Altschul et al. (1993) *J. Mol. Biol.* 215:403-410; see also www.ncbi.nlm.nih.gov/BLAST/) searches for similarity to sequences contained in the BLAST "nr" database (comprising all non-redundant GenBank CDS translations, sequences derived from the 3-dimensional structure Brookhaven Protein Data Bank, the last major
15 release of the SWISS-PROT protein sequence database, EMBL, and DDBJ databases). The cDNA sequences obtained in Example 1 were analyzed for similarity to all publicly available DNA sequences contained in the "nr" database using the BLASTN algorithm provided by the National Center for Biotechnology Information (NCBI). The DNA sequences were translated in all reading frames and compared for similarity to all publicly
20 available protein sequences contained in the "nr" database using the BLASTX algorithm (Gish and States (1993) *Nat. Genet.* 3:266-272) provided by the NCBI. For convenience, the P-value (probability) of observing a match of a cDNA sequence to a sequence contained in the searched databases merely by chance as calculated by BLAST are reported herein as "pLog" values, which represent the negative of the logarithm of the reported P-value.
25 Accordingly, the greater the pLog value, the greater the likelihood that the cDNA sequence and the BLAST "hit" represent homologous proteins.

EXAMPLE 3

Characterization of cDNA Clones Encoding Proteins

Similar to *Mus musculus* LPAAT

30 The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the proteins encoded by the cDNAs to an unknown protein from *Caenorhabditis elegans* and a putative LPAAT protein from *Mus musculus* (NCBI General Identifier Nos. 3878960 and 2317725, respectively). Shown in Table 3 are the BLAST results for individual ESTs ("EST") or for the sequences of contigs assembled from two or
35 more ESTs ("Contig"):

TABLE 3

BLAST Results for Sequences Encoding Polypeptides
Homologous to *Mus musculus* LPAAT

Clone	Status	BLAST pLog Score	
		3878960	2317725
Contig of: p0018.chssd06r p0104.cabbd29r cca.pk0027.c9 p0018.chstw94r p0094.csssl20r	Contig	59.40	57.70
sl2.pk121.a19	EST	15.22	10.09
Contig of: wlm1.pk0018.g6 wre1n.pk0040.h11 wre1n.pk0064.g7	Contig	54.30	50.52

- 5 The sequence of the entire cDNA insert in clones p0018.chssd06r and sl2.pk121.a19 was determined. Further sequencing and analysis of the DuPont proprietary EST database allowed the identification of catalpa, rice, and sorghum clones encoding polypeptides with similarities to *Mus musculus* LPAAT. The BLAST search using the sequences from clones listed in Table 4 revealed similarity of the proteins encoded by the cDNAs to an unknown
- 10 protein from *Caenorhabditis elegans* and a putative LPAAT protein from *Mus musculus* (NCBI General Identifier Nos. 3878960 and 2317725, respectively). Shown in Table 4 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of the entire protein encoded by a contig assembled from an FIS and one or more ESTs ("Contig*"), or the sequences of the entire protein
- 15 encoded by an FIS ("CGS"):

TABLE 4

BLAST Results for Sequences Encoding Polypeptides
Homologous to *Mus musculus* LPAAT

Clone	Status	BLAST pLog Score	
		3878960	2317725
ncs.pk0013.d2:fis	CGS	56.40	54.15
Contig of: ceb1.pk0011.d11 ceb5.pk0053.e3 p0010.cbpbq45r p0018.chssd06r:fis	Contig*	58.00	55.04
rlr2.pk0028.d6:fis	CGS	57.70	55.40
gdslc.pk002.a19:fis	FIS	58.10	45.52
sl2.pk121.a19:fis	CGS	57.70	53.00

In this type of plant LPAAT domain I consists of amino acids Asn-His-Thr-Ser-Met-Ile-Asp-Phe-Ile and domain II (62 amino acids downstream) consists of amino acids Leu-Ile-Phe-Pro-Glu-Gly-Thr-Cys.

5 The data in Table 5 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:2, 4, 6, 26, 28, 30, 32, and 34 and the *Caenorhabditis elegans* and *Mus musculus* sequences (NCBI General Identifier Nos. 3878960 and 2317725, respectively).

TABLE 5

10 Percent Identity of Amino Acid Sequences Deduced From the Nucleotide Sequences of cDNA Clones Encoding Polypeptides Homologous to *Mus musculus* LPAAT

SEQ ID NO.	Percent Identity to	
	3878960	2317725
2	38.5	35.1
4	39.3	29.9
6	39.8	35.9
26	31.8	35.4
28	32.1	36.1
30	31.9	37.4
32	33.5	36.1
34	32.2	35.4

15 Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3,
20 WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a corn, a sorghum, a soybean and a wheat LPAAT and entire catalpa, corn, rice, and soybean LPAAT proteins. These sequences represent the first catalpa, corn, rice, soybean, and wheat sequences encoding LPAAT proteins of this type.

25 EXAMPLE 4

Characterization of cDNA Clones Encoding LPAATs Similar to
Burkholderia pseudomallei LPAAT

The BLASTX search using the EST sequences from clones listed in Table 3 revealed similarity of the polypeptides encoded by the cDNAs to LPAAT from *Burkholderia*

pseudomallei (NCBI General Identifier No. 3135672). Shown in Table 6 are the BLAST results for individual ESTs ("EST") the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or for the sequences of contigs assembled from two or more ESTs ("Contig"):

TABLE 6

BLAST Results for Sequences Encoding Polypeptides Homologous to *Burkholderia pseudomallei* LPAAT

Clone	Status	BLAST pLog Score
		3135672
Contig of: ceb5.pk0049.b3 cen3n.pk0027.f6	Contig	9.52
sgs1c.pk001.i16	FIS	9.30
wre1n.pk0027.d4	EST	4.00

The sequence of the entire cDNA insert from clone wre1n.pk0027.d4 was determined. Further sequencing and analysis of the DuPont proprietary database allowed the identification of a catalpa clone with similarity to the *Burkholderia pseudomallei* LPAAT. The BLAST search using the sequences from clones listed in Table 7 revealed similarity of the polypeptides encoded by the *Arabidopsis thaliana* contig to similar to acyltransferase (NCBI General Identifier No. 6503307) and of the cDNAs to LPAAT from *Burkholderia pseudomallei* (NCBI General Identifier No. 3135672). Shown in Table 7 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones encoding the entire protein ("CGS"):

TABLE 7

BLAST Results for Sequences Encoding Polypeptides Homologous to *Burkholderia pseudomallei* LPAAT

Clone	Status	BLAST pLog Score	
		6503307	3135672
ncs.pk0009.f12: fis	CGS	87.00	10.22
wre1n.pk0027.d4: fis	CGS	83.52	11.40

In this type of plant LPAAT domain I consists of amino acids Asn-His-(Val or Ile)-Ser-Tyr-(Val, Ile, or Leu)-Asp-Ile-Leu and domain II (62 amino acids downstream) consists of amino acids Xaa1-(Leu or Ile)-Phe-Pro-Glu-Gly-Thr-Thr, where Xaa1 is Leu, Ile, Met or Tyr.

The data in Table 8 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs: 8, 10, 12, 36, and 38 and the *Burkholderia pseudomallei* sequence (NCBI General Identifier No. 3135672).

TABLE 8

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide
Sequences of cDNA Clones Encoding Polypeptides
Homologous to *Burkholderia pseudomallei* LPAAT

SEQ ID NO.	Percent Identity to 3135672
8	19.8
10	17.6
12	17.4
36	219.1
38	20.3

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS*, 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of a wheat LPAAT and entire corn, catalpa, soybean, and wheat LPAAT proteins. These sequences represent the first corn, catalpa, soybean, and wheat sequences encoding LPAATs of this type.

EXAMPLE 5

Characterization of cDNA Clones Encoding Putative LPAATs

The BLASTX search using the EST sequences from clones listed in Table 9 revealed similarity of the polypeptides encoded by the contig to an unknown protein from *Arabidopsis thaliana* (NCBI General Identifier No. 2979560). Shown in Table 9 are the BLAST results for individual ESTs ("EST"), the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), or the sequences of contigs assembled from two or more ESTs ("Contig"):

TABLE 9

BLAST Results for Sequences Encoding Polypeptides
Homologous to LPAATs

Clone	Status	BLAST pLog Score 2979560
ads1c.pk005.i10	FIS	52.00
Contig of: rls6.pk0076.d5 rlr24.pk0068.e3	Contig	22.70
scb1c.pk003.d18	EST	45.04

5 The sequence of the entire cDNA insert in clones rls6.pk0076.d5 and scb1c.pk003.d18 was determined. Further sequencing and analysis of the DuPont proprietary database allowed the identification of corn clones with similarities to the *Arabidopsis thaliana* putative protein. The BLAST search using the sequences from clones listed in Table 10 revealed similarity of the polypeptides encoded by the contig to an unknown protein from
10 *Arabidopsis thaliana* (NCBI General Identifier No. 2979560). Shown in Table 10 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), or the sequences of an FIS encoding the entire protein ("CGS"):

TABLE 10

BLAST Results for Sequences Encoding Polypeptides
Homologous to LPAATs

Clone	Status	BLAST pLog Score 2979560
Contig of: ceb1.mn0001.d12:fls cpe1c.pk006.e1	Contig	21.70
rls6.pk0076.d5:fls	FIS	67.52
scb1c.pk003.d18:fls	CGS	81.00

20 In this type of plant LPAATs domain I includes the amino acids Ser-Asn-His-(Val or Ile)-Ser-Tyr-Ile-Glu-Pro-Ile and domain II (61 amino acids downstream) includes the amino acids Leu-Leu-Phe-Pro-Glu-Gly-Thr-Thr-Thr.

25 The BLAST search using the sequences from clones listed in Table 11 revealed similarity of the polypeptides encoded by the contig to a member of the acyltransferase family from *Arabidopsis thaliana* (NCBI General Identifier No. 6503307). Shown in Table 11 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones ("FIS"), the sequences of contigs assembled from two or more ESTs ("Contig"), or the sequences of the entire protein encoded by an FIS ("CGS"):

TABLE 11

BLAST Results for Sequences Encoding Polypeptides
Homologous to LPAATs

Clone	Status	BLAST pLog Score 6503307
cco1n.pk062.p19:fis	CGS	119.00
rlr6.pk0094.f6:fis	CGS	111.00
sdp4c.pk006.n11:fis	FIS	95.52
Contig of: sgs1c.pk005.k7 sgs5c.pk0003.e7	Contig	6.52

5

In this type of plant LPAATs domain I includes the amino acids Ser-Asn-His-Val-Ser-Tyr-(Val or Leu)-Asp-Ile-Leu and domain II (61 amino acids downstream) includes the amino acids Leu-Phe-Pro-Glu-Gly-Thr-Thr-Thr.

10 The data in Table 12 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:14, 16, 18, 40, 42, 44, 46, 48, 50, and 52 and the *Arabidopsis thaliana* sequences (NCBI General Identifier No. 6503307).

TABLE 12

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide
Sequences of cDNA Clones Encoding Polypeptides
Homologous to LPAATs

15

SEQ ID NO.	Percent Identity to	
	2979560	6503307
14	36.3	13.2
16	32.8	13.8
18	65.4	16.8
40	27.0	21.1
42	50.2	16.9
44	65.4	19.7
46	18.0	54.6
48	18.1	52.5
50	11.2	63.7
52	12.4	19.5

20 Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default

parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones encode a substantial portion of an *Arabidopsis*, a corn, a rice, and a soybean LPAAT and an entire soybean LPAAT. These sequences represent the first corn, rice, soybean, and *Arabidopsis* sequences encoding LPAAT of this type.

EXAMPLE 6

Characterization of cDNA Clones Encoding Proteins

Similar to *Zea mays* LPAAT

The BLASTX search using the EST sequences from clones listed in Table 13 revealed similarity of the polypeptides encoded by the cDNAs to LPAAT from *Zea mays* (NCBI General Identifier No. 575960). Shown in Table 13 are the BLAST results for the sequences of contigs assembled from two or more ESTs ("Contig"):

TABLE 13

BLAST Results for Sequences Encoding Polypeptides
Homologous to *Zea mays* LPAAT

Clone	Status	BLAST pLog Score 575960
Contig of: rr1.pk0004.a10 rr1.pk0039.e10	Contig	57.70
Contig of: se4.cp0008.b2 sl2.pk0033.c1	Contig	67.15
Contig of: wlk1.pk0004.e7 wle1n.pk0002.g3	Contig	78.70

The sequence of the entire cDNA insert in clones rr1.pk0004.a10, sl2.pk0033.c1, and wlk1.pk0004.e7 was determined. The BLASTP search using the amino acid sequences from clones listed in Table 14 revealed similarity of the polypeptides encoded by the cDNAs to LPAATs from *Zea mays* and *Brassica napus* (NCBI General Identifier Nos. 1076821 and 4583544, respectively). Shown in Table 14 are the BLAST results for the sequences of the entire cDNA inserts comprising the indicated cDNA clones encoding the entire protein ("CGS"):

TABLE 14

BLAST Results for Sequences Encoding Polypeptides
Homologous to *Zea mays* LPAAT

Clone	Status	BLAST pLog Score	
		1076821	4583544
rr1.pk0004.a10:fis	CGS	> 254.00	149.00
sl2.pk0033.c1:fis	CGS	169.00	175.00
wlk1.pk0004.e7:fis	CGS	> 254.00	148.00

5 In this type of plant LPAAT domain I consists of amino acids Ser-Asn-His-Arg-Ser-Asp-Ile-Asp-Trp-Leu and domain II (69 amino acids downstream) consists of amino acids Ala-Leu-Phe-Val-Glu-Gly-Thr-Arg-Phe.

The data in Table 15 represents a calculation of the percent identity of the amino acid sequences set forth in SEQ ID NOs:20, 22, 24, 54, 56, and 58 and the *Zea mays* sequence
10 (NCBI General Identifier Nos. 1076821).

TABLE 15

Percent Identity of Amino Acid Sequences Deduced From the Nucleotide
Sequences of cDNA Clones Encoding Polypeptides Homologous
15 to *Zea mays* LPAAT

SEQ ID NO.	Percent Identity to 1076821
20	72.6
22	72.4
24	73.1
54	91.2
56	70.1
58	84.8

Sequence alignments and percent identity calculations were performed using the Megalign program of the LASERGENE bioinformatics computing suite (DNASTAR Inc., Madison, WI). Multiple alignment of the sequences was performed using the Clustal
20 method of alignment (Higgins and Sharp (1989) *CABIOS* 5:151-153) with the default parameters (GAP PENALTY=10, GAP LENGTH PENALTY=10). Default parameters for pairwise alignments using the Clustal method were KTUPLE 1, GAP PENALTY=3, WINDOW=5 and DIAGONALS SAVED=5. Sequence alignments and BLAST scores and probabilities indicate that the nucleic acid fragments comprising the instant cDNA clones
25 encode a substantial portion of and an entire rice, soybean, and wheat LPAAT. These sequences represent the first rice, soybean, and wheat sequences encoding LPAATs of this type.

EXAMPLE 7

Expression of Chimeric Genes in Monocot Cells

A chimeric gene comprising a cDNA encoding the instant polypeptides in sense orientation with respect to the maize 27 kD zein promoter that is located 5' to the cDNA fragment, and the 10 kD zein 3' end that is located 3' to the cDNA fragment, can be constructed. The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites (NcoI or SmaI) can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the digested vector pML103 as described below. Amplification is then performed in a standard PCR. The amplified DNA is then digested with restriction enzymes NcoI and SmaI and fractionated on an agarose gel. The appropriate band can be isolated from the gel and combined with a 4.9 kb NcoI-SmaI fragment of the plasmid pML103. Plasmid pML103 has been deposited under the terms of the Budapest Treaty at ATCC (American Type Culture Collection, 10801 University Blvd., Manassas, VA 20110-2209), and bears accession number ATCC 97366. The DNA segment from pML103 contains a 1.05 kb SalI-NcoI promoter fragment of the maize 27 kD zein gene and a 0.96 kb SmaI-SalI fragment from the 3' end of the maize 10 kD zein gene in the vector pGem9Zf(+) (Promega). Vector and insert DNA can be ligated at 15°C overnight, essentially as described (Maniatis). The ligated DNA may then be used to transform *E. coli* XL1-Blue (Epicurian Coli XL-1 Blue™; Stratagene). Bacterial transformants can be screened by restriction enzyme digestion of plasmid DNA and limited nucleotide sequence analysis using the dideoxy chain termination method (Sequenase™ DNA Sequencing Kit; U.S. Biochemical). The resulting plasmid construct would comprise a chimeric gene encoding, in the 5' to 3' direction, the maize 27 kD zein promoter, a cDNA fragment encoding the instant polypeptides, and the 10 kD zein 3' region.

The chimeric gene described above can then be introduced into corn cells by the following procedure. Immature corn embryos can be dissected from developing caryopses derived from crosses of the inbred corn lines H99 and LH132. The embryos are isolated 10 to 11 days after pollination when they are 1.0 to 1.5 mm long. The embryos are then placed with the axis-side facing down and in contact with agarose-solidified N6 medium (Chu et al. (1975) *Sci. Sin. Peking* 18:659-668). The embryos are kept in the dark at 27°C. Friable embryogenic callus consisting of undifferentiated masses of cells with somatic proembryoids and embryoids borne on suspensor structures proliferates from the scutellum of these immature embryos. The embryogenic callus isolated from the primary explant can be cultured on N6 medium and sub-cultured on this medium every 2 to 3 weeks.

The plasmid, p35S/Ac (obtained from Dr. Peter Eckes, Hoechst Ag, Frankfurt, Germany) may be used in transformation experiments in order to provide for a selectable marker. This plasmid contains the *Pat* gene (see European Patent Publication 0 242 236)

which encodes phosphinothricin acetyl transferase (PAT). The enzyme PAT confers resistance to herbicidal glutamine synthetase inhibitors such as phosphinothricin. The *pat* gene in p35S/Ac is under the control of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*.

The particle bombardment method (Klein et al. (1987) *Nature* 327:70-73) may be used to transfer genes to the callus culture cells. According to this method, gold particles (1 μ m in diameter) are coated with DNA using the following technique. Ten μ g of plasmid DNAs are added to 50 μ L of a suspension of gold particles (60 mg per mL). Calcium chloride (50 μ L of a 2.5 M solution) and spermidine free base (20 μ L of a 1.0 M solution) are added to the particles. The suspension is vortexed during the addition of these solutions. After 10 minutes, the tubes are briefly centrifuged (5 sec at 15,000 rpm) and the supernatant removed. The particles are resuspended in 200 μ L of absolute ethanol, centrifuged again and the supernatant removed. The ethanol rinse is performed again and the particles resuspended in a final volume of 30 μ L of ethanol. An aliquot (5 μ L) of the DNA-coated gold particles can be placed in the center of a Kapton™ flying disc (Bio-Rad Labs). The particles are then accelerated into the corn tissue with a Biolistic™ PDS-1000/He (Bio-Rad Instruments, Hercules CA), using a helium pressure of 1000 psi, a gap distance of 0.5 cm and a flying distance of 1.0 cm.

For bombardment, the embryogenic tissue is placed on filter paper over agarose-solidified N6 medium. The tissue is arranged as a thin lawn and covered a circular area of about 5 cm in diameter. The petri dish containing the tissue can be placed in the chamber of the PDS-1000/He approximately 8 cm from the stopping screen. The air in the chamber is then evacuated to a vacuum of 28 inches of Hg. The macrocarrier is accelerated with a helium shock wave using a rupture membrane that bursts when the He pressure in the shock tube reaches 1000 psi.

Seven days after bombardment the tissue can be transferred to N6 medium that contains glufosinate (2 mg per liter) and lacks casein or proline. The tissue continues to grow slowly on this medium. After an additional 2 weeks the tissue can be transferred to fresh N6 medium containing glufosinate. After 6 weeks, areas of about 1 cm in diameter of actively growing callus can be identified on some of the plates containing the glufosinate-supplemented medium. These calli may continue to grow when sub-cultured on the selective medium.

Plants can be regenerated from the transgenic callus by first transferring clusters of tissue to N6 medium supplemented with 0.2 mg per liter of 2,4-D. After two weeks the tissue can be transferred to regeneration medium (Fromm et al. (1990) *Bio/Technology* 8:833-839).

EXAMPLE 8

Expression of Chimeric Genes in Dicot Cells

A seed-specific expression cassette composed of the promoter and transcription terminator from the gene encoding the β subunit of the seed storage protein phaseolin from the bean *Phaseolus vulgaris* (Doyle et al. (1986) *J. Biol. Chem.* 261:9228-9238) can be used for expression of the instant polypeptides in transformed soybean. The phaseolin cassette includes about 500 nucleotides upstream (5') from the translation initiation codon and about 1650 nucleotides downstream (3') from the translation stop codon of phaseolin. Between the 5' and 3' regions are the unique restriction endonuclease sites Nco I (which includes the ATG translation initiation codon), Sma I, Kpn I and Xba I. The entire cassette is flanked by Hind III sites.

The cDNA fragment of this gene may be generated by polymerase chain reaction (PCR) of the cDNA clone using appropriate oligonucleotide primers. Cloning sites can be incorporated into the oligonucleotides to provide proper orientation of the DNA fragment when inserted into the expression vector. Amplification is then performed as described above, and the isolated fragment is inserted into a pUC18 vector carrying the seed expression cassette.

Soybean embryos may then be transformed with the expression vector comprising sequences encoding the instant polypeptides. To induce somatic embryos, cotyledons, 3-5 mm in length dissected from surface sterilized, immature seeds of the soybean cultivar A2872, can be cultured in the light or dark at 26°C on an appropriate agar medium for 6-10 weeks. Somatic embryos which produce secondary embryos are then excised and placed into a suitable liquid medium. After repeated selection for clusters of somatic embryos which multiplied as early, globular staged embryos, the suspensions are maintained as described below.

Soybean embryogenic suspension cultures can be maintained in 35 mL liquid media on a rotary shaker, 150 rpm, at 26°C with florescent lights on a 16:8 hour day/night schedule. Cultures are subcultured every two weeks by inoculating approximately 35 mg of tissue into 35 mL of liquid medium.

Soybean embryogenic suspension cultures may then be transformed by the method of particle gun bombardment (Klein et al. (1987) *Nature* (London) 327:70-73, U.S. Patent No. 4,945,050). A DuPont Biolistic™ PDS1000/HE instrument (helium retrofit) can be used for these transformations.

A selectable marker gene which can be used to facilitate soybean transformation is a chimeric gene composed of the 35S promoter from Cauliflower Mosaic Virus (Odell et al. (1985) *Nature* 313:810-812), the hygromycin phosphotransferase gene from plasmid pJR225 (from *E. coli*; Gritz et al. (1983) *Gene* 25:179-188) and the 3' region of the nopaline synthase gene from the T-DNA of the Ti plasmid of *Agrobacterium tumefaciens*. The seed

expression cassette comprising the phaseolin 5' region, the fragment encoding the instant polypeptides and the phaseolin 3' region can be isolated as a restriction fragment. This fragment can then be inserted into a unique restriction site of the vector carrying the marker gene.

- 5 To 50 μ L of a 60 mg/mL 1 μ m gold particle suspension is added (in order): 5 μ L DNA (1 μ g/ μ L), 20 μ L spermidine (0.1 M), and 50 μ L CaCl_2 (2.5 M). The particle preparation is then agitated for three minutes, spun in a microfuge for 10 seconds and the supernatant removed. The DNA-coated particles are then washed once in 400 μ L 70% ethanol and resuspended in 40 μ L of anhydrous ethanol. The DNA/particle suspension can
10 be sonicated three times for one second each. Five μ L of the DNA-coated gold particles are then loaded on each macro carrier disk.

- Approximately 300-400 mg of a two-week-old suspension culture is placed in an empty 60x15 mm petri dish and the residual liquid removed from the tissue with a pipette. For each transformation experiment, approximately 5-10 plates of tissue are normally
15 bombarded. Membrane rupture pressure is set at 1100 psi and the chamber is evacuated to a vacuum of 28 inches mercury. The tissue is placed approximately 3.5 inches away from the retaining screen and bombarded three times. Following bombardment, the tissue can be divided in half and placed back into liquid and cultured as described above.

- Five to seven days post bombardment, the liquid media may be exchanged with fresh
20 media, and eleven to twelve days post bombardment with fresh media containing 50 mg/mL hygromycin. This selective media can be refreshed weekly. Seven to eight weeks post bombardment, green, transformed tissue may be observed growing from untransformed, necrotic embryogenic clusters. Isolated green tissue is removed and inoculated into individual flasks to generate new, clonally propagated, transformed embryogenic suspension
25 cultures. Each new line may be treated as an independent transformation event. These suspensions can then be subcultured and maintained as clusters of immature embryos or regenerated into whole plants by maturation and germination of individual somatic embryos.

EXAMPLE 9

Expression of Chimeric Genes in Microbial Cells

- 30 The cDNAs encoding the instant polypeptides can be inserted into the T7 *E. coli* expression vector pBT430. This vector is a derivative of pET-3a (Rosenberg et al. (1987) *Gene* 56:125-135) which employs the bacteriophage T7 RNA polymerase/T7 promoter system. Plasmid pBT430 was constructed by first destroying the EcoR I and Hind III sites in pET-3a at their original positions. An oligonucleotide adaptor containing EcoR I and
35 Hind III sites was inserted at the BamH I site of pET-3a. This created pET-3aM with additional unique cloning sites for insertion of genes into the expression vector. Then, the Nde I site at the position of translation initiation was converted to an Nco I site using

oligonucleotide-directed mutagenesis. The DNA sequence of pET-3aM in this region, 5'-CATATGG, was converted to 5'-CCCATGG in pBT430.

Plasmid DNA containing a cDNA may be appropriately digested to release a nucleic acid fragment encoding the protein. This fragment may then be purified on a 1% NuSieve GTG™ low melting agarose gel (FMC). Buffer and agarose contain 10 µg/ml ethidium bromide for visualization of the DNA fragment. The fragment can then be purified from the agarose gel by digestion with GELase™ (Epicentre Technologies) according to the manufacturer's instructions, ethanol precipitated, dried and resuspended in 20 µL of water. Appropriate oligonucleotide adapters may be ligated to the fragment using T4 DNA ligase (New England Biolabs, Beverly, MA). The fragment containing the ligated adapters can be purified from the excess adapters using low melting agarose as described above. The vector pBT430 is digested, dephosphorylated with alkaline phosphatase (NEB) and deproteinized with phenol/chloroform as described above. The prepared vector pBT430 and fragment can then be ligated at 16°C for 15 hours followed by transformation into DH5 electrocompetent cells (GIBCO BRL). Transformants can be selected on agar plates containing LB media and 100 µg/mL ampicillin. Transformants containing the gene encoding the instant polypeptides are then screened for the correct orientation with respect to the T7 promoter by restriction enzyme analysis.

For high level expression, a plasmid clone with the cDNA insert in the correct orientation relative to the T7 promoter can be transformed into *E. coli* strain BL21(DE3) (Studier et al. (1986) *J. Mol. Biol.* 189:113-130). Cultures are grown in LB medium containing ampicillin (100 mg/L) at 25°C. At an optical density at 600 nm of approximately 1, IPTG (isopropylthio-β-galactoside, the inducer) can be added to a final concentration of 0.4 mM and incubation can be continued for 3 h at 25°. Cells are then harvested by centrifugation and re-suspended in 50 µL of 50 mM Tris-HCl at pH 8.0 containing 0.1 mM DTT and 0.2 mM phenyl methylsulfonyl fluoride. A small amount of 1 mm glass beads can be added and the mixture sonicated 3 times for about 5 seconds each time with a microprobe sonicator. The mixture is centrifuged and the protein concentration of the supernatant determined. One µg of protein from the soluble fraction of the culture can be separated by SDS-polyacrylamide gel electrophoresis. Gels can be observed for protein bands migrating at the expected molecular weight.

Activity assays may be conducted under well known experimental conditions which permit optimal enzymatic activity. For example, assays for LPAAT which incorporates medium-sized chain fatty acids are presented by Knutzon et al. (1995) *Plant Physiol.* 109:999-1006. Assays for LPAAT which incorporates fatty acids longer than 18 carbons are presented by Lassner et al. (1995) *Plant Physiol.* 109:1389-1394. Assays to investigate the fatty acid selectivity of LPAATs is presented by Löhden and Frentzen (1992) *Planta* 188:215-224.

CLAIMS

What is claimed is:

1. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:
 - 5 (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52, or
 - 10 (b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.
2. The isolated polynucleotide of Claim 1, wherein the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51, that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 15 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.
3. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are DNA.
4. The isolated polynucleotide of Claim 1 wherein the nucleotide sequences are RNA.
- 20 5. A chimeric gene comprising the isolated polynucleotide of Claim 1 operably linked to suitable regulatory sequences.
6. An isolated host cell comprising the chimeric gene of Claim 5.
7. A host cell comprising an isolated polynucleotide of Claim 1.
8. The host cell of Claim 7 wherein the host cell is selected from the group 25 consisting of yeast, bacteria, plant, and virus.
9. The host cell of claim 8 wherein the host cell is a virus.
10. A polypeptide of at least 100 amino acids that has at least 80% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 30 46, 48, 50, and 52.
11. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell, which comprises:
 - (a) constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from an isolated polynucleotide of 35 Claim 1;
 - (b) introducing the isolated polynucleotide into a plant cell;
 - (c) measuring the level of a polypeptide in the plant cell containing the polynucleotide; and

(d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the isolated polynucleotide.

12. The method of Claim 11 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:2, 4, 6, 8, 10, 12, 14, 16, 18, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, and 52.

13. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell which comprises:

- (a) constructing an isolated polynucleotide of Claim 1;
- (b) introducing the isolated polynucleotide into a plant cell;
- (c) measuring the level of polypeptide in the plant cell containing the polynucleotide; and

(d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the polynucleotide.

14. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

- (a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences; and
- (b) amplifying a nucleic acid sequence using the oligonucleotide primer.

15. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

- (a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such nucleotide sequences;
- (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;
- (c) isolating the identified DNA clone; and
- (d) sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

16. A composition comprising the isolated polynucleotide of Claim 1.

17. A composition comprising the isolated polynucleotide of Claim 10.

18. An isolated polynucleotide comprising the nucleotide sequence having at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs:1, 3, 5, 7, 9, 11, 13, 15, 17, 25, 27, 29, 31, 33, 35, 37, 39, 41, 43, 45, 47, 49, and 51 and the complement of such sequences.

5 19. A method for positive selection of a transformed cell comprising:
(a) transforming a host cell with the chimeric gene of Claim 5; and
(b) growing the transformed host cell under conditions which allow expression of the polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

10 20. The method of Claim 19 wherein the plant cell is a monocot.

21. The method of Claim 19 wherein the plant cell is a dicot.

22. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of:

15 (a) first nucleotide sequence encoding a polypeptide of at least 100 amino acids having at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58 or

(b) a second nucleotide sequence comprising the complement of the first nucleotide sequence.

20 23. The isolated polynucleotide of Claim 22, wherein the first nucleotide sequence comprises a nucleic acid sequence selected from the group consisting of SEQ ID Nos:19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

24. The isolated polynucleotide of Claim 22 wherein the nucleotide sequences are DNA.

25 25. The isolated polynucleotide of Claim 22 wherein the nucleotide sequences are RNA.

26. A chimeric gene comprising the isolated polynucleotide of Claim 22 operably linked to suitable regulatory sequences.

27. An isolated host cell comprising the chimeric gene of Claim 26.

30 28. A host cell comprising an isolated polynucleotide of Claim 22.

29. The host cell of Claim 28 wherein the host cell is selected from the group consisting of yeast, bacteria, plant, and virus.

30. The host cell of claim 29 wherein the host cell is a virus.

35 31. A polypeptide of at least 100 amino acids that has at least 95% identity based on the Clustal method of alignment when compared to a polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

32. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell, which comprises:

(a) constructing an isolated polynucleotide comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from an isolated polynucleotide of Claim 22;

(b) introducing the isolated polynucleotide into a plant cell;

5 (c) measuring the level of a polypeptide in the plant cell containing the polynucleotide; and

(d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the isolated polynucleotide.

10 33. The method of Claim 32 wherein the isolated polynucleotide consists of a nucleotide sequence selected from the group consisting of SEQ ID 19, 21, 23, 53, 55 and 57 that codes for the polypeptide selected from the group consisting of SEQ ID NOs:20, 22, 24, 54, 56, and 58.

15 34. A method of selecting an isolated polynucleotide that affects the level of expression of an LPAAT isozyme polypeptide in a plant cell which comprises:

(a) constructing an isolated polynucleotide of Claim 22;

(b) introducing the isolated polynucleotide into a plant cell;

(c) measuring the level of polypeptide in the plant cell containing the polynucleotide; and

20 (d) comparing the level of polypeptide in the plant cell containing the isolated polynucleotide with the level of polypeptide in a plant cell that does not contain the polynucleotide.

25 35. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

(a) synthesizing an oligonucleotide primer comprising a nucleotide sequence of at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences; and

(b) amplifying a nucleic acid sequence using the oligonucleotide primer.

30 36. A method of obtaining a nucleic acid fragment encoding an LPAAT isozyme polypeptide which comprises:

(a) probing a cDNA or genomic library with an isolated polynucleotide comprising at least one of 30 contiguous nucleotides derived from a nucleotide sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such nucleotide sequences;

35 (b) identifying a DNA clone that hybridizes with the isolated polynucleotide;

(c) isolating the identified DNA clone; and

(d) sequencing the cDNA or genomic fragment that comprises the isolated DNA clone.

37. A composition comprising the isolated polynucleotide of Claim 22.

38. A composition comprising the isolated polynucleotide of Claim 31.

5 39. An isolated polynucleotide comprising the nucleotide sequence having at least one of 30 contiguous nucleotides derived from a nucleic acid sequence selected from the group consisting of SEQ ID NOs:19, 21, 23, 53, 55, and 57 and the complement of such sequences.

40. A method for positive selection of a transformed cell comprising:

10 (a) transforming a host cell with the chimeric gene of Claim 26; and

(b) growing the transformed host cell under conditions which allow expression of the polynucleotide in an amount sufficient to complement a null mutant to provide a positive selection means.

41. The method of Claim 40 wherein the plant cell is a monocot.

15 42. The method of Claim 40 wherein the plant cell is a dicot.



SEQUENCE LISTING

14-93

<110> E. I. du Pont de Nemours and Company
 <120> Lysophosphatidic Acid Acetyltransferases

<130> BB1332

<141>

<141>

<151> 60/121,119

<151> 1999-February-22

<161> 58

<171> Microsoft Office 97

<210> 1

<211> 928

<212> DNA

<213> Zea mays

<220>

<221> unsure

<222> (858)

<230>

<231> unsure

<232> (876)

<240>

<241> unsure

<242> (897)

<400> 1

```

tttttttcc gtccatttcc tattgaaagg gcaagacaag ttgagaagta aaattgagag 60
gaacttgggt gaaatgatgt gcagtgtttt tgttgcttca tggactggag ttatcaagta 120
tcattgacca cgcccaagca caccacctca tcaggtattc gttgcaaacc atacatcgat 180
tatcatattc attattcttg agcaaatgac agcatttgct gtcatcatgc agaagcatcc 240
tggatgggtt ggattttatt agaagactat cttggaaagt gtcggttgca tctggtttaa 300
tcgtaatgat ctccgggacc gtgaagttac ggcacggaag ttacgtgac atgttcaaca 360
accagacaac aatcctctgt tgatttttcc ggaaggaact tgtgtgaaca accagtacac 420
ggtcatgttc aagaagggtg cctttgagct tggctgcgct gtatgtccaa tagctatcaa 480
gtacaataaa atatttggtg atgccttttg gaacagtaag aagcaatctt ttacaatgca 540
cttgggtccg ctgatgacat catgggctgt tgtgtgtgat gtttggtact tacctcctca 600
atatctgagg gagggagaga cggcaattgc atttgctgag agagtaaggg acatgatagc 660
tgctagagct ggactaaaga agttccttgg gatggctatc tgaaacacaa ccgtcctagt 720
cccaaacaca ctgaagagaa acaacgcata tttgccgaat ctgtcttgat gagactggag 780
gagaaatgaa gggacgtaaa gccgtacaag tgcacttcgt taggggttta catgcagcta 840
ccttgttatt ccgttggntt cccaaaaaaa aaaaantgag cctgggacac gtcaaaantga 900
ccacctccat tttggttggg taattttg 928

```

<210> 2

<211> 262

<212> PRT

<213> Zea mays



<400> 2
Phe Phe Pro Val His Phe Leu Leu Lys Gly Gln Asp Lys Leu Arg Ser
1 5 10 15
Lys Ile Glu Arg Lys Leu Val Glu Met Met Cys Ser Val Phe Val Ala
20 25 30
Ser Trp Thr Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr Arg
35 40 45
Pro His Gln Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile
50 55 60
Ile Leu Glu Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro
65 70 75 80
Gly Trp Val Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys
85 90 95
Ile Trp Phe Asn Arg Asn Asp Leu Arg Asp Arg Glu Val Thr Ala Arg
100 105 110
Lys Leu Arg Asp His Val Gln Gln Pro Asp Asn Asn Pro Leu Leu Ile
115 120 125
Phe Pro Glu Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys
130 135 140
Lys Gly Ala Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys
145 150 155 160
Tyr Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser
165 170 175
Phe Thr Met His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys
180 185 190
Asp Val Trp Tyr Leu Pro Pro Gln Tyr Leu Arg Glu Gly Glu Thr Ala
195 200 205
Ile Ala Phe Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly
210 215 220
Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser
225 230 235 240
Pro Lys His Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val Leu
245 250 255
Met Arg Leu Glu Glu Lys
260

<210> 3
<211> 519
<212> DNA
<213> Glycine max

<220>
<221> unsure
<222> (46)



<220>
<221> unsure
<222> (69)

<220>
<221> unsure
<222> (72)

<220>
<221> unsure
<222> (86)

<220>
<221> unsure
<222> (117)

<220>
<221> unsure
<222> (142)

<220>
<221> unsure
<222> (144)

<220>
<221> unsure
<222> (166)

<220>
<221> unsure
<222> (241)

<220>
<221> unsure
<222> (245)

<220>
<221> unsure
<222> (347)

<220>
<221> unsure
<222> (368) .. (369)

<220>
<221> unsure
<222> (371)

<220>
<221> unsure
<222> (404)

<220>
<221> unsure
<222> (413)

<220>
<221> unsure
<222> (422)



<220>
 <221> unsure
 <222> (436)

<220>
 <221> unsure
 <222> (438)

<220>
 <221> unsure
 <222> (479)

<220>
 <221> unsure
 <222> (489)

<220>
 <221> unsure
 <222> (493)

<220>
 <221> unsure
 <222> (504)

<220>
 <221> unsure
 <222> (508)..(509)

<220>
 <221> unsure
 <222> (516)

<400> 3
 ggaactagt ctgagtttt ttttttttt ttttggtcat ggaatnatt tcaggcaatt 60
 tcatgtaana tntacatgta tatcanaata gtaagtggag tacaaacaag gggtggngaa 120
 attcattact gaaaaagtaa ananatatat attatttttc ctcaaagcgc cgcaacacag 180
 attcancgaa tatttggttg tttcctttct tgtgcttggg actagggcga gaataactta 240
 natancatc ccaaggaacc tttttaagcc cagcacgatg tgagattatg tctctaactc 300
 tctctgcaaa ttcaatgggt gtctctcctg gcttcaaatt ttgtggntcc aagtaccata 360
 cctcacanno nacagcccaa gatgtcatta attgcaagag atgncctggg aangattgct 420
 tncgactatt ccaaanongc atcgacgaaa attttaatgt acttgattgc caccggggna 480
 aaatttgtnc agncaaagtc aaantgggnc ccttcntgg 519

<210> 4
 <211> 107
 <212> PRT
 <213> Glycine max

<220>
 <221> UNSURE
 <222> (24)

<220>
 <221> UNSURE
 <222> (36)

<220>
 <221> UNSURE
 <222> (43)



<221>

<221> UNSURE

<221> (79)

<221>

<221> UNSURE

<221> (97)

<400> 4

Pro Val Ala Ile Lys Tyr Ile Lys Ile Phe Val Asp Ala Val Trp Asn
 1 5 10 15

Ser Arg Lys Gln Ser Phe Thr Xaa His Leu Leu Gln Leu Met Thr Ser
 20 25 30

Trp Ala Val Xaa Cys Asp Val Trp Tyr Leu Xaa Pro Gln Asn Leu Lys
 35 40 45

Ile Gly Glu Thr Pro Ile Glu Phe Ala Glu Arg Val Arg Asp Ile Ile
 50 55 60

Ser His Arg Ala Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Xaa Lys
 65 70 75 80

Tyr Ser Arg Pro Ser Pro Lys His Arg Glu Gly Lys Gln Gln Ile Phe
 85 90 95

Xaa Glu Ser Val Leu Arg Arg Phe Glu Glu Lys
 100 105

<210> 5

<211> 1067

<212> DNA

<213> Triticum aestivum

<220>

<221> unsure

<222> (935)

<220>

<221> unsure

<222> (1009)

<220>

<221> unsure

<222> (1016)..(1017)

<220>

<221> unsure

<222> (1029)

<220>

<221> unsure

<222> (1034)..(1035)

<210>

<211> unsure

<212> (1061)



<400> 5
 tgcttcttggg actggagtda tcaagtacca tggaccacgc ccaagctcac gaccttatca 60
 ggtatttggtt gcaaacccata catcgatgat agattttatt attctggagc agatgacagc 120
 atttgctgtc atcatgcaaaa agcatccctgg atgggttggg tttattcaga agactattct 180
 agaaagtgtg gttgcattorg ggtttaaccc taatgatctc aaggatcgtg aagtagtttg 240
 agaaagtta cgtgatcaag ttcagcatcc agacaacaat cctctcttga ttttcccgga 300
 aggaacttgt gtttaataatc agtacactgt gatgttcaag aagggtgctt ttgagcttgg 360
 ctgtgctgta tgtccaatag ctatcaaata taataaaata tttgttgacg ccttctggaa 420
 tagtaagaag caatctttta caatgcattt ggttcgtctt atgacatcat gggctgttgt 480
 ttgtgatgtt tgggtcttggg aaacctcagta totcagggaa ggggagacag cgatagaatt 540
 tactgaaaga gtgaggggaca tgatagctgc tcgggctggt ctttaagaagg ttccatggga 600
 tggctatctg aaacataacc gccctagccc caaacatacc gaggaaaagc agcgcatgtt 660
 tgctgaatct gtgttgagga gactagagga aaactaaata gctatcaatc aactcacggt 720
 ctccctggta gttaggggat ttcccttag ttgcttga atctgttaat cacccaagtg 780
 agacttgggg catgtggaaa tgaccacccg agttttgctg taaatttgtt tgcggtttga 840
 cagaatcagt agcatgtgct tggcaagaaa gaactattga atcaaccttg ctatacatc 900
 gacactagtc cgatttttct acaccacaga tcaanogttg atccctgaac aaactgcagt 960
 gaacacagat ttgcgtgtac acaaattgac atggacatgt ccatagggnt cgcattnatg 1020
 gatcgtgchna agtnnttaat actaaagatg gtaggtaacc naacatt 1067

<210> 6
 <211> 231
 <212> PRT
 <213> Triticum aestivum

<400> 6
 Ala Ser Trp Thr Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Ser
 1 5 10 15
 Arg Pro Tyr Gln Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe
 20 25 30
 Ile Ile Leu Glu Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His
 35 40 45
 Pro Gly Trp Val Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Val
 50 55 60
 Ala Ser Gly Phe Asn Arg Asn Asp Leu Lys Asp Arg Glu Val Val Gly
 65 70 75 80
 Arg Lys Leu Arg Asp Gln Val Gln His Pro Asp Asn Asn Pro Leu Leu
 85 90 95
 Ile Phe Pro Glu Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe
 100 105 110
 Lys Lys Gly Ala Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile
 115 120 125
 Lys Tyr Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln
 130 135 140
 Ser Phe Thr Met His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val
 145 150 155 160
 Cys Asp Val Trp Ser Trp Glu Pro Gln Tyr Leu Arg Glu Gly Glu Thr
 165 170 175



Ala Ile Glu Phe Thr Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala
180 185 190

Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro
195 200 205

Ser Pro Lys His Thr Glu Glu Lys Gln Arg Met Phe Ala Glu Ser Val
210 215 220

Leu Arg Arg Leu Glu Glu Asn
225 230

<210> 7
<211> 1043
<212> DNA
<213> Zea mays

<400> 7
gacgcgcgtg cacgcgtgtc gtggatgcag atggggggcg gccgaggttg gcgggggtgga 60
ggaggaaggg cgtgcgcgga tcgggggtgc cgcctcaccg ggtgatgctc ttcgtcttcg 120
ggttctactg gatccgcgag accgcgagaa ggccactaa tgcctaagggt ttaaatacagg 180
accaatttga agaataccaa aggcacaggg caattgtatc taatcatgtc tcttatgtgg 240
atattcttta tcacatgtca gcaccccttc caagttttgt tgcctaaggag tcagtgtcca 300
ggttgccact tattggtctc ataagcaatt gtcttggatg catttttgtt caacgagaat 360
cgaagtcttc agaagctaaa ggtgtctcag gcgcgtgaac tgaaaggatc caagacgttt 420
gtcaagataa gaatacccca atgatgttgt tgtttcccgga gggaactact acaaattgggg 480
attaccttct tccatttaag actggagcct ttcttgcagg tgcaccagtg cagccagtca 540
ttttgaaata cctttacagg agatttagtc cagcatggga ttcaatggat ggagcacgtc 600
atgtgttttt gctgctctgt caatttgtaa atcacatgga ggtgggtccgg ttgctgttat 660
actatccttc tcaactagaa aaagaagatc ctaagctcta cgcataataat gtcagaaaaac 720
taatagcaat ggagggcaat ttagttcttt ctaattttgg gctggcagag aagcgcgtgt 780
accatgcagc actgactggt agtagcttac ctggcgctag aatagagaaa gatgattgaa 840
agacgttgcg tcgttttttc tgtaacagac agccgaggaa caacttaaaaa tgtaactgtg 900
tgcggttttt tatacctgta atgtggcagt ttatttgttt gaggaggctg ttgagtacct 960
ttctcatact acattgtaca aaaacaatgt ccaatgtcca ttatagtttg atgagggttcg 1020
tcttccaaaa aaaaaaaaaa aaa 1043

<210> 8
<211> 278
<212> PRT
<213> Zea mays

<400> 8
Arg Ala Cys Thr Leu Phe Val Asp Ala Asp Gly Gly Arg Pro Arg Leu
1 5 10 15
Ala Gly Trp Arg Arg Lys Ala Val Leu Arg Ser Gly Cys Ala Leu Ser
20 25 30
Arg Val Met Leu Phe Val Phe Gly Phe Tyr Trp Ile Arg Glu Thr Arg
35 40 45
Arg Arg Ser Thr Asn Ala Lys Gly Leu Asn Gln Asp Gln Phe Glu Glu
50 55 60
Ser Gln Arg Pro Gly Ala Ile Val Ser Asn His Val Ser Tyr Val Asp
65 70 75 80
Ile Leu Tyr His Met Ser Ala Ser Phe Pro Ser Phe Val Ala Lys Glu
85 90 95



Ser Val Ser Arg Leu Pro Leu Ile Gly Leu Ile Ser Asn Cys Leu Gly
 100 105 110
 Cys Ile Phe Val Gln Arg Glu Ser Lys Ser Ser Glu Ala Lys Gly Val
 115 120 125
 Ser Gly Ala Val Thr Glu Arg Ile Gln Asp Val Cys Gln Asp Lys Asn
 130 135 140
 Thr Pro Met Met Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Asp
 145 150 155 160
 Tyr Leu Leu Pro Phe Lys Thr Gly Ala Phe Leu Ala Gly Ala Pro Val
 165 170 175
 Gln Pro Val Ile Leu Lys Tyr Pro Tyr Arg Arg Phe Ser Pro Ala Trp
 180 185 190
 Asp Ser Met Asp Gly Ala Arg His Val Phe Leu Leu Leu Cys Gln Phe
 195 200 205
 Val Asn His Met Glu Val Val Arg Leu Pro Val Tyr Tyr Pro Ser Gln
 210 215 220
 Leu Glu Lys Glu Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg Lys Leu
 225 230 235 240
 Ile Ala Met Glu Gly Asn Leu Val Leu Ser Asn Ile Gly Leu Ala Glu
 245 250 255
 Lys Arg Val Tyr His Ala Ala Leu Thr Gly Ser Ser Leu Pro Gly Ala
 260 265 270
 Arg His Glu Lys Asp Asp
 275

<210> 9

<211> 1349

<212> DNA

<213> Glycine max

<400> 9

aagaacctga cccaggatga ggatcgcggtg agcaactcctc ttcagatccg cacaagcatt 60
 gcataatcaaa tcaagcatcc tgttccttat ctctgtctct gcatttccct tctttcttct 120
 tctctctctc tctctaaaa cctaattcta tacatggaag ggaaatctca aatctaataga 180
 ctaattaatt aatccatcga tcaagcatgg agtccgaact caaagacctc aattcgaagc 240
 cgcggaacgg caacggcaac agcggttcgg atgaccgtcc tctgctgaag ccggagcctc 300
 cgggtctccg cgacagcatc gccgatatgg agaagaagtt cgcgcgttac gtccgcgcgg 360
 acgtgtacgg caccatggga cgcggcgagt tgcctcccaa ggagaagctc ttgctcggtt 420
 tcgcgttggt cactcttctc cccattcgag tcgtctctgc cgtcaccata ttgctctttt 480
 attacttaat ttgtagggtt tgcactctct tctctgcgcc cactggcgaa gaggaacagg 540
 aagattacgc tcacatgagt ggggtggagga gaaccattat tgtttcgtgt ggacgcgcgc 600
 tctccagact catgcttttc attttcgggt tttattggat ccccgaatcg aactctgcct 660
 ctcaggaga caagagtcgg cagcccgagg agttgaggag acctggcgta ataatttcta 720
 atcatgtgtc gtacttggtt attttgtatc acatgtcttc ctcatctcct agttttgttg 780
 ctaagagatc agtggctaaa ctcccgctag tcggtctcat cagcaagtgc cttgggtgtg 840
 totatgttca gcgggaatca aggtcatcag acttcaaggg tgtttcagct gttgtcactg 900
 acagaattcg agaagctcat cagaatgagt ctgctccatt aatgatgta tttccagaag 960
 gtacaaccac aatggagag ttcctccttc cattcaagac tggtggtttt ttggcaaaagg 1020



caccggtaact tccgtgtgata ttacgatatac attaccagag atttagccct gccctgggatt 1080
 ccataatctgg agtgogccat gtgatatttc tccgtgtgca gtttgtgaat tatatggagg 1140
 tgatccgatt accgtgtttac catccttcac agcaggagat ggatgatccc aaactatacg 1200
 ctaataaatgt tagaagggtg atgggtactg agggtaattt gatactttct gatattgggc 1260
 taqctgaaaa accaatatat caccgtgata tccatggtaa taatagccctg cctagtgttt 1320
 tgcacagaa agacgaatga taatttcat 1349

<210> 10
 <211> 377
 <212> PRT
 <213> Glycine max

<400> 10
 Met Glu Ser Glu Leu Lys Asp Leu Asn Ser Lys Pro Pro Asn Gly Asn
 1 5 10 15
 Gly Asn Ser Val Arg Asp Asp Arg Pro Leu Leu Lys Pro Glu Pro Pro
 20 25 30
 Val Ser Ala Asp Ser Ile Ala Asp Met Glu Lys Lys Phe Ala Ala Tyr
 35 40 45
 Val Arg Arg Asp Val Tyr Gly Thr Met Gly Arg Gly Glu Leu Pro Pro
 50 55 60
 Lys Glu Lys Leu Leu Leu Gly Phe Ala Leu Val Thr Leu Leu Pro Ile
 65 70 75 80
 Arg Val Val Leu Ala Val Thr Ile Leu Leu Phe Tyr Tyr Leu Ile Cys
 85 90 95
 Arg Val Cys Thr Leu Phe Ser Ala Pro Thr Gly Glu Glu Glu Gln Glu
 100 105 110
 Asp Tyr Ala His Met Ser Gly Trp Arg Arg Thr Ile Ile Val Ser Cys
 115 120 125
 Gly Arg Ala Leu Ser Arg Leu Met Leu Phe Ile Phe Gly Phe Tyr Trp
 130 135 140
 Ile Pro Glu Ser Asn Ser Ala Ser Gln Glu Asp Lys Ser Arg Gln Pro
 145 150 155 160
 Glu Glu Leu Arg Arg Pro Gly Val Ile Ile Ser Asn His Val Ser Tyr
 165 170 175
 Leu Asp Ile Leu Tyr His Met Ser Ser Ser Phe Pro Ser Phe Val Ala
 180 185 190
 Lys Arg Ser Val Ala Lys Leu Pro Leu Val Gly Leu Ile Ser Lys Cys
 195 200 205
 Leu Gly Cys Val Tyr Val Gln Arg Glu Ser Arg Ser Ser Asp Phe Lys
 210 215 220
 Gly Val Ser Ala Val Val Thr Asp Arg Ile Arg Glu Ala His Gln Asn
 225 230 235 240
 Glu Ser Ala Pro Leu Met Met Leu Phe Pro Glu Gly Thr Thr Thr Asn
 245 250 255



Gly Glu Phe Leu Leu Pro Phe Lys Thr Gly Gly Phe Leu Ala Lys Ala
 260 265 270
 Pro Val Leu Pro Val Ile Leu Arg Tyr His Tyr Gln Arg Phe Ser Pro
 275 280 285
 Ala Trp Asp Ser Ile Ser Gly Val Arg His Val Ile Phe Leu Leu Cys
 290 295 300
 Gln Phe Val Asn Tyr Met Glu Val Ile Arg Leu Pro Val Tyr His Pro
 305 310 315 320
 Ser Gln Gln Glu Met Asp Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg
 325 330 335
 Arg Leu Met Ala Thr Glu Gly Asn Leu Ile Leu Ser Asp Ile Gly Leu
 340 345 350
 Ala Glu Lys Arg Ile Tyr His Ala Ala Leu Asn Gly Asn Asn Ser Leu
 355 360 365
 Pro Ser Val Leu His Gln Lys Asp Glu
 370 375

<210> 11
 <211> 585
 <212> DNA
 <213> Triticum aestivum

<220>
 <221> unsure
 <222> (363)

<220>
 <221> unsure
 <222> (391)

<220>
 <221> unsure
 <222> (404)

<220>
 <221> unsure
 <222> (433)

<220>
 <221> unsure
 <222> (439)

<220>
 <221> unsure
 <222> (449)

<220>
 <221> unsure
 <222> (470)



<120>
 <121> unsure
 <122> (510)

<130>
 <131> unsure
 <132> (527)

<140>
 <141> unsure
 <142> (532)

<150>
 <151> unsure
 <152> (535)

<160>
 <161> unsure
 <162> (539)

<170>
 <171> unsure
 <172> (557)

<180>
 <181> unsure
 <182> (562)

<190>
 <191> unsure
 <192> (571)

<400> 11
 caaggggttga ggaggggagga cgtgctgcgt gctggcgcgg tgttgctcgg ggcaatgctg 60
 ttgtgtgtcg ggttctactg gatccccgtg tccgatcgaa gcttccccc aa tgcgaggat 120
 gtacctaag atcactatga agaactggaa agaccagggg cgattgtatc taatcatgtg 180
 tcatatgtgg acattcttta tcatatgtca gtttctctc cgagttttgt tgotagaac 240
 tccgtgtcca agttgcggtt gattggtctc ataagcaaat gtcttgggtg catttttgtt 300
 caacgagaac caaatgttca gattctaaag ggtctcaagt gctgtaactg aaagtccatg 360
 agtccacaag gacgagaatc cctatatcta ncttttctg aggtacact acaatgggat 420
 tctctccat tanacaganc ttcttgcang gacatgcaac tgtatttggg atacctacag 480
 agattatcca cctgggacca tgatgggacn caagtttttg ccccgcnatt tnaantaana 540
 aggttccctt ctgaaanact cncaaaaaga ngttcaatca gcaaa 585

<10> 12
 <11> 194
 <12> PRT
 <13> Triticum aestivum

<200>
 <21> UNSURE
 <22> (120)

<210>
 <22> UNSURE
 <23> (130)

<200>
 <21> UNSURE
 <22> (134)



<220>
 <221> UNSURE
 <222> (144)

<220>
 <221> UNSURE
 <222> (148)

<220>
 <221> UNSURE
 <222> (149)

<220>
 <221> UNSURE
 <222> (156)

<220>
 <221> UNSURE
 <222> (175)

<220>
 <221> UNSURE
 <222> (177)..(178)..(179)

<220>
 <221> UNSURE
 <222> (185)

<220>
 <221> UNSURE
 <222> (187)

<220>
 <221> UNSURE
 <222> (190)

<400> 12

Gln Gly Leu Arg Arg Glu Ala Val Leu Arg Ala Gly Arg Val Leu Ser
 1 5 10 15

Arg Ala Met Leu Phe Val Phe Gly Phe Tyr Trp Ile Pro Val Ser Asp
 20 25 30

Arg Ser Phe Pro Asn Ala Glu Asp Val Pro Lys Asp His Tyr Glu Glu
 35 40 45

Leu Glu Arg Pro Gly Ala Ile Val Ser Asn His Val Ser Tyr Val Asp
 50 55 60

Ile Leu Tyr His Met Ser Ala Ser Ser Pro Ser Phe Val Ala Lys Asn
 65 70 75 80

Ser Val Ser Lys Leu Pro Leu Ile Gly Leu Ile Ser Lys Cys Leu Gly
 85 90 95

Cys Ile Phe Val Gln Arg Glu Pro Asn Val Gln Ile Leu Lys Gly Leu
 100 105 110



Lys Cys Cys Asn Lys Ser Met Xaa Ser Gln Gly Arg Glu Ser Leu Tyr
 115 120 125
 Leu Xaa Phe Pro Glu Xaa Thr Leu Gln Trp Asp Tyr Ser Pro Leu Xaa
 130 135 140
 Arg Xaa Ser Cys Xaa Asp Met Gln Leu Tyr Leu Xaa Tyr Leu Gln Arg
 145 150 155 160
 Leu Ser Thr Trp Asp His Asp Gly Thr Gln Val Phe Ala Pro Xaa Phe
 165 170 175
 Xaa Xaa Xaa Arg Val Pro Ser Glu Xaa Leu Xaa Lys Arg Xaa Ser Ile
 180 185 190
 Ser Lys

<210> 13
 <211> 1501
 <212> DNA
 <213> Arabidopsis thaliana

<400> 13
 atgcbgaatc atgtggatta ctoggatctg taccagatgt atcctcttct cttttggcta 60
 tcagtggata agaaggaaag ggaacactgc tcggagagag attgctccga ttgttgtatc 120
 aaatcatgtt tcttatattg aaccaatctt ctacttctat gaattatcac cgaccattgt 180
 tccatcggag tcacatgatt cacttccatt tgttggaaat attatcaggg caatgcaggt 240
 gatataatgt aatagattct cacagacatc aagggaagaat gctgtgcatg aaataaagag 300
 aaaagcttcc tgcgatagat ttctcgtct gctgttattc ccgaaggaa ccacgactaa 360
 tgggaaagtt cttatttctt tccaaactgg tgccttcac cctggttacc ctattcaacc 420
 tctagtatgc cggtatcccc atgtacattt tgatcaatcc tggggaaata tctctttgtt 480
 gacgttcatt tttagaatgt tcaactcagt tcacaatttc atggaggttg aatatcttcc 540
 tctactctat cccagtgaag agcaaaagca g. tctgtg cgtctctcac agaagactag 600
 tcatucaatt gcaacatctt tgaatgtct ccaaacatcc cattcttttg cggacttgat 660
 cctatcaaac aaagcaactg agttaaagct ggagaacccc tcaaattaca tgattgaaat 720
 gccaagagtt gagtcgtat tccatgtaag cagcttagag gcaacgcgat ttttggatac 780
 attcttttcc atgattccgg actcagagtg acgtgttagg ctacatgact ttcttcgggg 840
 tcttaaaactg aaaccttgcc ctctttctaa aaggatattt gagttcatcg atgtggagaa 900
 gctcggatca atcactttca aacagttctt gttgcctcg ggccacgtgt tgacacagcc 960
 gctttttaag caaacatgag agctagcctt tccccattgc gatgcagatg gagatggcta 1020
 tattacaatt caagaactcg gagaagctct caaaaaacaca atcccaaact tgaacaagga 1080
 cgagattcga ggaatgtacc atttgctaga cgcagaccaa gatcaaagaa tcagccaaaa 1140
 tgaattgttg tctgtcttaa gaagaaaccc tcttctcata gccatctttg cacctgactt 1200
 ggccccaaca taacacagag agacaaaatg gctggctaag atttgtggtg cgatgattgt 1260
 aaacttgtct ttgtggtata ttattatacc ttttgttttg tcttcatatt tgatttcagc 1320
 tagtaaaaaa aggggactgc tatgttttta gctatatat ataccctctt ccaacatgga 1380
 tccatccttt tgagtgttgg actataactg cttgtcgttt tccaccccaa aaaacgctat 1440
 ggtgtttgct cctctagttc tgagcaaaact ttgctgtaaa aaaaaaaaaa aaaaaaaaaa 1500
 a 1501

<210> 14
 <211> 403
 <212> PRT
 <213> Arabidopsis thaliana

<400> 14
 Cys Arg Ile Met Trp Ile Thr Arg Ile Cys Thr Arg Cys Ile Leu Phe
 1 5 10 15



Ser Phe Gly Tyr Gln Trp Ile Arg Arg Lys Gly Lys Pro Ala Arg Arg
 20 25 30
 Glu Ile Ala Pro Ile Val Val Ser Asn His Val Ser Tyr Ile Glu Pro
 35 40 45
 Ile Phe Tyr Phe Tyr Glu Leu Ser Pro Thr Ile Val Ala Ser Glu Ser
 50 55 60
 His Asp Ser Leu Pro Phe Val Gly Thr Ile Ile Arg Ala Met Gln Val
 65 70 75 80
 Ile Tyr Val Asn Arg Phe Ser Gln Thr Ser Arg Lys Asn Ala Val His
 85 90 95
 Glu Ile Lys Arg Lys Ala Ser Cys Asp Arg Phe Pro Arg Leu Leu Leu
 100 105 110
 Phe Pro Glu Gly Thr Thr Thr Asn Gly Lys Val Leu Ile Ser Phe Gln
 115 120 125
 Leu Gly Ala Phe Ile Pro Gly Tyr Pro Ile Gln Pro Val Val Val Arg
 130 135 140
 Tyr Pro His Val His Phe Asp Gln Ser Trp Gly Asn Ile Ser Leu Leu
 145 150 155 160
 Thr Leu Met Phe Arg Met Phe Thr Gln Phe His Asn Phe Met Glu Val
 165 170 175
 Glu Tyr Leu Pro Val Ile Tyr Pro Ser Glu Lys Gln Lys Gln Asn Ala
 180 185 190
 Val Arg Leu Ser Gln Lys Thr Ser His Ala Il la Thr Ser Leu Asn
 195 200 205
 Val Val Gln Thr Ser His Ser Phe Ala Asp Leu Met Leu Leu Asn Lys
 210 215 220
 Ala Thr Glu Leu Lys Leu Glu Asn Pro Ser Asn Tyr Met Val Glu Met
 225 230 235 240
 Ala Arg Val Glu Ser Leu Phe His Val Ser Ser Leu Glu Ala Thr Arg
 245 250 255
 Phe Leu Asp Thr Phe Val Ser Met Ile Pro Asp Ser Ser Gly Arg Val
 260 265 270
 Arg Leu His Asp Phe Leu Arg Gly Leu Lys Leu Lys Pro Cys Pro Leu
 275 280 285
 Ser Lys Arg Ile Phe Glu Phe Ile Asp Val Glu Lys Val Gly Ser Ile
 290 295 300
 Thr Phe Lys Gln Phe Leu Phe Ala Ser Gly His Val Leu Thr Gln Pro
 305 310 315 320
 Leu Phe Lys Gln Thr Cys Glu Leu Ala Phe Ser His Cys Asp Ala Asp
 325 330 335



Gly Asp Gly Tyr Ile Thr Ile Gln Glu Leu Gly Glu Ala Leu Lys Asn
 340 345 350

Thr Ile Pro Asn Leu Asn Lys Asp Glu Ile Arg Gly Met Tyr His Leu
 355 360 365

Leu Asp Asp Asp Gln Asp Gln Arg Ile Ser Gln Asn Asp Leu Leu Ser
 370 375 380

Lys Leu Arg Arg Asn Pro Leu Leu Ile Ala Ile Phe Ala Pro Asp Leu
 385 390 395 400

Ala Pro Thr

<210> 15
 <211> 692
 <212> DNA
 <213> Oryza sativa

<220>
 <221> unsure
 <222> (446)

<220>
 <221> unsure
 <222> (579)

<220>
 <221> unsure
 <222> (677)

<400> 15
 gttctaaacc gctctctctc gctctgcttc cgcaccccat ggctttctcga aaccctagcc 60
 ccgctctccct ctccacgcgc ctctctctcc actccatctc gccacgcgc accaccaacg 120
 gccacgcgcgc gcaccataac cagcagcagc acgacgagga gtcgccaaac gtgtgcgcgc 180
 gcgatgggcgc aggagggggg gacccgttcg cgttcctatc ggaggatcgc ccggcgtgct 240
 gctcccccgcg ggggggtctcc ccggcgcacc cgttcgcgaa cgggacgcgc gggcggtgcg 300
 gggcgtaaga gctcgtgagg gcgctcgtgt gcgcgcgcgt ggcggcgcgc aggcctggtgc 360
 tcttcgggct ctccatcgcg gtggggtacg ccgccacgtg ggtggcgctc cgcgggtgcg 420
 tccacgtgcg ggagcgggcg gcgcangagg gcgcgcggcc catgcgcgcg tggcgccgcg 480
 gccctatgtg gatcacgcgc attccgcgcg ctgcctctc ttctccttcg gatacattgg 540
 ataacggagaa aggaaaaacc ccctagaaac ttcaactatnt ttctaaatca tgttcatcat 600
 aqaaccatat actctcatag cttccgacat cgttctcaaa tccatatcat acattttgaa 660
 aatttcagca tcagtantag ttaaaatccc aa 692

<210> 16
 <211> 174
 <212> PRT
 <213> Oryza sativa

<220>
 <221> UNSURE
 <222> (136)

<400> 16
 Met Ala Ser Arg Asn Pro Ser Pro Ala Ser Leu Ser Thr Pro Leu Leu
 1 5 10 15



Ser Asp Ser Ile Ser Pro Thr Pro Thr Thr Asn Gly His Ala Gly His
 20 25 30
 His Asn His Asp Asp Asp Asp Glu Glu Ser Pro Thr Val Cys Gly Gly
 35 40 45
 Asp Gly Gly Gly Gly Gly Asp Pro Phe Ala Phe Leu Ser Glu Asp Arg
 50 55 60
 Pro Ala Trp Trp Ser Pro Arg Gly Val Ser Pro Ala Asp Pro Phe Arg
 65 70 75 80
 Asn Gly Thr Pro Gly Trp Cys Gly Ala Tyr Glu Leu Val Arg Ala Leu
 85 90 95
 Val Cys Ala Pro Val Ala Ala Ala Arg Leu Val Leu Phe Gly Leu Ser
 100 105 110
 Ile Ala Val Gly Tyr Ala Ala Thr Trp Val Ala Leu Arg Gly Trp Val
 115 120 125
 Asp Val Arg Glu Arg Ala Ala Xaa Glu Gly Ala Gly Pro Met Pro Ala
 130 135 140
 Trp Arg Arg Arg Leu Met Trp Ile Thr Arg Ile Pro Arg Ala Ala Ser
 145 150 155 160
 Ser Ser Pro Ser Asp Thr Leu Asp Lys Glu Lys Gly Lys Pro
 165 170

<110> 17
 <111> 480
 <112> DNA
 <113> Glycine max

<120>
 <21> unsure
 <22> (189)

<120>
 <21> unsure
 <22> (195)

<120>
 <21> unsure
 <22> (284)

<120>
 <21> unsure
 <22> (290)

<120>
 <21> unsure
 <22> (303)

<120>
 <21> unsure
 <22> (362)



<220>
 <221> unsure
 <222> (366)

<220>
 <221> unsure
 <222> (377)..(378)

<220>
 <221> unsure
 <222> (399)

<220>
 <221> unsure
 <222> (419)

<220>
 <221> unsure
 <222> (426)

<220>
 <221> unsure
 <222> (428)

<220>
 <221> unsure
 <222> (432)

<220>
 <221> unsure
 <222> (454)

<220>
 <221> unsure
 <222> (475)

<400> 17
 gggacgacga cgaattctcc gtgcgcgcac cgtccaccct ggaccocgtc cgcaaccgca 60
 cgcgcggcgat cgaaggggctc tacgagtggg ccaagacggc gctgtgcctg ccgctggcgg 120
 cactgcggct cgcgcgtgtc gggctctgcc tgcgggtggg gtacgtggcg acgaaggtgg 180
 cactggcang gtggnaggac aaggagaatc ccattgcbaa gtggaggtgt agggttatgt 240
 ggatcacgcg cttgtgcgcc aaatgtattc tcttctcctt tggntatcan tggataaaaac 300
 gqnaagggaa acctgcacca aggggaaatt gctccaataa attgtatcta aaccatgttt 360
 cntaanagtg agcctannct tcttatttct aagaattant tcttaacaat ggtgggaanc 420
 tgaagncnca anaactccata tctttttgtt gggnaaccaat taatagagca aatgnaagtc 480

<210> 18
 <211> 107
 <212> PRT
 <213> Glycine max

<220>
 <221> UNSURE
 <222> (63)

<220>
 <221> UNSURE
 <222> (65)



<220>
 <221> UNSURE
 <222> (96)

<220>
 <221> UNSURE
 <222> (101)

<400> 18
 Asp Asp Asp Asp Phe Ser Val Pro Pro Pro Ser Thr Leu Asp Pro Phe
 1 5 10 15
 Arg Asn Arg Thr Pro Ala Ile Glu Gly Leu Tyr Glu Trp Ala Lys Thr
 20 25 30
 Ala Leu Cys Leu Pro Leu Ala Ala Leu Arg Leu Ala Leu Phe Gly Leu
 35 40 45
 Cys Leu Ala Val Gly Tyr Val Ala Thr Lys Val Ala Leu Ala Xaa Trp
 50 55 60
 Ala Asp Lys Glu Asn Pro Met Pro Lys Trp Arg Cys Arg Val Met Trp
 65 70 75 80
 Ile Thr Arg Leu Cys Ala Lys Cys Ile Leu Phe Ser Phe Gly Tyr Xaa
 85 90 95
 Trp Ile Lys Arg Xaa Gly Lys Pro Ala Pro Arg
 100 105

<210> 19
 <211> 784
 <212> DNA
 <213> Oryza sativa

<220>
 <221> unsure
 <222> (560)

<220>
 <221> unsure
 <222> (648)

<220>
 <221> unsure
 <222> (670)

<220>
 <221> unsure
 <222> (739)

<220>
 <221> unsure
 <222> (758)

<400> 19
 cttctcgtcg ccggtggatt cgcgcgcgcgc tcgcgcgcgc ccgcgcggagg aggaggacga 60
 ggagagggcg ctccctcggg ggtgagcacc cagccaccct ggcccgttgc ctctcttcg 120
 catctcggcc ccgcgagatt ggaagtgagg gcagggcagg gcggcagggg ccattggcgg 180
 cccactcgtg ctctcgtcgc tccgcctcgc ctctctcttc ctctctcgcg gcctcaacgc 240



```

catccaggcc gtccctgttcc tctcgataag gcgcgtctcg aagagcttgt accggcggtat 300
caacagggtc ttggccgagc tgcctgtggt tcagctgggc tggcttgtgg attgggtgggc 360
aggagttaag atacaactgc atgctgatga cgaacttac aaggcaatgg ggaatgagca 420
tgcaattgtc atatcaaatc atcggagcga tatcgattgg cttattgggt ggaatttggg 480
cacagcgctc aaggatgcct tgggaagtac acttgcctgt atgaagaaac atccgaaatc 540
cttcgaatta ttgggtctgg ccatgttgtc tgcagaatac cctcttttgg gaaaaggact 600
gggcaaaagga tgaaaagaca ttcaaatggg ggcccccaaa gggtgaanga cttccccaga 660
cafttgggcn accctttttg ttttaaggacc cctttaccca acaaaaactcc aacaactcaa 720
ggagtatctg ttcacaggnt tgcacaccca agaaatgnat gatcacgtca aagggtattgt 780
aacac
784

```

<210> 20
 <211> 146
 <212> PRT
 <213> Oryza sativa

<220>
 <221> UNSURE
 <222> (130)

<400> 20
 Met Ala Val Pro Leu Val Leu Val Val Leu Pro Leu Gly Leu Leu Phe
 1 5 10 15
 Leu Leu Ser Gly Leu Asn Ala Ile Gln Ala Val Leu Phe Leu Ser Ile
 20 25 30
 Arg Pro Phe Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Phe Leu Ala
 35 40 45
 Glu Leu Leu Trp Leu Gln Leu Val Trp Leu Val Asp Trp Trp Ala Gly
 50 55 60
 Val Lys Ile Gln Leu His Ala Asp A - Glu Thr Tyr Lys Ala Met Gly
 65 70 75 80
 Asn Glu His Ala Leu Val Ile Ser Asn His Arg Ser Asp Ile Asp Trp
 85 90 95
 Leu Ile Gly Trp Ile Leu Gly Thr Ala Leu Lys Asp Ala Leu Gly Ser
 100 105 110
 Thr Leu Ala Val Met Lys Lys His Pro Lys Ser Phe Gln Leu Leu Gly
 115 120 125
 Trp Xaa Met Leu Phe Ala Glu Tyr Pro Phe Leu Gly Lys Gly Leu Gly
 130 135 140
 Lys Gly
 145

<210> 21
 <211> 584
 <212> DNA
 <213> Glycine max

<220>
 <221> unsure
 <222> (17)..(18)



*2200
 *2201 - unsure
 *2202 - (33)

*2203
 *2204 - unsure
 *2205 - (38) .. (39)

*2206
 *2207 - unsure
 *2208 - (519)

*2209
 *2210 - unsure
 *2211 - (543)

*2212
 *2213 - unsure
 *2214 - (546)

*2215
 *2216 - unsure
 *2217 - (575)

*4000 - 21
 cgtttgctga cctgaacnnc ggtttttttt ttnggggnnc acggtgtttc gttgcgttgt 60
 gctctgtctt gctcctttgg gcctgggctg ggctgggctg ggctgggctg ggcattggcta 120
 ttgcagcagc ggccgtgggtg gtaccattgg gcctgctctt cttegcctcc ggctccttg 180
 ttaattctcat tcaggcaata tgctatgtcg tcgtaaggcc ggtgtcgaaa agtttgtaca 240
 aaaggatcaa ccgggtagta gcagagctct tgtggctgga gcttgtatgg cttattgatt 300
 ggtggcaggg agttaaggtc caaatattca cagatcatga aacctttcgt ttaatgggta 360
 aaqagcatgc acttgtgata agcaatcaca gaagtatat tgattggctt gttggatggg 420
 ttccagctca gcgttcaggt tgtcttggca gcactctaag ctgtgatgaa gaaatcttca 480
 aagtttctgc cggtcattgg ctggccaatg tgg ttctng agtaaccttt tctggagaag 540
 aanttinggc aaagatgaaa gcccatctaaa gtcangcatc ccgg 584

*210 - 22
 *211 - 116
 *212 - PRT
 *213 - Glycine max

*4000 - 22
 Met Ala Ile Ala Ala Ala Val Val Val Pro Leu Gly Leu Leu Phe
 1 5 10 15
 Phe Ala Ser Gly Leu Leu Val Asn Leu Ile Gln Ala Ile Cys Tyr Val
 20 25 30
 Val Val Arg Pro Val Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Val
 35 40 45
 Val Ala Glu Leu Leu Trp Leu Glu Leu Val Trp Leu Ile Asp Trp Trp
 50 55 60
 Ala Gly Val Lys Val Gln Ile Phe Thr Asp His Glu Thr Phe Arg Leu
 65 70 75 80
 Met Gly Lys Glu His Ala Leu Val Ile Ser Asn His Arg Ser Asp Ile
 85 90 95



Asp Trp Leu Val Gly Trp Val Ser Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110

Ser Thr Leu Ser
 115

<210> 23
 <211> 570
 <212> DNA
 <213> Triticum aestivum

<220>
 <221> unsure
 <222> (510)

<220>
 <221> unsure
 <222> (516)

<220>
 <221> unsure
 <222> (518)

<400> 23
 gagaggagac gggggggggg ccattggcgat tcccctcgtg ctcgctcctgc tcccgcctcgg 60
 cctcctctctc ctctctctcgg gctcgtcgt caacactgtc caggccgtat tgttcttgac 120
 gataaggcca ttctcgaagc gattgtaccg gcagatcaac gtattcctgg ccgagttgtt 180
 ctgggttcag ctgactctggg ttgtggactg gtgggcaggt attaaggtac aggtgtatgc 240
 ggatccagaa acttggaacc taatgggcaa agagcacgce cttctcatat ccaatcatcg 300
 aagtgcacatt gattggctgg ttggatggat tttagcacag cgttcaggat gtcttggaag 360
 cgcataagct ataatgaaga aatcctcaaa gttccttcca gttattgggt ggtccatgtg 420
 gtttcagaa tactcttttg gagagaactg gcaaaggatg aaaaacacta aatcgggtct 480
 caaggtgaaa actccagata ttggctgccc ttgtgnangg tcaaattact cacaaacttt 540
 acagtaagaa atcatccaag ggttcacgc 570

<210> 24
 <211> 160
 <212> PRT
 <213> Triticum aestivum

<400> 24
 Met Ala Ile Pro Leu Val Leu Val Leu Leu Pro Leu Gly Leu Leu Phe
 1 5 10 15
 Leu Leu Ser Gly Leu Val Val Asn Thr Val Gln Ala Val Leu Phe Leu
 20 25 30
 Thr Ile Arg Pro Phe Ser Lys Arg Leu Tyr Arg Gln Ile Asn Val Phe
 35 40 45
 Leu Ala Glu Leu Leu Trp Leu Gln Leu Ile Trp Leu Val Asp Trp Trp
 50 55 60
 Ala Gly Ile Lys Val Gln Val Tyr Ala Asp Pro Glu Thr Trp Lys Leu
 65 70 75 80
 Met Gly Lys Glu His Ala Leu Leu Ile Ser Asn His Arg Ser Asp Ile
 85 90 95



Asp Trp Leu Val Gly Trp Ile Leu Ala Gln Arg Ser Gly Cys Leu Gly
100 105 110

Ser Ala Ile Ala Ile Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
115 120 125

Gly Trp Ser Met Trp Phe Ala Glu Tyr Ser Phe Gly Glu Asn Trp Gln
130 135 140

Arg Met Lys Asn Thr Lys Ser Gly Leu Lys Val Lys Thr Pro Asp Ile
145 150 155 160

<210> 25

<211> 1337

<212> DNA

<213> Catalpa speciosa

<400> 25

```

gcacgagagg ctaaaggaca atgagcaagc taaaaacatc cagctccgaa ttggatttgg 60
atcaccccaa tatcgaagac tatcttccat ccggatccat tcaagagcct caccggcaagc 120
tcgccttgcg tgatttgcgc gatatttccac caactctaac tgaggcagct ggtgccattg 180
ttgatgactc cttcacgaga tgccttcaagt caaatccgcc agaaccctgg aactggaaca 240
tatatttgtt tcccttgtgg tgcttaggag ttgttgcag atatggtctt cttttccctt 300
taagggtaat agtgttgaca ataggatgga ttatatctt ctcagtctat ttccctgtgc 360
atttctgtt aaaagggcat gacaaaattga gaaaaaatt agagagaggt ctagtggagt 420
tgatgtgcag ttttttgtt gcatcatgga ctggggttgt caagtaacct ggtccgcggc 480
ccagcatggg gctaagcag gtttttgttg ctaatcacac atccatgatt gatttcattg 540
ttttggaaca aatgactgca ttgacagtga ttatgcagaa gcacctggg tgggtaggac 600
tattgcagag cactattttg gagagtctag gatgtatctg gttcaaccgg tcagagtcca 660
aggacagtga aattgttgca aaaaagctaa gagatcatgt ccatggcgct gataataatc 720
ctctcttat attcccgaa ggaacatgtg tgaataacca ctacactgtg atgtttaaga 780
agggtgcatt tgaacttgga tgcactgtct gtccaatcgc aatcaagtat aacaagattt 840
ttgtgpatgc cttctggaac agcagaaaagc aatcctttac aatgcacttg ttgcagctta 900
tgacatcttg ggcgttgtc tgtgatgtt ggtacctgg. tctcaaaat ctaaaacctg 960
gggaaacacc aattgaattt gctgagaggg tgagggggcat tattctctgt cgaqcaggcc 1020
ttaagaaggt gccgtgggat ggatatttga agtactctcg ccccagccca aagcatctg 1080
agcgaaagba acaaagcttc gcagagtcag ttctccatca cctggaagag aaatagattg 1140
atgataaata attttgttat ttactgtctt caatttgtaa gatcaagttt gttagctgtt 1200
ttgaaattba atcttatttg tcaactataaa gaggatttca gttcttcaat tgacataatg 1260
aaatttcctt gatacgtcgt tgaagaggaa aatacaatat gaagtgttga aaaaaaaaaa 1320
aaaaaaaaaa aaaaaaaa

```

<210> 26

<211> 371

<212> PRT

<213> Catalpa speciosa

<400> 26

Met Ser Lys Leu Lys Thr Ser Ser Ser Glu Leu Asp Leu Asp His Pro
1 5 10 15

Asn Ile Glu Asp Tyr Leu Pro Ser Gly Ser Ile Gln Glu Pro His Gly
20 25 30

Lys Leu Arg Leu Arg Asp Leu Leu Asp Ile Ser Pro Thr Leu Thr Glu
35 40 45

Ala Ala Gly Ala Ile Val Asp Asp Ser Phe Thr Arg Cys Phe Lys Ser
50 55 60



Asn Pro Pro Glu Pro Trp Asn Trp Asn Ile Tyr Leu Phe Pro Leu Trp
 65 70 75 80
 Cys Leu Gly Val Val Val Arg Tyr Gly Leu Leu Phe Pro Leu Arg Val
 85 90 95
 Ile Val Leu Thr Ile Gly Trp Ile Ile Phe Leu Ser Cys Tyr Phe Pro
 100 105 110
 Val His Phe Leu Leu Lys Gly His Asp Lys Leu Arg Lys Lys Leu Glu
 115 120 125
 Arg Gly Leu Val Glu Leu Met Cys Ser Phe Phe Val Ala Ser Trp Thr
 130 135 140
 Gly Val Val Lys Tyr His Gly Pro Arg Pro Ser Met Arg Pro Lys Gln
 145 150 155 160
 Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Val Leu Glu
 165 170 175
 Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly Trp Val
 180 185 190
 Gly Leu Leu Gln Ser Thr Ile Leu Glu Ser Leu Gly Cys Ile Trp Phe
 195 200 205
 Asn Arg Ser Glu Ser Lys Asp Arg Glu Ile Val Ala Lys Lys Leu Arg
 210 215 220
 Asp His Val His Gly Ala Asp Asn Asn Pro Leu Leu Ile Phe Pro Glu
 225 230 235 240
 Gly Thr Cys Val Asn Asn His Tyr Thr Val Met Phe Lys Lys Gly Ala
 245 250 255
 Phe Glu Leu Gly Cys Thr Val Cys Pro Ile Ala Ile Lys Tyr Asn Lys
 260 265 270
 Ile Phe Val Asp Ala Phe Trp Asn Ser Arg Lys Gln Ser Phe Thr Met
 275 280 285
 His Leu Leu Gln Leu Met Thr Ser Trp Ala Val Val Cys Asp Val Trp
 290 295 300
 Tyr Leu Glu Pro Gln Asn Leu Lys Pro Gly Glu Thr Pro Ile Glu Phe
 305 310 315 320
 Ala Glu Arg Val Arg Gly Ile Ile Ser Val Arg Ala Gly Leu Lys Lys
 325 330 335
 Val Pro Trp Asp Gly Tyr Leu Lys Tyr Ser Arg Pro Ser Pro Lys His
 340 345 350
 Arg Glu Arg Lys Gln Gln Ser Phe Ala Glu Ser Val Leu His His Leu
 355 360 365
 Glu Glu Lys
 370



<210> 27
 <211> 1582
 <212> DNA
 <213> Zee mays

<400> 27
 cctcgcccca tcccggaact ttccctggcg ggcgcgccat ctccatcgggc gggggcggtgc 20
 ggccgggtggc cgaagccctt aggcgatggc gacctcgtct gtggcgggcg acatggagct 120
 ggaccgggcca aacctggagg actacctccc gcccgactcg ctcccgccagg aggcgcgccg 180
 gaattctccat ctgcgcgata tgcctggacat ctgcgcgggtg ctccaccgagg cagcggggtgc 240
 cattgtcgat gactccttca cacgggtgctt taagtcaaat tctccagagc catggaattg 300
 caacatatat ctgttccctt tatgggtgctt tgggttagta ataagatatg gattactct 360
 tccactgagg tccctaacgc ttgcaatagg atgggttagca ttttttgctg ccttttttcc 420
 tgtccatttc ctattgaaag gtcaagacaa gttgagaagt aaaattgaga ggaagttggt 480
 tgaaatgatg tgcagtgttt ttgttgcttc atggactgga gttatcaagt atcatggacc 540
 accgccaagc acacgacctc atcagggtatt cgttgcaaac catacatcga tgatagattt 600
 cattattctg gagcaaatga cagcatttgc tgtcatcatg cagaagcacc ctggatgggt 660
 tggattttatt cagaagacta tcttggaag tgtcggttgc atctggttta atcgtaatga 720
 tctccgggac cgtgaagtta cggcacggaa gttacgtgat catgttcaac aaccagacaa 780
 caatctctct ttgatttttc cgggaaggaa ttgtgtgaac aaccagtaca cgtcatgtt 840
 caagaagggt gcccttgagc ttggctgcgc tgtatgtcca atagctatca agtacaataa 900
 aatatttgtt gatgcctttt ggaacagtaa gaagcaatct tttaaatgc acttggtccg 960
 gctgatgaca tcatgggctg ttgtgtgtga tgtttggtac ttacctctc aatatctgag 1020
 ggaggcgagc acggcaattg catttgcctg gagagtaagg gacatgatag ctgctagagc 1080
 tggactaaag aaggttccct gggatggcta tctgaaacac aaccgtccta gtcccaaca 1140
 cactgaagag aaacaacgca tatttgccga atctgtcttg atgagactgg aggagaaatg 1200
 aagggacgta aagcgcgtaca agtgcacttc gttagggttt tacatgcagc taccttgtaa 1260
 ttccgttggc ttccagaaaa aaaaaagtga gccctgggaca cgtcaagtga ccacctcagt 1320
 ttgttgtaa atttggtact agtttgatag gattattagt atgtacttat caggaaaaa 1380
 attctcagta tgtgttttgg ctgcccttc aatgataggt cagtgattaa caccgaagca 1440
 ttgtgctctc gtgagatgct gtgttggtct taatatattg accgtactgt accatgggtt 1500
 aaatgtgatt attgaagcaa tgtgaatgga ttagctggct aagaaaaaaa aaaaaaaa 1560
 aaaaaaaaaa aaaaaaaaaa ag 1582

<210> 28
 <211> 371
 <212> PRT
 <213> Zee mays

<400> 28
 Met Ala Thr Ser Ser Val Ala Ala Asp Met Glu Leu Asp Arg Pro Asn
 1 5 10 15
 Leu Glu Asp Tyr Leu Pro Pro Asp Ser Leu Pro Gln Glu Ala Pro Arg
 20 25 30
 Asn Leu His Leu Arg Asp Leu Leu Asp Ile Ser Pro Val Leu Thr Glu
 35 40 45
 Ala Ala Gly Ala Ile Val Asp Asp Ser Phe Thr Arg Cys Phe Lys Ser
 50 55 60
 Asn Ser Pro Glu Pro Trp Asn Trp Asn Ile Tyr Leu Phe Pro Leu Trp
 65 70 75 80
 Cys Phe Gly Val Val Ile Arg Tyr Gly Leu Leu Phe Pro Leu Arg Ser
 85 90 95
 Leu Thr Leu Ala Ile Gly Trp Leu Ala Phe Phe Ala Ala Phe Phe Pro
 100 105 110



Val His Phe Leu Leu Lys Gly Gln Asp Lys Leu Arg Ser Lys Ile Glu
 115 120 125
 Arg Lys Leu Val Glu Met Met Cys Ser Val Phe Val Ala Ser Trp Thr
 130 135 140
 Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr Arg Pro His Gln
 145 150 155 160
 Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Ile Leu Glu
 165 170 175
 Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly Trp Val
 180 185 190
 Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys Ile Trp Phe
 195 200 205
 Asn Arg Asn Asp Leu Arg Asp Arg Glu Val Thr Ala Arg Lys Leu Arg
 210 215 220
 Asp His Val Gln Gln Pro Asp Asn Asn Pro Leu Leu Ile Phe Pro Glu
 225 230 235 240
 Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys Lys Gly Ala
 245 250 255
 Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys Tyr Asn Lys
 260 265 270
 Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser Phe Thr Met
 275 280 285
 His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys Asp Val Trp
 290 295 300
 Tyr Leu Pro Pro Gln Tyr Leu Arg Glu Gly Glu Thr Ala Ile Ala Phe
 305 310 315 320
 Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly Leu Lys Lys
 325 330 335
 Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser Pro Lys His
 340 345 350
 Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val Leu Met Arg Leu
 355 360 365
 Glu Glu Lys
 370

<210> 29
 <211> 1422
 <212> DNA
 <213> Oryza sativa

<400> 29
 gcacgagatc actgcgaaga ttctctcggc ggccggcggag gggatcgacg gagggggggga 60
 tggcgacctc gtcggtggcg ggggacatcg agctggaccg gccgaacctg gaggactacc 120




```

ccccatccga ctcgctgcgc caggagtccc ccaggaatct ccattctggc gatctgctgg 180
acatctcgcc ggtgctcaat gaagcagcgg gcgccatcgt cgatgattca ttcacacggt 240
gctttaagtc aaattctcca gagccatgga attggaacat ttatttatcc ccattgtggt 300
gcttgggagt agtgataaga tacggaatac tattcccgct gaggggccta actctcttag 360
ttgcatggtt agcattcttt gctgcctttt ttctgtaca ttctttattg aaagctcaaa 420
agatgagaag taaaaatagag agaaagctgg ttgaaatgat gtgcagtgtt ttgtgtgctt 480
cttgcaactgg agtgatcaag tatcatgggc ctgcaccaag cacacggcct catcaggtat 540
ttgttgcaaa ccatacatcg atgatagatt tcattattct ggagcagatg acagcatttg 600
ctgtcattat gcaaaagcat cctggatggg ttggatttat tcagaagact atcttgaaaa 660
gtgttggttg catctgggtt aatcgcaatg atctcaagga tegtgaagtg gttgcaaaaa 720
agttacgaga tcatgttcaa catccagaca gcaatcctct cctgattttc cctgaaggaa 780
ttgtgtttaa caaccagtac actgtcatgt tcaagaaggg tgcttttgag cttggctgtg 840
ctgtatgccc aatagctatc aaatacaata aaatatttgt tgatgccttc tggaaatagta 900
agaagcaatc gtttacaatg cacttggtta ggcttatgac atcatgggca gttgtgtgtg 960
atgtatggta cttggagcct cagtatctga gggatggaga aacagcaatt gaatttgctg 1020
aaagagtaag agacatgata gctgctagag ctggtcttaa gaaggttccg tgggacgggt 1080
atctgaaaca caaccgccct agtcccaaac acactgaaga gaagcagcgc atctttgctg 1140
actctgtgtt gcgagactg gaggaagct aaacagatat caatcaactc tgggtgctcat 1200
tggtgagtcc aggttactaa tgtctagtgt tgtatctggg tctctggagt atgtggaaat 1260
taccactgca gttttgttgt aaattgtttg cagcttgaca gaatcaacat ttaatagcct 1320
gtattagcca agattttatg attggttagg gttaacacat aaatattata ccttcccaaa 1380
tgatgtatta atacttacct tcaaaaaaaaa aaaaaaaaaa ac 1422

```

<210> 30
 <211> 370
 <212> PRT
 <213> *Oryza sativa*

<400> 30
 Met Ala Thr Ser Ser Val Ala Gly Asp Ile Glu Leu Asp Arg Pro Asn
 1 5 10 15
 Leu Glu Asp Tyr Leu Pro Ser Asp Ser Leu Pro Gln Glu Phe Pro Arg
 20 25 30
 Asn Leu His Leu Arg Asp Leu Leu Asp Ile Ser Pro Val Leu Thr Glu
 35 40 45
 Ala Ala Gly Ala Ile Val Asp Asp Ser Phe Thr Arg Cys Phe Lys Ser
 50 55 60
 Asn Ser Pro Glu Pro Trp Asn Trp Asn Ile Tyr Leu Phe Pro Leu Trp
 65 70 75 80
 Cys Leu Gly Val Val Ile Arg Tyr Gly Ile Leu Phe Pro Leu Arg Gly
 85 90 95
 Leu Thr Leu Leu Val Gly Trp Leu Ala Phe Phe Ala Ala Phe Phe Pro
 100 105 110
 Val His Phe Leu Leu Lys Gly Gln Lys Met Arg Ser Lys Ile Glu Arg
 115 120 125
 Lys Leu Val Glu Met Met Cys Ser Val Phe Val Ala Ser Trp Thr Gly
 130 135 140
 Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr Arg Pro His Gln Val
 145 150 155 160



Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Ile Leu Glu Gln
 165 170 175
 Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly Trp Val Gly
 180 185 190
 Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly Cys Ile Trp Phe Asn
 195 200 205
 Arg Asn Asp Leu Lys Asp Arg Glu Val Val Ala Lys Lys Leu Arg Asp
 210 215 220
 His Val Gln His Pro Asp Ser Asn Pro Leu Leu Ile Phe Pro Glu Gly
 225 230 235 240
 Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe Lys Lys Gly Ala Phe
 245 250 255
 Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile Lys Tyr Asn Lys Ile
 260 265 270
 Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln Ser Phe Thr Met His
 275 280 285
 Leu Val Arg Leu Met Thr Ser Trp Ala Val Val Cys Asp Val Trp Tyr
 290 295 300
 Leu Glu Pro Gln Tyr Leu Arg Asp Gly Glu Thr Ala Ile Glu Phe Ala
 305 310 315 320
 Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala Gly Leu Lys Lys Val
 325 330 335
 Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro Ser Pro Lys His Lys
 340 345 350
 Glu Glu Lys Gln Arg Ile Phe Ala Asp Ser Val Leu Arg Arg Leu Glu
 355 360 365
 Glu Ser
 370
 <210> 31
 <211> 1392
 <212> DNA
 <213> Sorghum
 <400> 31
 gcacgagcca ggaatctcca tctgcgcgat ctgcttgaca tctcgccggt gctaaccgag 60
 gcagcgggtg ccatagtcga tgattcattc acgcgctgct ttaagtcgaa ttctccagaa 120
 ccatggaact ggaacatata ttgtttccct ttatgggtgct tcggtgtagt aattcgatat 180
 ggattactct tccactgag gtcccttaacg cttgcaatag gatggttagc attttttgct 240
 gcctttttcc ccgtgcattt cctattgaaa ggtcaagaca agttgagaaa taaaattgag 300
 aggaagtggg ttgaaatgat gtgcagtgtt ttgtttgctt catggactgg agtgatcaag 360
 taccatggac cagccccaag cacacgaact catcagggtat ttgttgcaaa ccatacatca 420
 atgatagatt tcattattct ggagcaaatg acagcatttg ctgtcatcat gcagaagcat 480
 cctggatggg ttggatttat tcagaagact atcttggaag gtgtgggttg catctgggtt 540
 aacogtaatg atctccggga tctggaagtt acggcacgga agttgcgtga tcatgttcaa 600
 catccagaca aaaacctctt cttgattttt ccagaaggaa cttgtgttaa caaccagtat 660
 acgggtcatgt tcaagaaggg tgcctttgag cttgggtgtg ctgtctgtcc aatagctatc 720



```

aaatacaata aaatatttgt tgatgccttt tggaaacagta agaagcaatc ttttacgatg 780
caattgggtcc gcttgatgac atcatgggct gttgtgtgtg atgttttgta cttggagcct 840
caatatctga gggagggaga gactgcaatt gcgtttgctg agagagtaag ggacatgata 900
gcagctagag ctgggtcttaa gaagggtccc tgggatggct atctgaaaca caaccgccct 960
agtcccaaac acaccgaaca gaagcaacgc atattgcgcg aatctgttct gaggagacta 1020
ggggagaaaat gaagagacat caaacactac aagcgcattt ggtagtggtt ttaccgttca 1080
gctaccttgt aattcggttg gctccccgaa aaaaaaaaaagt ccgggacacg tcaagtgcct 1140
agcttagttt tgttgtaaat ttattagaaa ttgacagaa ttggtagtgt gaacttacca 1200
agaaaaggaag aatagccgca tgtgtgtgtg ctgttcattc tatgattggt taggaattga 1260
cacttgaaac acggtactct attcagaggc tgtgtccgta tttatgaatc gacgatgtaa 1320
tgggttttaatt tcatgtgatt attgattcaa taatatgagt agattaaaaa aaaaaaaaaa 1380
aaaaaaaaaa aa 1392

```

<210> 32
 <211> 343
 <212> PRT
 <213> Sorghum

<400> 32
 Ala Arg Ala Arg Asn Leu His Leu Arg Asp Leu Leu Asp Ile Ser Pro
 1 5 10 15
 Val Leu Thr Glu Ala Ala Gly Ala Ile Val Asp Asp Ser Phe Thr Arg
 20 25 30
 Cys Phe Lys Ser Asn Ser Pro Glu Pro Trp Asn Trp Asn Ile Tyr Leu
 35 40 45
 Phe Pro Leu Trp Cys Phe Gly Val Val Ile Arg Tyr Gly Leu Leu Phe
 50 55 60
 Pro Leu Arg Ser Leu Thr Leu Ala Ile Gly Trp Leu Ala Phe Phe Ala
 65 70 75 80
 Ala Phe Phe Pro Val His Phe Leu Leu Lys Gly Gln Asp Lys Leu Arg
 85 90 95
 Asn Lys Ile Glu Arg Lys Leu Val Glu Met Met Cys Ser Val Phe Val
 100 105 110
 Ala Ser Trp Thr Gly Val Ile Lys Tyr His Gly Pro Arg Pro Ser Thr
 115 120 125
 Arg Pro His Gln Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe
 130 135 140
 Ile Ile Leu Glu Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His
 145 150 155 160
 Pro Gly Trp Val Gly Phe Ile Gln Lys Thr Ile Leu Glu Ser Val Gly
 165 170 175
 Cys Ile Trp Phe Asn Arg Asn Asp Leu Arg Asp Arg Glu Val Thr Ala
 180 185 190
 Arg Lys Leu Arg Asp His Val Gln His Pro Asp Lys Asn Pro Leu Leu
 195 200 205
 Ile Phe Pro Glu Gly Thr Cys Val Asn Asn Gln Tyr Thr Val Met Phe
 210 215 220



Lys Lys Gly Ala Phe Glu Leu Gly Cys Ala Val Cys Pro Ile Ala Ile
 225 230 235 240
 Lys Tyr Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Lys Lys Gln
 245 250 255
 Ser Phe Thr Met His Leu Val Arg Leu Met Thr Ser Trp Ala Val Val
 260 265 270
 Cys Asp Val Trp Tyr Leu Glu Pro Gln Tyr Leu Arg Glu Gly Glu Thr
 275 280 285
 Ala Ile Ala Phe Ala Glu Arg Val Arg Asp Met Ile Ala Ala Arg Ala
 290 295 300
 Gly Leu Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys His Asn Arg Pro
 305 310 315 320
 Ser Pro Lys His Thr Glu Glu Lys Gln Arg Ile Phe Ala Glu Ser Val
 325 330 335
 Leu Arg Arg Leu Glu Glu Lys
 340

<210> 33
 <211> 1466
 <212> DNA
 <213> Glycine max

<400> 33
 tctctctctc tctctctctc tctctctctc tctctctctg gacaaaattg cccctccatca 60
 ctttccctgt tagagttggt ttcgcaacc taccatgcaa ttcctcacct gaatccgttt 120
 tctattgcca cgttgggac gaaaagtcta gtttaaccac acgtttgtgg ttgtagtggg 180
 agcgtaacga agatgaatgg cattgggaaa ctcaaactgt cgagttctga attggacctt 240
 cacattgaag attacctacc ttctggatcc agtggtcaac aagaacggca tggcaagctc 300
 cgactgtgtg atttgcctaga catttctcct agtctatctg aggcagcagc tggcattgta 360
 gatgatacat tcacaagggt cttcaagtca aatcctccag aaccttggaa ctggaatggt 420
 tatttgtttc ctttgtggtg ctgtggagtt gtggttcgat atttgatttt gttccctatt 480
 aggattctag tgttggcatt aggatggatt atatttcttt cagccttcct tccagtgcac 540
 tccctcctga aaggaaatga tgatttgagg aaaaagattg agaggtgttt ggtggagatg 600
 atgtgcagtt tcttgttgc atcatggact ggggttgtca agtaccatgg gccaaagacct 660
 agtatccgac caaaacaggt ttttgtggcc aatcatactt ccatgattga ttccattatc 720
 ttagaacaga tgactgcatt tgctgttatt atgcagaagc atcctggatg ggttggatta 780
 ttgcagagca ccattttgga gagtgtgggg tgtatctggt tcaatcgtac agaggcaaa 840
 gatcgagaaa ttgtggcaag gaaattgagg gatcatgtcc tgggagctaa caataacctt 900
 cttctcatat ttctgaagg aacttgtgta aataatcact actctgtcat gttcaagaag 960
 ggtgcatttg aacttggctg cacaatttgc ccagttgcaa tcaagtacaa taaaattttc 1020
 gtcgatgctt ttggaatag tcgaaagcaa tcattcacca ctcatctctt gcaattaatg 1080
 acatcttggg ctgtagtgtg tgatgtttgg tacttggagc cacaaaattt gaagccagga 1140
 gagacaccca ttgaatttgc agagagagtt agagacataa tctcacatcg tgetgggctt 1200
 aaaaagggtc cttgggatgg atatctgaag tattctcgcc ctagtcccaa gcacagagaa 1260
 gqaaagcaac aaatatctgc tgagtctgtg ttgcggcgct ttgaggaaaa ataattgtata 1320
 tctttttact ttttcagtaa tgattttctc caaccttgt ttgtactcca cttactacta 1380
 tgatatacat gtagatetta catgaaattg cctgaaaatt ttccatgacc aaaaaaaaaa 1440
 aaaaaaaact cgagactagt tctctc 1466

<210> 34
 <211> 373



<212> PRT

<213> Glycine max

<400> 34

```

Met Asn Gly Ile Gly Lys Leu Lys Ser Ser Ser Ser Glu Leu Asp Leu
  1              5              10              15

His Ile Glu Asp Tyr Leu Pro Ser Gly Ser Ser Val Gln Gln Glu Arg
      20              25              30

His Gly Lys Leu Arg Leu Cys Asp Leu Leu Asp Ile Ser Pro Ser Leu
      35              40              45

Ser Glu Ala Ala Arg Ala Ile Val Asp Asp Thr Phe Thr Arg Cys Phe
      50              55              60

Lys Ser Asn Pro Pro Glu Pro Trp Asn Trp Asn Val Tyr Leu Phe Pro
      65              70              75              80

Leu Trp Cys Cys Gly Val Val Val Arg Tyr Leu Ile Leu Phe Pro Ile
      85              90              95

Arg Ile Leu Val Leu Ala Leu Gly Trp Ile Ile Phe Leu Ser Ala Phe
      100              105              110

Ile Pro Val His Ser Leu Leu Lys Gly Asn Asp Asp Leu Arg Lys Lys
      115              120              125

Ile Glu Arg Cys Leu Val Glu Met Met Cys Ser Phe Phe Val Ala Ser
      130              135              140

Trp Thr Gly Val Val Lys Tyr His Gly Pro Arg Pro Ser Ile Arg Pro
      145              150              155              160

Lys Gln Val Phe Val Ala Asn His Thr Ser Met Ile Asp Phe Ile Ile
      165              170              175

Leu Glu Gln Met Thr Ala Phe Ala Val Ile Met Gln Lys His Pro Gly
      180              185              190

Trp Val Gly Leu Leu Gln Ser Thr Ile Leu Glu Ser Val Gly Cys Ile
      195              200              205

Trp Phe Asn Arg Thr Glu Ala Lys Asp Arg Glu Ile Val Ala Arg Lys
      210              215              220

Leu Arg Asp His Val Leu Gly Ala Asn Asn Asn Pro Leu Leu Ile Phe
      225              230              235              240

Pro Glu Gly Thr Cys Val Asn Asn His Tyr Ser Val Met Phe Lys Lys
      245              250              255

Gly Ala Phe Glu Leu Gly Cys Thr Ile Cys Pro Val Ala Ile Lys Tyr
      260              265              270

Asn Lys Ile Phe Val Asp Ala Phe Trp Asn Ser Arg Lys Gln Ser Phe
      275              280              285

Thr Thr His Leu Leu Gln Leu Met Thr Ser Trp Ala Val Val Cys Asp
      290              295              300

```



Val Trp Tyr Leu Glu Pro Gln Asn Leu Lys Pro Gly Glu Thr Pro Ile
305 310 315 320

Glu Phe Ala Glu Arg Val Arg Asp Ile Ile Ser His Arg Ala Gly Leu
325 330 335

Lys Lys Val Pro Trp Asp Gly Tyr Leu Lys Tyr Ser Arg Pro Ser Pro
340 345 350

Lys His Arg Glu Gly Lys Gln Gln Ile Phe Ala Glu Ser Val Leu Arg
355 360 365

Arg Phe Glu Glu Lys
370

<210> 35

<211> 1384

<212> DNA

<213> Catalpa speciosa

<400> 35

```

gcaccaggta ggtttctgtc gagcattttg ttgtttgttt tggggttcta ttggattggt 60
gaaaccagta aggggaattga ggttgatggg caggggaata atgagtcctgc atctaggaat 120
cggtatgaag aggtggaagg aactgggggt attgtatcca atcatatata ttatatagat 180
atcctgtatc acatgtcttc ctctttccca agtttcgttt ccaagagatc cgctcgctaaa 240
cttctccttg ttggtcttgt gagcaagtgt cttggtttgt tatatgtaca gcgtgagtta 300
aagtgtctgg atttcaaggg ggtatcaggt gttgtcactg aaagaattca agaagctcat 360
caaaataagt ttgtccaaa gatgataatt tcccagaag gcacaactac aaatggggac 420
ttctctcttc cattcaagac tgggtgcatt ttggcaaagg ctccagtact tctgtcatt 480
ttaagatatt cgtaccagag atttagtccc gcgtgggact ctatttctgg ggctcgccat 540
gtgattcttc ttctctgtca gtttgtaaat tacattgaag tgacacattt gcctgtttat 600
catcgtctcg aacaagaaaa ggaagatccc aagctttctg ctgaaaatgt taggcttctg 660
atgggtcgtg agggtaattt gattctttct gatattggat tggcggagaa acgagtttat 720
catggtgtct tcaatgggtt actttgtcaa agataatcca gcttcgctat attgattgta 780
taaatgtatt ttttgacttc cataaaaacta ataactaagc ccataaatta cgctggaaga 840
ggtcattgat ctccatcgtc tatacgattt ctaactatta tctggacatc ttagttactg 900
cttcagcttt ggtaaggatc ctctaaagct gtctctattt gatacattag gcgctctggc 960
ttaatacaga acgtggaagc cgatgttgta ttaacgacgt tgggtgaacat ggagctattg 1020
cttctacttg aaatttgacc atccattatt tgattcttga gacatgaagt tgagaaatta 1080
gagttcgttt gagattagcc ataaatcgca tttctctaac agtttgttct actgggtacg 1140
gtattagttt ccccttgtat atagcacaaat gcaaagtctg tagttaacta ctttgttttg 1200
atcttctctt ttgtttgctt tattgcaacg ttaggagttg taaatatcct taaaatctag 1260
ttggattagc atagttaatt gtgaaatatg tagtggtgcc tgagaatggt cttggattgg 1320
aagctttgct tcttctggga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1380
aaaa 1384

```

<210> 36

<211> 251

<212> PRT

<213> Catalpa speciosa

<400> 36

Ala Arg Gly Arg Phe Leu Ser Arg Ile Leu Leu Phe Val Phe Gly Phe
1 5 10 15

Tyr Trp Ile Gly Glu Thr Ser Lys Gly Ile Glu Val Asp Gly Gln Gly
20 25 30



gacacgacgac	gggttgagga	gggaggccgt	gctgcgtgct	ggccgcgtgt	tgtcgcgggc	60
aatgctgttc	gtgttcgggt	tctactggat	ccccgtgtcc	gacgaaagt	cccccaatgc	120
cgaggatgta	cctaaagatc	actatgaaga	actggaaaga	ccaggggcga	ttgtatctaa	180
tcatgtgtca	tatgtggaca	ttctttatca	tatgtcagct	tcttctccga	gttttggttc	240
taagaactca	gtgtccaga	tgcggtgat	tgggtccta	agcaaattgc	ttgggtgcac	300
ttttgttcaa	cgagaatcca	aatggtcaga	ttctaaagg	gtctcagggt	ctgtaactga	360
aaggctccat	gagggtttcac	aagacgagaa	ttccctatg	atcttactct	ttcctgaggg	420
tactactacg	aatggggatt	accttctccc	atttaagaca	ggagcctttc	ttgcaagggc	480
accattgcaa	cctgtaattt	tgagatatcc	ttacaggaga	tttagtccag	cctgggactc	540
catgcatggg	gcacgtcatg	tgtttttgt	cctctgtcaa	tttgcaaat	acatagaggt	600
ggttcgcctt	gctgtatact	atccttctga	gcagaagaa	caggatccta	gagtcctatg	660
caacaacgct	agaaaattgc	ttgcgactga	gggtaattta	gttctgtcta	atcttgggct	720



```

ggctgaaaaag cgtgtgtatc atgcgggcact taatggtaat agtcctcgtg cctctgcatca 780
gaaagatgat tgaagccct tgcacacac tctgtacact atctgttgag gtgattgttaa 840
gaatgtatgc caacttttagc tgatcatgtg attcatgggt tctctgtttg aggagtatgt 900
tgattgatga aaacattata cctattttga gatgaattcc ctccttatac tacattgtat 960
agaaaccatt aaacattata gttaataat aatgtctggc ataattgttt tgcctgttca 1020
aaaaaaaaaa aaaaaaaaaa aa 1040

```

<210> 38
 <211> 261
 <212> PRT
 <213> Triticum aestivum

<400> 38

Cln Gly Leu Arg Arg Glu Ala Val Leu Arg Ala Gly Arg Val Leu Ser
 1 5 10 15

Arg Ala Met Leu Phe Val Phe Gly Phe Tyr Trp Ile Pro Val Ser Asp
 20 25 30

Arg Ser Phe Pro Asn Ala Glu Asp Val Pro Lys Asp His Tyr Glu Glu
 35 40 45

Leu Glu Arg Pro Gly Ala Ile Val Ser Asn His Val Ser Tyr Val Asp
 50 55 60

Ile Leu Tyr His Met Ser Ala Ser Ser Pro Ser Phe Val Ala Lys Asn
 65 70 75 80

Ser Val Ser Lys Leu Pro Leu Ile Gly Leu Ile Ser Lys Cys Leu Gly
 85 90 95

Cys Ile Phe Val Gln Arg Glu Ser Lys Cys Ser Asp Ser Lys Gly Val
 100 105 110

Ser Gly Ala Val Thr Glu Arg Leu His Glu Val Ser Gln Asp Glu Asn
 115 120 125

Ser Pro Met Ile Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Asp
 130 135 140

Tyr Leu Leu Pro Phe Lys Thr Gly Ala Phe Leu Ala Arg Ala Pro Leu
 145 150 155 160

Gln Pro Val Ile Leu Arg Tyr Pro Tyr Arg Arg Phe Ser Pro Ala Trp
 165 170 175

Asp Ser Met Asp Gly Ala Arg His Val Phe Leu Leu Leu Cys Gln Phe
 180 185 190

Ala Asn Tyr Ile Glu Val Val Arg Leu Pro Val Tyr Tyr Pro Ser Glu
 195 200 205

Gln Glu Lys Gln Asp Pro Arg Val Tyr Ala Asn Asn Val Arg Lys Leu
 210 215 220

Leu Ala Thr Glu Gly Asn Leu Val Leu Ser Asn Leu Gly Leu Ala Glu
 225 230 235 240

Lys Arg Val Tyr His Ala Ala Leu Asn Gly Asn Ser Pro Arg Ala Leu
 245 250 255



His Gln Lys Asp Asp
260

<210> 39
<211> 1459
<212> DNA
<213> Zea mays

<220>
<221> unsure
<222> (203)

<400> 39
gtttccaaatc atatctcgtc catagaaccc atattcttct tctatgaatt gttcccaacc 60
attgttttgt cagagtctca tgaatgcccta ccatttgttg gaacaattrat tccagcgtatg 120
cagggttatat atgttgacag attctcacca gcttctcgga aggcgtgctgt aaatgaaata 180
aagaagaagg cagcttgcaa tancctcccg cgggtcctgt tattccctga aggcaccaca 240
acaaatggga gattcctgat ttctgttcaa catggtgcgt tcataacctg ctacctgtt 300
caacctgttg ttgtccatta tccacatgtg cactttgatc aatcatgggg aaatatatcg 360
ttattaaagc tcatgttcaa gatgttcaca cagtttcata atttcatgga ggtagagtac 420
cttctgtttg tctacctctc tgagatcaag caagagaatg ccttccattc tgcagaggat 480
accaactatg ctatggcacg tgccttgaat gccttgccga cttattattc atggcgatct 540
tatgattatg gcacgagcag tagaagctgg aaagggtgaac tgcctcaaatt atatggtaga 600
aatggcttgg gttaaagatg tttacgggtat aagcacagca gaagtgatgg aactatttga 660
acatttcttg gctatgaatc cagataacga tggacgtgtg aaagctgaag atttctgggc 720
tcatatttgg ctggattgca gtctctctgt caagaagata tttcactatt tccatttaga 780
cattaagggg ttgattacgt tccgtcagtt cttgggttggg tgcgcgcacc tgagggaagca 840
accaactgtc cagggttctt gcgagaccgc ctttgagaag tgcgggggtc ctgaaacgtc 900
tgagatctcc agggcacagc tagctgatct cttgcggtta agcatgggtc caccctctga 960
tgataagatg ctggagctgt tcaagacgtt cgaatgtatg ggcgacgaga agatcagcag 1020
ggacgacttc atggcgtgtc ttgggaggtt cccgttctct atcgcgttct ttgctgcctt 1080
gatcaatggg gaagtgtaca tccagatagt ctgaatgaat gcctgaggca aagcgatgcc 1140
gcgtaaaagg ctggagctgc cagtgcacag cgtaggcagg ggatccctcc gtttatgcaa 1200
tgttgatacc caccgggtgc tcttccactt tgagacccaa gcaactgtat tattgggtat 1260
tgtgttgcac caagtggctg accagtgtat tgcgtcgatt ttgtttagtt gtttctgttc 1320
aattattatt ggccatttac cgaatctgtt gagatacggc ctggactagt agattgtcga 1380
tggaactcag aacgcaaata gaaagcatct gtaatctgaa ctaactgaga aaacatttaa 1440
aaaaaaaaa aaaaaaaaaa 1459

<210> 40
<211> 204
<212> PRT
<213> Zea mays

<220>
<221> UNSURE
<222> (68)

<400> 40
Val Ser Asn His Ile Ser Tyr Ile Glu Pro Ile Phe Phe Phe Tyr Glu
1 5 10 15
Leu Phe Pro Thr Ile Val Ser Ser Glu Ser His Asp Ala Leu Pro Phe
20 25 30
Val Gly Thr Ile Ile Arg Ala Met Gln Val Ile Tyr Val Asp Arg Phe
35 40 45



Ser Pro Ala Ser Arg Lys Ala Ala Val Asn Glu Ile Lys Arg Lys Ala
 50 55 60
 Ala Cys Asn Xaa Phe Pro Arg Val Leu Leu Phe Pro Glu Gly Thr Thr
 65 70 75 80
 Thr Asn Gly Arg Phe Leu Ile Ser Phe Gln His Gly Ala Phe Ile Pro
 85 90 95
 Gly Tyr Pro Val Gln Pro Val Val Val His Tyr Pro His Val His Phe
 100 105 110
 Asp Gln Ser Trp Gly Asn Ile Ser Leu Leu Lys Leu Met Phe Lys Met
 115 120 125
 Phe Thr Gln Phe His Asn Phe Met Glu Val Glu Tyr Leu Pro Val Val
 130 135 140
 Tyr Pro Pro Glu Ile Lys Gln Glu Asn Ala Leu His Phe Ala Glu Asp
 145 150 155 160
 Thr Ser Tyr Ala Met Ala Arg Ala Leu Asn Ala Leu Pro Thr Tyr Tyr
 165 170 175
 Ser Trp Arg Phe Tyr Asp Tyr Gly Thr Ser Ser Arg Ser Trp Lys Gly
 180 185 190
 Glu Leu Leu Lys Leu Tyr Gly Arg Asn Gly Leu Gly
 195 200

<210> 41
 <211> 2115
 <212> DNA
 <213> Oryza sativa

<400> 41
 gcacgaggtt ctaaccggcc tectctcgcc tgcctccgc caccatggc ttctcgaaac 60
 cctagccccg cctccctctc cagcgcgtc ctctccgact ccatctcgcc cagccccacc 120
 accaacggcc acgcggggca ccataaccac gacgacgac acgaggagtc gccaacggtg 180
 tgcggcgggc atggcggagg agggggggac ccgttcgcgt tctatcggg ggcgcggccg 240
 gcgtgggtgt cgcgcggggg ggtgtccccg gcgcaccgt tccgcaacgg gacgcggggg 300
 tgggtgcggg cgtacgagct cgtgagggcg ctggtgtgcg cgcgggtggc ggcggcgagg 360
 ctggtgctgt tccggctctc catcgcggtg gggtaacgcg ccacgtgggt ggcgctccgc 420
 ggggtgggtc acgtgcggga ggcggcgggc caggagggcg ccgggccccat gccggcgtgg 480
 cgccgcgcgc tcatgtggat cagcgggatc tccgcgcgt gcctcctctt ctcttcgga 540
 taccattgga taaggaggaa aggaaaacc gcgcctagag agcttgacc tatagttgtc 600
 tcaaactcatg tatcatacat agaaccata tacttctct atgagctgt cccgacaatc 660
 gtttcttcag attctcatga ttccatacca ttgtttggaa caattatccg agcaatgcag 720
 gttatatatg ttgacagatt ctgcgcagct tcaagggaagt ctgctgtaaa tgaaataaag 780
 gatgtgattt cagagaaaag cggcttgcaa tagcttccca cgtgtcttgt tattcccgga 840
 aggcacgaca acaaatggaa gatttctgat ttctttccaa catggtgcat tcatacctgg 900
 ctaccctgtt caacctgtta ttgtgcgcta tccacatgtg cactttgatc aatcatgggg 960
 aaatatatca ttaggaaagc tcatgttcaa gatgtttacc cagtttcaca atttcattga 1020
 ggtagagtac ctccctgttg tttaaccacc tgagatcaag caagagaatg ccttctattt 1080
 tgcagagaac actagctatg ctatggcaca tgcaactta gttattccaa cctcttattt 1140
 atatggggat tcaatgatca tggctcgagc agtggaagat ggaaagggtg actgtcctaa 1200
 ttatatgggt gagatggctt gggtaaaaga aacatatggt gtgagcacat cagaagcaat 1260
 ggcactcttg gaagactttt tgtgtatgag ccagacaaag gacggacgtg tgaatgcgca 1320
 agatttttgg gctcattttg gccttaattg caccctctt tgcaagaaga tatttcagta 1380
 cttcgatttt gaagccaagg aatccatcac attcgcgcag ttcttgattg gatgtgcgca 1440



```

cctcaggaag cagccatcgt ttcaggacgc ctgcgaaaacc ggcgtttgaga ggtgtaggaa 1500
tcccttaaca tctccatcgt gcagggagca gctcgccgat gtcctgcggt caagcatgct 1560
tgagctgatg accgataatg gcatgatgaa gctgttcaag acgttggacg tcgacgatga 1620
cgacggaatg agcaaggatg acctgatggc atcccttagg aagctccctt tcatgatcgc 1680
gtctctcccg ggcgggatca acggggaaat ctacatcgag atagtgtgat cgaatggatt 1740
gatgcagggg gagagcaaaa atgggtggatg gcagtgttga acgcggtggg agacgacaga 1800
cgctcgtctg tttttagagg gatggtttcc aaccgcttca ccgtccatgt agctttctca 1860
ggcgtgttgg actaaagtgg ctaaccggta tagtgcgcaa tttgtttca tategtaaaa 1920
atatatatat atatccatag aaaagctgtc gcgtgatggc acgtcggatt gtgcaatgtg 1980
gatatgatac tgtacaacat tggccaactt ggcgtgcac atagaaaact ttttttgggt 2040
ttgggttggg ttggctaact ggatggatga ttacaaaact ctttttgggt aaaaaaaaaa 2100
aaaaaaaaaa aaaaaa                                     2115

```

<210> 42
 <211> 255
 <212> PRT
 <213> Oryza sativa

<400> 42
 Met Ala Ser Arg Asn Pro Ser Pro Ala Ser Leu Ser Thr Pro Leu Leu
 1 5 10 15
 Ser Asp Ser Ile Ser Pro Thr Pro Thr Thr Asn Gly His Ala Gly His
 20 25 30
 His Asn His Asp Asp Asp Asp Glu Glu Ser Pro Thr Val Cys Gly Gly
 35 40 45
 Asp Gly Gly Gly Gly Gly Asp Pro Phe Ala Phe Leu Ser Glu Asp Arg
 50 55 60
 Pro Ala Trp Trp Ser Pro Arg Gly Val Ser Pro Ala Asp Pro Phe Arg
 65 70 75 80
 Asn Gly Thr Pro Gly Trp Cys Gly Ala Tyr Glu Leu Val Arg Ala Leu
 85 90 95
 Val Cys Ala Pro Val Ala Ala Ala Arg Leu Val Leu Phe Gly Leu Ser
 100 105 110
 Ile Ala Val Gly Tyr Ala Ala Thr Trp Val Ala Leu Arg Gly Trp Val
 115 120 125
 Asp Val Arg Glu Arg Ala Ala Gln Glu Gly Ala Gly Pro Met Pro Ala
 130 135 140
 Trp Arg Arg Arg Leu Met Trp Ile Thr Arg Ile Ser Ala Arg Cys Ile
 145 150 155 160
 Leu Phe Ser Phe Gly Tyr His Trp Ile Arg Arg Lys Gly Lys Pro Ala
 165 170 175
 Pro Arg Glu Leu Ala Pro Ile Val Val Ser Asn His Val Ser Tyr Ile
 180 185 190
 Glu Pro Ile Tyr Phe Phe Tyr Glu Leu Phe Pro Thr Ile Val Ser Ser
 195 200 205
 Asp Ser His Asp Ser Ile Pro Phe Val Gly Thr Ile Ile Arg Ala Met
 210 215 220



Gln Val Ile Tyr Val Asp Arg Phe Ser Pro Ala Ser Arg Lys Ser Ala
225 230 235 240

Val Asn Glu Ile Lys Asp Val Ile Ser Glu Lys Gly Gly Leu Gln
245 250 255

<210> 43
<211> 2041
<212> DNA
<213> Glycine max

<400> 43
gcacgaggcg acgacgaaga cttctccgtg ccgccaccgt ccaccctgga cccgttccgc 60
aacccacagc cggcgatcga ggggctctac gagggggcca agacggcgct gtgcctgccg 120
ctggcgggcg tggcgctcgc gctgttcggg ctctgcctcg cggtggggta cgtggcgacg 180
aagggtggcg tggcagggtg gaaggacaag gagaatccca tggccaagtg gaggtgtagg 240
gttatgtgga tcacgcgctt gtgcgccaga tgtattctct tctcctttgg ctatcagtg 300
ataaaacgga aaggaaaacc tgcaccaagg gaaattgctc caataattgt atctaaccat 360
gtttcttata ttgagcctat cttctatttc tatgaattat ttcttaccat tgtggcagct 420
gagttctatg actccatacc tttgtttggc accattatta gagcaatgca ggtcatatat 480
gttaacagat tcttaccatc atcaagggaag cagggtgtta gggaaataaa gaaatctgct 540
ttcaagggaac tgaataacag agaagggcct cttgtgataa atttccctga gtactattat 600
ttcccgaggg aacaacaact aatggcagga accttatctc cttccaactt ggtgcattta 660
tccctggata cccaatccag cctgtaatta tacgctatcc tcatgtacac tttgaccaat 720
cctggggtaa tgtttctttg ggaaagctta tgttcagaat gttcaactca tttcacaact 780
tttttgaggt agaatatctt cctgtcattt atccccctgga tgataaggaa actgctgtac 840
attttcggga gaggactagc cgtgctatcg caactgcact aaatgctgtc cagacaggac 900
attcttatgg agacataatg cttcatatga aagcacaaga agcaaaacag gagaacccct 960
caagttttat ggttgaaatg accaagggtg aatcattatt tcatatcagc agcacggaag 1020
ctgtggactt tctggataaa tcttggcca tgaatcctga tcccagtggc cgtgttcaat 1080
atcatgactt cttgagggtt ttaagactta aggccttgcc actatctgca aagatatttt 1140
cattcattga tgtggagaag agtgggacaa ttacgttcag acagttcttg tatggatctg 1200
cccatgttat gtcccaacct gggttcgatc aaacctttga agaagccttt gctggctgtg 1260
gcggtgcagt aaagacctat gttgttgaa cagagttacg agatttcac caacctgcta 1320
tcttcaattg gaggtaggat gaggtccatg agttttttat gttatttgac aatgataatg 1380
atggaagaat tgacaagaat gactttcttt catgccttag aagaaatcct cttctcatag 1440
catttttacc acctcagcca cagcaaaaag aatttgaagg taatggagtg atagaaatag 1500
tgtgatggat ggatttcaca ttcagggtctt ttgtggacta caaagaaaag aaatgggtag 1560
ggattcctgg ggaatacata cagtatagga tgcagtggcc tcattttttt ttttttttcc 1620
ttttctcttt taattttttt acctgtctct gattaattac tcgtaaaagca taactatttg 1680
gtgaagatct gtgccatcca tctgtcttca tttgatgttt tttgttagct aggtcagttt 1740
tgcacagcta gatgtcagtt acctggatgt tgtgatcaca ccgatccaac atttgagttt 1800
tgggttcagg accatgctga catttagggt ccatgtgggt catgtaaagt ttgaaccaac 1860
gtgtcaattt gtaacaaaca ttataactgt attttttttc aaagatgtga acatgaagaa 1920
agtaatgtaa tttattttga aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaactcgag 1980
gggggggccc gttgttttcg aggtcgacgt gctcgataag attgtatcca caccgagcgc 2040
g 2041

<210> 44
<211> 228
<212> PRT
<213> Glycine max

<400> 44
Ala Arg Gly Asp Asp Asp Asp Phe Ser Val Pro Pro Pro Ser Thr Leu
1 5 10 15
Asp Pro Phe Arg Asn Arg Thr Pro Ala Ile Glu Gly Leu Tyr Glu Trp
20 25 30



Ala Lys Thr Ala Leu Cys Leu Pro Leu Ala Ala Leu Arg Leu Ala Leu
 35 40 45

Phe Gly Leu Cys Leu Ala Val Gly Tyr Val Ala Thr Lys Val Ala Leu
 50 55 60

Ala Gly Trp Lys Asp Lys Glu Asn Pro Met Pro Lys Trp Arg Cys Arg
 65 70 75 80

Val Met Trp Ile Thr Arg Leu Cys Ala Arg Cys Ile Leu Phe Ser Phe
 85 90 95

Gly Tyr Gln Trp Ile Lys Arg Lys Gly Lys Pro Ala Pro Arg Glu Ile
 100 105 110

Ala Pro Ile Ile Val Ser Asn His Val Ser Tyr Ile Glu Pro Ile Phe
 115 120 125

Tyr Phe Tyr Glu Leu Phe Pro Thr Ile Val Ala Ala Glu Ser His Asp
 130 135 140

Ser Ile Pro Phe Val Gly Thr Ile Ile Arg Ala Met Gln Val Ile Tyr
 145 150 155 160

Val Asn Arg Phe Leu Pro Ser Ser Arg Lys Gln Ala Val Arg Glu Ile
 165 170 175

Lys Lys Ser Ala Phe Lys Glu Leu Asn Asn Arg Glu Gly Pro Leu Val
 180 185 190

Ile Asn Phe Leu Glu Tyr Tyr Tyr Phe Pro Arg Glu Gln Gln Leu Met
 195 200 205

Ala Gly Thr Leu Ser Pro Ser Asn Leu Val His Leu Ser Leu Asp Thr
 210 215 220

Gln Ser Ser Leu
 225

<210> 45
 <211> 1502
 <212> DNA
 <213> Zea mays

<400> 45
 gcacgaggtc gtctcaccba tgccgatccg gcgtcagcgc tagggttagg gtctctctctg 60
 cgccctttatc gccatggctc ctaacgaagc cgctagcatc accaccccggt ccgagccgga 120
 gagcgtgggc ggcagtgaga tgagcagcga agacatggcc gccgccagtc cgctctctctc 180
 gtcgtctctcc cctctccctt cccctccgc agcccccgtg ctggagagca tagaggaact 240
 ggaccggaag tacgcacogt acgcgcggcg ggacgcgtac ggaccgatgg ggctcggccc 300
 cgtgagcgca gccgaggctg cgcggctggc gtttgccgcg gtcgtgctgg tcccgcctccg 360
 tgtcgtggca ggtgttctcg tactcgtggc ctactacctc gtgtgccgcg tgtgcacgct 420
 gcgggtggag gaggaccggg agggcggcga aggggatggg tacgcgcggt tggaccgggtg 480
 gaggcgggcg ggggctgtgc ggtgcggccg cgcactcgct cgcgccatgt tgtttgtctt 540
 cgggttctat tggatccgag agtacgacag ccgccttccc aatgctgagg atggccatgt 600
 ggaccagtct aaagaaatcg aaaggcctgg ggcaattgtg tctaatacatg tatcttatgt 660
 ggatattctt tatcacatgt cagcctcttt tctagtttt gttgctaaga gatcagtggc 720
 tagattgcct ctagtggctc tcataagcaa atgtcttgga tgcatttttg ttcagcggga 780
 gtcgaaaaca ccagatttca aagggtgtttc aggtgctgta tctgaaagaa tccatcgtgc 840



```

tcattcaacag aaaaatgcac caatgatgct acttcttccct gaggggcacaa ctacaaatgg 900
ggattatctc cttccattca aaacagggtgc tttctttgca aaggcaccag ttcaaccagt 960
cattttgaga tatccttaca aaagatttaa tgcagcatgg gattccatgt caggggcacg 1020
tcattgtattt ctgtgtctct gtcaatttgt aaattaccta gaggtgggtcc gottaccagt 1080
tactatctct ttgagcaag aaaaggatca tcttaacctc tatgcaaaaca atgtacggaa 1140
actgatggca gtggaggga acttgattct ttcagacctt gggctggcgg agaagcgagt 1200
gtacgatgcc gcactgaatg gtaatagtct agctcgtgct ttacatcaga aagatgattg 1260
aaatgccatg ctatcgtgct tccataatac tggcttgctt gtaactgtgt gcttgcttgt 1320
gcctcgtcat ggttgagagg aatgtcgtga atatactatc cggcataaat ctgtaaaagta 1380
atttaccaac tgtcatagtt cagtaattat gttgggttata ctctacatg gttgggcctc 1440
cgcacatttg atcctgtggt caatccatgt gagccttttt tactaaaaaa aaaaaaaaaa 1500
aa 1502

```

<210> 46
 <211> 395
 <212> PRT
 <213> Zea mays

<400> 46

Met Ala Pro Asn Glu Ala Ala Ser Ile Thr Thr Pro Ser Glu Pro Glu
 1 5 10 15

Ser Val Gly Gly Ser Glu Met Ser Ser Glu Asp Met Ala Ala Ala Ser
 20 25 30

Pro Leu Leu Ser Ser Ser Ser Pro Ser Pro Ser Pro Ser Ala Ala Pro
 35 40 45

Val Leu Glu Ser Ile Glu Glu Leu Asp Arg Lys Tyr Ala Pro Tyr Ala
 50 55 60

Arg Arg Asp Ala Tyr Gly Pro Met Gly Leu Gly Pro Val Ser Ala Ala
 65 70 75 80

Glu Ala Ala Arg Leu Ala Phe Ala Ala Val Val Leu Val Pro Leu Arg
 85 90 95

Val Val Ala Gly Val Leu Val Leu Val Val Tyr Tyr Leu Val Cys Arg
 100 105 110

Val Cys Thr Leu Arg Val Glu Glu Asp Arg Glu Gly Gly Glu Gly Asp
 115 120 125

Gly Tyr Ala Arg Leu Asp Gly Trp Arg Arg Ala Gly Ala Val Arg Cys
 130 135 140

Gly Arg Ala Leu Ala Arg Ala Met Leu Phe Val Phe Gly Phe Tyr Trp
 145 150 155 160

Ile Arg Glu Tyr Asp Ser Arg Leu Pro Asn Ala Glu Asp Gly His Val
 165 170 175

Asp Gln Ser Lys Glu Ile Glu Arg Pro Gly Ala Ile Val Ser Asn His
 180 185 190

Val Ser Tyr Val Asp Ile Leu Tyr His Met Ser Ala Ser Phe Pro Ser
 195 200 205

Phe Val Ala Lys Arg Ser Val Ala Arg Leu Pro Leu Val Gly Leu Ile
 210 215 220



Ser Lys Cys Leu Gly Cys Ile Phe Val Gln Arg Glu Ser Lys Thr Pro
225 230 235 240

Asp Phe Lys Gly Val Ser Gly Ala Val Ser Glu Arg Ile His Arg Ala
245 250 255

His Gln Gln Lys Asn Ala Pro Met Met Leu Leu Phe Pro Glu Gly Thr
260 265 270

Thr Thr Asn Gly Asp Tyr Leu Leu Pro Phe Lys Thr Gly Ala Phe Leu
275 280 285

Ala Lys Ala Pro Val Gln Pro Val Ile Leu Arg Tyr Pro Tyr Lys Arg
290 295 300

Phe Asn Ala Ala Trp Asp Ser Met Ser Gly Ala Arg His Val Phe Leu
305 310 315 320

Leu Leu Cys Gln Phe Val Asn Tyr Leu Glu Val Val Arg Leu Pro Val
325 330 335

Tyr Tyr Pro Ser Gln Gln Glu Lys Asp Asp Pro Lys Leu Tyr Ala Asn
340 345 350

Asn Val Arg Lys Leu Met Ala Val Glu Gly Asn Leu Ile Leu Ser Asp
355 360 365

Leu Gly Leu Ala Glu Lys Arg Val Tyr His Ala Ala Leu Asn Gly Asn
370 375 380

Ser Leu Ala Arg Ala Leu His Gln Lys Asp Asp
385 390 395

<210> 47

<211> 1555

<212> DNA

<213> Oryza sativa

<400> 47

```
gcacgaggtt taaaccacgt ctctgcgcca tctctctcatg cctaccact gctagggttc 60
gcccctaagc cccccacoot ctccgccatg gctctccctc tccacgacgc caccacctcc 120
ccctccgacc ccgacgacct cggcggcggc ggcgaggagg aggaggagag gctcgcctcg 180
aagccgctgc tctcgtcccc gtccacctat ccttcgcggg ggacggagga gggcgctcgag 240
gagctggagc tgcaccggag gtacgcgcgc tacgcgaggg gggacgcgta cggggcgatg 300
ggcgggggccc cctggggcgc ggcggggggc gggcggttg cggtgggcgc cgcggtgctc 360
ttcccgctcc ggctcgccgc gggcggtgctc gtgctcgctc cctactacct cgtgtgcccgc 420
gtgtgcacgc tgcgtgtgga ggaggaggag cgcgagggtg gcggtggcgg cgcggttggg 480
gaagtggagg gggacgggta cgcgcggctc gaggggtgga ggcgtgaggg cgtcgtgccc 540
tgcggccgcg cgtcgcgcgc cgcctatgctg ttctctctcg gcttctactg gatccgcgag 600
tacgactgcc gcttccctga tgcgtgaggat gagcatcagg aacagtccaa agaattggga 660
agaccagggg cagtagtata taatcatgta tcttatgttg atattcttta ccacatgtca 720
tcttctctcc caagctttgt tgccaagaga tcagtggcca gattgcccac ggttggtctc 780
ataagcaaat gtcttgatg catttttgt cagcgggaat ctaaaacctc agatttcaaa 840
ggcgtttcag gtgctgtgac tgagagaatc caacgggctc atcaacagaa gaattctcca 900
atgatgttac ttttccctga aggcacaact acaaatggtg attatctcct ccttttcaag 960
acaggagcat ttcttgcaaa agcaccagtg aagccagtca ttttaagata tctttacaag 1020
agatttagtc cagcatggga ttcgatgtct ggggctcggc atgtatttct gctcctttgt 1080
caatttgtaa ataacctga ggtgatccat ctgcctgtgt attaccatc tgagcaagag 1140
aaggaagatc ctaagctgta cgcaaataat gtacggaaat tgatggcagt ggaggggaac 1200
```



```

ttgattcttt ctgatcttgg gctagcagag aagcgtgtgt accatgcggc attgaatggt 1260
aataatagtc tacctcgtgc ttacatcag aaagatgatt gaaatgcctt gccatcggcg 1320
ttctgtatac tgatgctgag tgacttgctt gtaatatgag tacaagttec tgggtgttgc 1380
tgattcttca tgttgagagg agctatgta atatctccc agtaaaactgt aaaattattt 1440
gtccatagtg tggttcagta atcatgtcag ttatcatga ttacattcac atgtctggga 1500
cacacttcac catgcaatcc atcagatgtga gctttataaa aaaaaaaaaa aaaaaa 1555

```

<210> 48

<211> 404

<212> PRT

<213> *Oryza sativa*

<400> 48

```

Met Ala Leu Pro Leu His Asp Ala Thr Thr Ser Pro Ser Asp Pro Asp
  1              5              10              15

```

```

Asp Leu Gly Gly Gly Gly Glu Glu Glu Glu Arg Leu Ala Ser Lys
          20              25              30

```

```

Pro Leu Leu Ser Ser Pro Ser Thr Tyr Pro Ser Ala Gly Thr Glu Glu
          35              40              45

```

```

Gly Val Glu Glu Leu Glu Leu Asp Arg Arg Tyr Ala Pro Tyr Ala Arg
          50              55              60

```

```

Arg Asp Ala Tyr Gly Ala Met Gly Arg Gly Pro Leu Gly Ala Ala Gly
          65              70              75              80

```

```

Ala Gly Arg Leu Ala Val Gly Ala Ala Val Leu Phe Pro Leu Arg Leu
          85              90              95

```

```

Ala Ala Gly Val Leu Val Leu Val Ala Tyr Tyr Leu Val Cys Arg Val
          100              105              110

```

```

Cys Thr Leu Arg Val Glu Glu Glu Glu Arg Glu Gly Gly Gly Gly Gly
          115              120              125

```

```

Ala Ala Gly Glu Val Glu Gly Asp Gly Tyr Ala Arg Leu Glu Gly Trp
          130              135              140

```

```

Arg Arg Glu Gly Val Val Arg Cys Gly Arg Ala Leu Ala Arg Ala Met
          145              150              155              160

```

```

Leu Phe Val Phe Gly Phe Tyr Trp Ile Arg Glu Tyr Asp Cys Arg Phe
          165              170              175

```

```

Pro Asp Ala Glu Asp Glu His Gln Glu Gln Ser Lys Glu Leu Gly Arg
          180              185              190

```

```

Pro Gly Ala Val Val Ser Asn His Val Ser Tyr Val Asp Ile Leu Tyr
          195              200              205

```

```

His Met Ser Ser Ser Phe Pro Ser Phe Val Ala Lys Arg Ser Val Ala
          210              215              220

```

```

Arg Leu Pro Met Val Gly Leu Ile Ser Lys Cys Leu Gly Cys Ile Phe
          225              230              235              240

```

```

Val Gln Arg Glu Ser Lys Thr Ser Asp Phe Lys Gly Val Ser Gly Ala
          245              250              255

```



Val Thr Glu Arg Ile Gln Arg Ala His Gln Gln Lys Asn Ser Pro Met
260 265 270

Met Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Asp Tyr Leu Leu
275 280 285

Pro Phe Lys Thr Gly Ala Phe Leu Ala Lys Ala Pro Val Lys Pro Val
290 295 300

Ile Leu Arg Tyr Pro Tyr Lys Arg Phe Ser Pro Ala Trp Asp Ser Met
305 310 315 320

Ser Gly Ala Arg His Val Phe Leu Leu Leu Cys Gln Phe Val Asn Asn
325 330 335

Leu Glu Val Ile His Leu Pro Val Tyr Tyr Pro Ser Glu Gln Glu Lys
340 345 350

Glu Asp Pro Lys Leu Tyr Ala Asn Asn Val Arg Lys Leu Met Ala Val
355 360 365

Glu Gly Asn Leu Ile Leu Ser Asp Leu Gly Leu Ala Glu Lys Arg Val
370 375 380

Tyr His Ala Ala Leu Asn Gly Asn Asn Ser Leu Pro Arg Ala Leu His
385 390 395 400

Gln Lys Asp Asp

<210> 49
<211> 1072
<212> DNA
<213> Glycine max

<400> 49
gacgagggga agattacggt catatgagtg ggttgaggag aaccgtcatt gtttctgtgtg 60
gacgagggcct ctccagagtc atgctcttca ttttoggctt ttattggatc cccgaatcca 120
actctgcttc tcaggaagac cggagtcagc ctgaagagtt ggggagacct agcgtataaa 180
tatctaataca tgtgtcatac ttggatattt tgtatcacat gtctctctca ttcccaagtt 240
ttgttgctaa gagatcagtg gctaaaacttc cgctcattgg tctcatcagc aagtgccttg 300
gttgtgtgta tgttcagcgg gaatcaaagt catcggactt caagggtgtt tcagctgttg 360
tcactgacag aattcaagaa gctcatcaga atgagtcctg tccattaatg atgttatctc 420
cagaagggaac aaccacaaat ggagagttcc tcttccatt caagactggt ggttttttgg 480
caaaggcacc agtacttct gtgattttta gatataatta ccagagattt agccccgcct 540
gggattccat atctgggggtg cgccatgtaa tatttctct gtgtcagttt gtgaattata 600
tggaggtgat ccgagtacct gtttaccatc cctcacagca ggagatgaat gatcccaaac 660
tatatgctaa taatgttaga aggttgatgg ctactgaggg taatttgata ctttctgata 720
ttgggttagc tgaaaaacga atatatacag ctgctctcaa tggtaataat agcatgccta 780
gtgttttgca tcagaaagac gaatgataat ttcattggccc cgtctcaaa tgaaatgtag 840
ttccagtcga gttttagttt caaacttagt atctgtttat gaatggacag cttgtgtgaa 900
gggtatagct aaatagtata cattcaccta aacatctgaa tggtagttgt gtaattttct 960
tgtaaataac gtgaccaata atgttttaat tgtggtgaa ctcaatttga ggcacacaat 1020
tcaagatcta taagttaaac tgttcttcgt tcaaaaaaaaa aaaaaaaaaa aa 1072

<210> 50
<211> 267
<212> PRT
<213> Glycine max



<400> 50
 Thr Arg Glu Asp Tyr Ala His Met Ser Gly Leu Arg Arg Thr Val Ile
 1 5 10 15
 Val Ser Cys Gly Arg Ala Leu Ser Arg Val Met Leu Phe Ile Phe Gly
 20 25 30
 Phe Tyr Trp Ile Pro Glu Ser Asn Ser Ala Ser Gln Glu Asp Arg Ser
 35 40 45
 Gln Pro Glu Glu Leu Gly Arg Pro Ser Val Ile Ile Ser Asn His Val
 50 55 60
 Ser Tyr Leu Asp Ile Leu Tyr His Met Ser Ser Ser Phe Pro Ser Phe
 65 70 75 80
 Val Ala Lys Arg Ser Val Ala Lys Leu Pro Leu Ile Gly Leu Ile Ser
 85 90 95
 Lys Cys Leu Gly Cys Val Tyr Val Gln Arg Glu Ser Lys Ser Ser Asp
 100 105 110
 Phe Lys Gly Val Ser Ala Val Val Thr Asp Arg Ile Gln Glu Ala His
 115 120 125
 Gln Asn Glu Ser Ala Pro Leu Met Met Leu Phe Pro Glu Gly Thr Thr
 130 135 140
 Thr Asn Gly Glu Phe Leu Leu Pro Phe Lys Thr Gly Gly Phe Leu Ala
 145 150 155 160
 Lys Ala Pro Val Leu Pro Val Ile Leu Arg Tyr His Tyr Gln Arg Phe
 165 170 175
 Ser Pro Ala Trp Asp Ser Ile Ser Gly Val Arg His Val Ile Phe Leu
 180 185 190
 Leu Cys Gln Phe Val Asn Tyr Met Glu Val Ile Arg Val Pro Val Tyr
 195 200 205
 His Pro Ser Gln Gln Glu Met Asn Asp Pro Lys Leu Tyr Ala Asn Asn
 210 215 220
 Val Arg Arg Leu Met Ala Thr Glu Gly Asn Leu Ile Leu Ser Asp Ile
 225 230 235 240
 Gly Leu Ala Glu Lys Arg Ile Tyr His Ala Ala Leu Asn Gly Asn Asn
 245 250 255
 Ser Met Pro Ser Val Leu His Gln Lys Asp Glu
 260 265

<210> 51
 <211> 838
 <212> DNA
 <213> Glycine max



<220>
 <221> unsure
 <222> (205)

<220>
 <221> unsure
 <222> (779)

<220>
 <221> unsure
 <222> (814)

<400> 51
 gagagaaacta gtctcagcca ttttccattt ctttccactt ttatgttttc aggtcatata 60
 tgttaacaga ttcttaccat catcaaggaa gcaggctgtt agggaaataa agagaagggc 120
 ctcttgcaat agattttctc gagtactatt atttcccagag ggaacaacaa caaatggcag 180
 gaaccttata cctttccaaat ttgngcatt tatccctgga tacccaatcc agcctgtaat 240
 tgtacgtat cctcatgtgc actttgacca atcctgggggt catgtttctt tgggaaagct 300
 tatgttcaga atgttcactc aatttcacaa cttttttgag gtagaatata ttctgtcat 360
 ttatcccttg gatgataagg aaactgctgt acattttcgg gagaggacta gccgtgctat 420
 cgcaactgca cttaaagtctg tccagacagg acattcttat ggagacataa tgcttcatat 480
 gaaagcacaac gaagcaaaac aggagaaccc ctcaagtttt atgggttgaat tgaccaaggt 540
 ggaatcagtg agtccctaaa agcaaatgac cttaccattt cttttttttt tctgccattt 600
 tcaagtcctt tgtaaattat ctttttcttt aactttttta gtaggatatt taggttaaag 660
 cttttgaagt acatgcaaat gccacagtaa ccttttgctt atgccaatgg atgacagaca 720
 taagtacccc aggtggctg cataatgttg gggccttcta atctatggga aatatgtant 780
 gaaaggggag aatattttaa ttgtgatttg tggnaataag gggataatat gacataag 838

<210> 52
 <211> 185
 <212> PRT
 <213> Glycine max

<400> 52
 Arg Glu Leu Val Ser Ala Ile Phe His Phe Phe Pro Leu Leu Cys Phe
 1 5 10 15
 Gln Val Ile Tyr Val Asn Arg Phe Leu Pro Ser Ser Arg Lys Gln Ala
 20 25 30
 Val Arg Glu Ile Lys Arg Arg Ala Ser Cys Asn Arg Phe Pro Arg Val
 35 40 45
 Leu Leu Phe Pro Glu Gly Thr Thr Thr Asn Gly Arg Asn Leu Ile Ser
 50 55 60
 Phe Gln Leu Gly Ala Phe Ile Pro Gly Tyr Pro Ile Gln Pro Val Ile
 65 70 75 80
 Val Arg Tyr Pro His Val His Phe Asp Gln Ser Trp Gly His Val Ser
 85 90 95
 Leu Gly Lys Leu Met Phe Arg Met Phe Thr Gln Phe His Asn Phe Phe
 100 105 110
 Glu Val Glu Tyr Leu Pro Val Ile Tyr Pro Leu Asp Asp Lys Glu Thr
 115 120 125
 Ala Val His Phe Arg Glu Arg Thr Ser Arg Ala Ile Ala Thr Ala Leu
 130 135 140



Asn Ala Val Gln Thr Gly His Ser Tyr Gly Asp Ile Met Leu His Met
145 150 155 160

Lys Ala Gln Glu Ala Lys Gln Glu Asn Pro Ser Ser Phe Met Val Glu
165 170 175

Met Thr Lys Val Glu Ser Val Ser Pro
180 185

<210> 53
<211> 1632
<212> DNA
<213> Oryza sativa

<400> 53
cttcctcgtcg ccggtggatt cgcgcgcgcgc tccgcgcgcgc ccgcgcggagg aggaggacga 60
ggagagggcg ctccttcggg ggtgagcacc cagccacctc ggcccgttgc ctccctcttcg 120
catctcgggc ccgcgagatt ggaagtggagg gcagggcagg gcggcagggg ccatggcggt 130
cccaactcgtg ctgcctcgtgc tccgcctcgc cctcctcttc ctccctctccg gcctcatcat 240
caacgccacc caggccgtcc tgtttctctc gataaggccg ttctcgaaga gcttgtagcg 300
ggggatcaac aggttcttgg ccgagctgct gtggcttcag ctgggtctggc ttgtggattg 360
gtgggcaggga gtttaagatac aactgcctgc tgatgacgaa acttacaagg caatggggaa 420
tgagcatgca ctgtctcatat caaataatcg gagcgatcc gattggctta ttgggtggat 480
tttggcacag cgtccaggat gccttggaag tacacttgc tttatgaaga aatcatcgaa 540
attccttcca gttattggct ggtccatgtg gtttgcagaa tacctctttt tggaaaggag 600
ctgggcaaaag gatgaaaaga cattgaaatg gggcctccaa aggttgaagg acttccccag 660
accatttttg ctagcccttt ttgttgaggg cactcgtttt actccagcaa agcttctagc 720
agctcaggag tatgctgttt cacagggttt gccagcacc ccagaaatgtat tgattccacg 780
tacaaggga tttgtatcag ctgtaactat tatgcgggat tttgttccag ctatttatga 840
tacaacagta attattccaa aagattcacc tcaaccaaca atgctgcgga ttttgaaagg 900
gcaatcttca gtggtacatg ttgcgatgaa acgtcatgca atgagtgaaga tgccaaagtc 960
aqaagacgat gtttcaaaaat ggtgcaaaaga catctttgta gcaaaggatg cattactgga 1020
taagcatttg gcgacaggca cttttgatga ggagattaga ccaattggcc gccagtaaaa 1080
atcattgctg gtgactttgt tttggctcat tctcctttta tatggcgccg tcaagctctt 1140
cctatggact caactcctgt cgacatggaa aggagtcggg ttacgggccc ttgggctcgc 1200
actggtgacg gcggtcatgc atgtcttcat catgttctcg cagtcagagc gatcgagctc 1260
auccaaggcg gctcggaacc gtgtcaagaa agattgaaag agatgaagat agagtctgca 1320
gcttatcaat gggagctacc aattaatgg gtattgaatt catgtaggca acaaaaattga 1380
gggcctaate ttctctgtat aatgcaccaa aagggttctt acagaactga atgctgaat 1440
agagagattc taggagattt ggtgaactag caactctgag ctctgttgtg ctgtattttc 1500
agagaatgtt ttttttgga gaacaggaat tgtactactt gtattttatt gaacttctac 1560
atcagtctgg atttgttcag aagaccttta gtgatttatg tatcagtga acttaaaaaa 1620
aaaaaaaaaa aa 1632

<210> 54
<211> 374
<212> PRT
<213> Oryza sativa

<400> 54
Met Ala Val Pro Leu Val Leu Val Val Leu Pro Leu Gly Leu Leu Phe
1 5 10 15
Leu Leu Ser Gly Leu Ile Ile Asn Ala Ile Gln Ala Val Leu Phe Leu
20 25 30
Ser Ile Arg Pro Phe Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Phe
35 40 45



Leu Ala Glu Leu Leu Trp Leu Gln Leu Val Trp Leu Val Asp Trp Trp
 50 55 60
 Ala Gly Val Lys Ile Gln Leu His Ala Asp Asp Glu Thr Tyr Lys Ala
 65 70 75 80
 Met Gly Asn Glu His Ala Leu Val Ile Ser Asn Asn Arg Ser Asp Ile
 85 90 95
 Asp Trp Leu Ile Gly Trp Ile Leu Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110
 Ser Thr Leu Ala Val Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
 115 120 125
 Gly Trp Ser Met Trp Phe Ala Glu Tyr Leu Phe Leu Glu Arg Ser Trp
 130 135 140
 Ala Lys Asp Glu Lys Thr Leu Lys Trp Gly Leu Gln Arg Leu Lys Asp
 145 150 155 160
 Phe Pro Arg Pro Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
 165 170 175
 Thr Pro Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Val Ser Gln Gly
 180 185 190
 Leu Pro Ala Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
 195 200 205
 Ser Ala Val Thr Ile Met Arg Asp Phe Val Pro Ala Ile Tyr Asp Thr
 210 215 220
 Thr Val Ile Ile Pro Lys Asp Ser Pro Gln Pro Thr Met Leu Arg Ile
 225 230 235 240
 Leu Lys Gly Gln Ser Ser Val Val His Val Arg Met Lys Arg His Ala
 245 250 255
 Met Ser Glu Met Pro Lys Ser Glu Asp Asp Val Ser Lys Trp Cys Lys
 260 265 270
 Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Leu Ala Thr
 275 280 285
 Gly Thr Phe Asp Glu Glu Ile Arg Pro Ile Gly Arg Pro Val Lys Ser
 290 295 300
 Leu Leu Val Thr Leu Phe Trp Ser Cys Leu Leu Leu Tyr Gly Ala Val
 305 310 315 320
 Lys Leu Phe Leu Trp Thr Gln Leu Leu Ser Thr Trp Lys Gly Val Gly
 325 330 335
 Phe Thr Gly Leu Gly Leu Ala Leu Val Thr Ala Val Met His Val Phe
 340 345 350
 Ile Met Phe Ser Gln Ser Glu Arg Ser Ser Ser Ala Lys Ala Ala Arg
 355 360 365



Asn Arg Val Lys Lys Asp
370

<210> 55
<211> 1498
<212> DNA
<213> Glycine max

<400> 55
gcacqaggtt ccgtttgctg aactgacctc ggaaatccaa agagggaaaac tcacgggtgtt 60
tcgtttgcgtt gtgctctgct ctgctccttt gggcctgggc tgggctgggc tgggctgggc 120
tgggcattggc tattgcagca gggccgtgg tggtaaccat gggcctgctc ttcttgcct 180
ccggcctcct tgttaatctc attcaggcaa tatgctatgt cgtcgttaagg ccggtgtcga 240
aaagtttgta cagaaggatc aaccgggtag tagcagagct cttgtggctg gagcttgtat 300
ggcttattga ttggtgggca ggagttaagg tccaaatatt cacagatcat gaaacctttc 360
gtttaatggg taaagagcat gcacttgtga taagcaatca cagaagtgat attgattggc 420
ttgttggatg ggtttcagct cagcgttcag gttgtcttgg cagcactcta gctgtgatga 480
agaaatcttc aaagtttctg ccggtcattg gctggtaaat gtggttttct gactatcttt 540
ttctggagag aagttgggca aaggatgaaa gcacattaaa gtcaggcatc cagcgactga 600
gtgatttccc tcttcccttt tggctagctc tctttgtaga aggaacgctt ttacacagg 660
ccaaactatt agctgctcag gaatatgcca ctccactgg attgctctgt cctagaaatg 720
ttttgattcc aagaactaag ggttttgttt ctgcagtaag tcatatgccc tcatattgtc 780
ctgcatttta tgatgtaaca gtagccatcc ctaagagttc ccttgcctct acaatgctaa 840
gactcttcaa gggacaacct tcagtggtgc atgttcatat caagaggcat ttgatgaagg 900
aactgccaga tacagatgag gctgttgctc aatggtgtcg agatatattt gtggccaagg 960
atgtcttgtt agacaaacat atggctgagg gtacttttag tgatcaagag ctgcaggata 1020
ctggctgacc aataaagtct cttctggtag ttatatcttg ggctgtctg gttgttgagg 1080
ggtctgtaaa gttcctgcaa tggctctctg tactctcttc ctggaagggt gttgcatttt 1140
cagcttttgg tttggcagtt gttactgcac ttatgcaaat tctgattcaa ttctcacagt 1200
cagagcgttc aaaccgggc aagatcgtgc ctgcaaagtc aaaaaacaag ggtcttcat 1260
tcatctggcg aacttaaaagt tgcatttatg tgtgatgagt gactcatgta atactcatta 1320
tttggctttc aacatcttat catagtatgc ttctattcta tatatgtact attatgaatg 1380
cttatcgatt cattgttttt aatttaatta ggatatcctt ttgtattgac agtctagggg 1440
ctctaga aaaattcaac cacctatttt attttaaaaa aaaaaaaaaa aaaaact 1498

<210> 56
<211> 377
<212> PRT
<213> Glycine max

<400> 56
Met Ala Ile Ala Ala Ala Ala Val Val Val Pro Leu Gly Leu Leu Phe
1 5 10 15
Phe Ala Ser Gly Leu Leu Val Asn Leu Ile Gln Ala Ile Cys Tyr Val
20 25 30
Val Val Arg Pro Val Ser Lys Ser Leu Tyr Arg Arg Ile Asn Arg Val
35 40 45
Val Ala Glu Leu Leu Trp Leu Glu Leu Val Trp Leu Ile Asp Trp Trp
50 55 60
Ala Gly Val Lys Val Gln Ile Phe Thr Asp His Glu Thr Phe Arg Leu
65 70 75 80
Met Gly Lys Glu His Ala Leu Val Ile Ser Asn His Arg Ser Asp Ile
85 90 95



Asp Trp Leu Val Gly Trp Val Ser Ala Gln Arg Ser Gly Cys Leu Gly
 100 105 110
 Ser Thr Leu Ala Val Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
 115 120 125
 Gly Trp Ser Met Trp Phe Ser Glu Tyr Leu Phe Leu Glu Arg Ser Trp
 130 135 140
 Ala Lys Asp Glu Ser Thr Leu Lys Ser Gly Ile Gln Arg Leu Ser Asp
 145 150 155 160
 Phe Pro Leu Pro Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
 165 170 175
 Thr Gln Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Thr Ser Thr Gly
 180 185 190
 Leu Pro Val Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
 195 200 205
 Ser Ala Val Ser His Met Arg Ser Phe Val Pro Ala Ile Tyr Asp Val
 210 215 220
 Thr Val Ala Ile Pro Lys Ser Ser Pro Ala Pro Thr Met Leu Arg Leu
 225 230 235 240
 Phe Lys Gly Gln Pro Ser Val Val His Val His Ile Lys Arg His Leu
 245 250 255
 Met Lys Glu Leu Pro Asp Thr Asp Glu Ala Val Ala Gln Trp Cys Arg
 260 265 270
 Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Met Ala Glu
 275 280 285
 Gly Thr Phe Ser Asp Gln Glu Leu Gln Asp Thr Gly Arg Pro Ile Lys
 290 295 300
 Ser Leu Leu Val Val Ile Ser Trp Ala Cys Leu Val Val Ala Gly Ser
 305 310 315 320
 Val Lys Phe Leu Gln Trp Ser Ser Leu Leu Ser Ser Trp Lys Gly Val
 325 330 335
 Ala Phe Ser Ala Phe Gly Leu Ala Val Val Thr Ala Leu Met Gln Ile
 340 345 350
 Leu Ile Gln Phe Ser Gln Ser Glu Arg Ser Asn Pro Ala Lys Ile Val
 355 360 365
 Pro Ala Lys Ser Lys Asn Lys Gly Ser
 370 375

<210> 57

<211> 1415

<212> DNA

<213> Triticum aestivum



<400> 57

```

gcacgaggag aggagacgag gggggggcca tggcgattcc cctcgtgctc gtcctgctcc 60
cgctgggctt cctcttccct cctccggccc tggctgtcaa cactgtccag gccgtattgt 120
tcttgacgat aaggccatto tcgaagcgat tgtaccggca gatcaacgta ttcctggcgg 180
agttgtttgt ccttcagctg atctggcttg tggactgggt gccaggtatt aaggtacagg 240
tgtatcggga tcacagaaact tggaaactaa tgggcaaaaga gcacgcccct ctcatatccc 300
atcagcgaag tgacattgat tggctgggtg gatggatttt agcacagcgt tcaggatgtc 360
ttggaagcgc aatagctata atgaagaaat cctcaaagtt ccttccagtt attggttggg 420
ccatgtgggt tgcagaatac ctcttttttg agagaagctg ggcaaaggat gaaaaaacac 480
ttaaactcggg tcttcaaagg ttgaaagact tccccagatc attttggctt gccctttttg 540
ttgaggggtac aagattttact ccagcaaaac ttttagcagc tcaagaatat gcagttctac 600
aggggtttgac agcgcctagg aatgtgctga ttcacgaac aaagggattt gtatcagctg 660
taagtattat gcgtgacttt gtcccagcta tctacgatac aacagtgatt attccggaag 720
attcgcttaa accaacaatg ctgcgtattc ttcagggaca atcatcagtt gttcatgtcc 780
gcataaaacg ccattcaatg agtgatatgc ctaactcgga tgaggatgtt tcaaaatggt 840
gcaaaagatat attttagca aaggacgcgt tattggacaa acatatagca actggtactt 900
ttgatgagga aattatacca attggcgcgt cagtgaatc tttgatgggt gtcctgtctt 960
ggtcatgtct cctcctatat ggtgctcata gattcttaca gtggaccag ccttgttcca 1020
cgtggaaagg agtgatcctc tttgcttctg gattggcaat ggtaaccgcc gttatgcatt 1080
tattatcat gttctcgcag gccgagcgc caagctctgc gaaagcagca agggaccgag 1140
tgaagaagga ttgatagctc gtgtgaaatt cagtctatag gggaactgcc aatttattat 1200
gttcagaata tatgtagaca caggtcccat ggtcaaactc tagtatgtcc ttgttgtcct 1260
cggtaagagc ttcaggaatt ttgtgtggcg agaactgtga gctttcttcc ttctttctct 1320
actttgtaat gacttgtaaa gatttgcttt gccataccag gaatcgctgc tcgaatttat 1380
cgaagctctt ttttatcaaa aaaaaaaaaa aaaaa 1415

```

<210> 58

<211> 374

<212> PRT

<213> Triticum aestivum

<400> 58

```

Met Ala Ile Pro Leu Val Leu Val Leu Leu Pro Leu Gly Leu Leu Phe
  1             5             10             15

Leu Leu Ser Gly Leu Val Val Asn Thr Val Gln Ala Val Leu Phe Leu
      20             25             30

Thr Ile Arg Pro Phe Ser Lys Arg Leu Tyr Arg Gln Ile Asn Val Phe
      35             40             45

Leu Ala Glu Leu Leu Trp Leu Gln Leu Ile Trp Leu Val Asp Trp Trp
      50             55             60

Ala Gly Ile Lys Val Gln Val Tyr Ala Asp Pro Glu Thr Trp Lys Leu
      65             70             75             80

Met Gly Lys Glu His Ala Leu Leu Ile Ser Asn His Arg Ser Asp Ile
      85             90             95

Asp Trp Leu Val Gly Trp Ile Leu Ala Gln Arg Ser Gly Cys Leu Gly
     100             105             110

Ser Ala Ile Ala Ile Met Lys Lys Ser Ser Lys Phe Leu Pro Val Ile
     115             120             125

Gly Trp Ser Met Trp Phe Ala Glu Tyr Leu Phe Leu Glu Arg Ser Trp
     130             135             140

```



Ala Lys Asp Glu Lys Thr Leu Lys Ser Gly Leu Gln Arg Leu Lys Asp
 145 150 155 160
 Phe Pro Arg Ser Phe Trp Leu Ala Leu Phe Val Glu Gly Thr Arg Phe
 165 170 175
 Thr Pro Ala Lys Leu Leu Ala Ala Gln Glu Tyr Ala Val Ser Gln Gly
 180 185 190
 Leu Thr Ala Pro Arg Asn Val Leu Ile Pro Arg Thr Lys Gly Phe Val
 195 200 205
 Ser Ala Val Ser Ile Met Arg Asp Phe Val Pro Ala Ile Tyr Asp Thr
 210 215 220
 Thr Val Ile Ile Pro Glu Asp Ser Pro Lys Pro Thr Met Leu Arg Ile
 225 230 235 240
 Leu Gln Gly Gln Ser Ser Val Val His Val Arg Ile Lys Arg His Ser
 245 250 255
 Met Ser Asp Met Pro Asn Ser Asp Glu Asp Val Ser Lys Trp Cys Lys
 260 265 270
 Asp Ile Phe Val Ala Lys Asp Ala Leu Leu Asp Lys His Ile Ala Thr
 275 280 285
 Gly Thr Phe Asp Glu Glu Ile Ile Pro Ile Gly Arg Pro Val Lys Ser
 290 295 300
 Leu Met Val Val Leu Ser Trp Ser Cys Leu Leu Leu Tyr Gly Ala His
 305 310 315 320
 Arg Phe Leu Gln Trp Thr Gln Leu Leu Ser Thr Trp Lys Gly Val Ile
 325 330 335
 Leu Phe Ala Ser Gly Leu Ala Met Val Thr Ala Val Met His Val Phe
 340 345 350
 Ile Met Phe Ser Gln Ala Glu Arg Ser Ser Ser Ala Lys Ala Ala Arg
 355 360 365
 Asp Arg Val Lys Lys Asp
 370



(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 August 2000 (24.08.2000)

PCT

(10) International Publication Number
WO 00/49156 A3

- (51) International Patent Classification⁷: C12N 15/54, 15/82, C12Q 1/68, C12N 9/10
- (21) International Application Number: PCT/US00/04526
- (22) International Filing Date: 22 February 2000 (22.02.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/121,119 22 February 1999 (22.02.1999) US
- (71) Applicant (for all designated States except US): **E.I. DU PONT DE NEMOURS AND COMPANY** [US/US]; 1007 Market Street, Wilmington, DE 19898 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CAHOON, Edgar, B.** [US/US]; 2331 West 18th Street, Wilmington, DE 19806 (US). **CAHOON, Rebecca, E.** [US/US]; 2331 West 18th Street, Wilmington, DE 19806 (US). **HIITZ, William, D.** [US/US]; 404 Hillside Road, Wilmington, DE 19807 (US). **KINNEY, Anthony, J.** [GB/US]; 609 Lore Avenue, Wilmington, DE 19809 (US). **RIPP, Kevin, G.** [US/US]; 2310 West 18th Street, Wilmington, DE 19806 (US).
- (74) Agent: **KENING, Li**; E.I. Du Pont de Nemours and Company, Legal Patent Records Center, 1007 Market Street, Wilmington, DE 19898 (US).
- (81) Designated States (national): AE, AL, AU, BA, BB, BG, BR, CA, CN, CR, CU, CZ, DM, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, ZA.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
With international search report.
- (88) Date of publication of the international search report:
15 February 2001
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: LYSOPHOSPHATIDIC ACID ACETYLTRANSFERASES

(57) Abstract: An isolated nucleic acid fragment encoding an LPAAT isozyme is disclosed. Construction of a chimeric gene encoding all or a portion of the LPAAT isozyme, in sense or antisense orientation, wherein expression of the chimeric gene results in production of altered levels of the LPAAT isozyme in a transformed host cell is also disclosed.



WO 00/49156 A3



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04526

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/54 C12N15/82 C12Q1/68 C12N9/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12Q

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	BROWN, A.P. ET AL.: "Isolation and characterization of a maize cDNA that complements a 1-acyl-sn-glycerol-3-phosphate acyltransferase mutant of Escherichia coli and encodes a protein which has similarities to other acyltransferases." PLANT MOLECULAR BIOLOGY, vol. 26, 1994, pages 211-23, XP002143283 the whole document ---	
A	WO 95 27791 A (CALGENE INC ;DAVIES HUW MAELOR (US); HAWKINS DEBORAH (US); NELSEN) 19 October 1995 (1995-10-19) the whole document --- -/--	



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

26 July 2000

Date of mailing of the international search report

08.11.00

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Smalt, R



INTERNATIONAL SEARCH REPORT

In International Application No

PCT/US 00/04526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 96 24674 A (GENE SHEARS PTY LTD ;SLABAS ANTONI RYSZARD (GB); BROWN ADRIAN PAUL) 15 August 1996 (1996-08-15) the whole document ---	
A	ZOU J ET AL: "Modification of seed oil content and acyl composition in the Brassicacea by expression of a yeast sn-2 acyltransferase gene" PLANT CELL,US,AMERICAN SOCIETY OF PLANT PHYSIOLOGISTS, ROCKVILLE, MD, vol. 9, no. 9, June 1997 (1997-06), pages 909-923-923, XP002122743 ISSN: 1040-4651 the whole document ---	
P,X	DATABASE EMBL - EMBEST_PLN3 [Online] Entry/Acc.no. Aw065739, 18 October 1999 (1999-10-18) WALBOT, V.: "614060H09.y1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143284 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBEST_PLN2 [Online] Entry/Acc.no. A1939764, 4 August 1999 (1999-08-04) WALBOT, V.: "618028B06.x1 618 - Inbred Tassel cDNA Library Zea mays cDNA, mRNA sequence." XP002143464 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBEST_PLN3 [Online] Entry/Acc.no. AW065739, 18 October 1999 (1999-10-18) WALBOT, V.: "614060H09.y1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143465 the whole document ---	1-4,7,8, 16,18
P,X	DATABASE EMBL - EMBEST_PLN3 [Online] Entry/Acc.no. Aw055524, 26 September 1999 (1999-09-26) WALBOT, V.: "614082G11.x1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence" XP002143466 the whole document ---	1-4,7,8, 16,18

	-/--	



INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/04526

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	DATABASE EMBL - EMBEST_PLN1 [Online] Entry/Acc.no. Ai783420, 2 July 1999 (1999-07-02) WALBOT, V.: "614011F05.x1 614 - root cDNA library from Walbot Lab Zea mays cDNA, mRNA sequence." XP002143467 the whole document ---	1-4,7,8, 16,18
E	WO 00 18889 A (CALGENE LLC) 6 April 2000 (2000-04-06) the whole document -----	1-20



INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 00/04526

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Claims 1-20, all partially.

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-20, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 2,8,28,40, or 46, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

1.1. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.2.

1.2. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.8.

1.3. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.28.

1.4. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.40.

1.5. Claims: 1-20, all partially

As subject 1, but limited to the specific amino acid sequence with seq.ID.46.

2. Claims: 42 completely, and 1-19,21-40 partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 4,10,18,22,34,44,50,52, or 56, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

3. Claims: 1-20,22-41, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 6,12,24,38, or 58, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

4. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to seq.ID.14, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

5. Claims: 1-20,22-41, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 16,20,30,42,48, or 54, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.



FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

6. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to one of seq.ID's 26 or 36, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

7. Claims: 1-19,21, all partially

Polypeptide of at least 100 amino acids having 80% homology to seq.ID.32, isolated polynucleotide comprising a sequence encoding said polypeptide and further comprising the complement to said sequence, chimeric gene comprising said polynucleotide, host cell comprising said chimeric gene, method of selecting an oligonucleotide of at least 30 nucleotides of said polynucleotide which affects expression of an LPAAT isoenzyme, method of obtaining a nucleic acid encoding an LPAAT using said oligonucleotide, compositions of said polynucleotide or said oligonucleotide, and method of positive selection of a transformed cell using said polynucleotide.

Please note that all inventions mentioned under item 1, although not necessarily linked by a common inventive concept, could be searched without effort justifying an additional fee.



INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/04526

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9527791 A	19-10-1995	US 5563058 A	08-10-1996
		US 6093568 A	25-07-2000
		US 5824858 A	20-10-1998
		US 5910630 A	08-06-1999
		CA 2186607 A	19-10-1995
		EP 0754232 A	22-01-1997
		JP 9511650 T	25-11-1997
		US 5968791 A	19-10-1999
WO 9624674 A	15-08-1996	AU 4669096 A	27-08-1996
		CA 2212570 A	15-08-1996
		CA 2235267 A	24-04-1997
		EP 0808368 A	26-11-1997
WO 0018889 A	06-04-2000	NONE	



1

2

3

4